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Autophagy is a conserved and highly regulated process in eukaryotic cells that plays an 
important role in maintaining cellular homeostasis. During macroautophagy a double 
membrane grows de novo that encloses cytoplasmic cargo and after its fusion an 
autophagosome vesicle is formed. The autophagosome then fuses with the vacuole or 
lysosome, where its content is degraded. The Atg12~Atg5/Atg16 complex is an essential part 
of the core autophagy machinery and localizes to the outside of the growing isolation 
membrane. The complex also acts as an E3-like ligase for the lipidation of ubiquitin-like 
Atg8. The PROPPIN (β-propeller that binds polyphosphoinositides) Atg21 determines the site 
of Atg8 lipidation in yeast by interacting with both the coiled coil domain of Atg16 and Atg8. 
In my first project, I obtained first low resolution insights into the interactions of Atg21 with 
the coiled coil domain of Atg16. The 4.0 Å crystal structure shows that the Ashbya gossypii 
Atg16 coiled coil domain is at the center of the Atg21-Atg16 complex and interacts with two 
Kluyveromyces lactis Atg21 molecules on either site of the C-terminal ends of the coiled coil 
dimer. The two Atg21 molecules adopt a reversed V shape and their PI(3)P binding sites are 
located opposite to the Atg16 binding site. The structure thus shows how membrane bound 
Atg21 can bind an Atg16 dimer. However, at 4.0 Å resolution molecular details of complex 
interaction are not visible. I also determined crystal structure of the coiled coil domain of 
AgAtg16 comprising residues 43-108 at 3.4 Å resolution. Analysis of Atg21-Atg16 complex 
formation by analytic gel filtration revealed the importance of residues KlAtg21 R103E and 
AgAtg16 (70-124) D78R for binding. The structure of Atg21-Atg16 complex gives more 
insights into the coordination of Atg8 lipidation. 
The coiled coil domain of mammalian Atg16 is an effector of Golgi-resident Rab33B. In my 
second project, I determined the crystal structure of murine Rab33B with the Atg16L1 coiled 
coil domain at 3.47 Å resolution. The structure revealed that two Rab33B molecules form a 
complex with the diverging C-termini of one Atg16L1 dimer. Protein-protein interactions 
observed in the structure were confirmed by cross linking of the Rab33B(30-202)Q92L-
Atg16L1(153-210) complex and analysis by mass spectrometry. Based on the structure 
Rab33B and Atg16L1 mutants were designed to verify the Rab33B-Atg16L1 interactions. 
Both in vivo and in vitro pull-down experiments showed that selected single point mutations 
II 
disrupted complex formation. Furthermore, immunofluorescence studies showed that these 
mutations abolished co-localization of Rab33B and Atg16L1 in cells. The Rab33B binding 
site of Atg16 identified in this study comprises residues 191-208 and is in close proximity of 
the PROPPIN WIPI2B binding site (207-230) and could explain how Golgi-derived vesicles 
can be recruited into close proximity of the isolation membrane by binding of Atg16 to both 
Rab33B and WIPI2B, providing a source of lipids to the growing isolation membrane. 
In my third project, I characterized the SCOC-FEZ1 complex that has a regulatory role in 
autophagy. Complex formation is mediated through the dimeric coiled coil domains of both 
proteins. Crystals diffracting up to 2.2 Å resolution were obtained but due a twinning problem 
the structure could not be determined. However, I gained new insights into SCOC-FEZ1 
complex formation through biophysical experiments. I showed that the two dimers interact 
with a 1:1 stoichiometry with SEC-MALLS experiments. Cross-linking and analysis by mass 
spectroscopy revealed that FEZ1 most likely a forms parallel coiled coil dimer and that the 
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1. Introduction  
 
1.1. Overview on autophagy  
Autophagy (Greek for “self eating”) unites a number of highly conserved cellular processes 
that involve the degradation of cytoplasmic components in the yeast vacuole or lysosomes in 
animal cells. Autophagy occurs from yeast to humans. It plays an important role in cell 
survival and maintenance, during starvation parts of the cytoplasm and organelles are 
unspecific degraded to recover energy and to gain building blocks that are recycled for protein 
synthesis (Fig. 1.1.1.) [113]. To maintain cell homeostasis autophagy is functional in the 
specific degradation of protein aggregates and damaged organelles like mitochondria, 
peroxisomes or the endoplasmic reticulum (ER) that are too large to be handled by the 
ubiquitin-proteasome pathway [64, 65]. In addition autophagy can remove intracellular 
pathogens [38, 89].  
 
Figure 1.1.1.: Schematic overview on macroautophagy. Upon induction de novo formation of an 
isolation membrane occurs at the preautophagosomal assembly site (PAS). The expanding double 
membraned phagophore engulfs its cargo and then closes to form the autophagosome. Upon fusion 
with the lysosome or vacuole the inner autophagosomal membrane and cargo are degraded and 
recycled. 
 
There are two main types of non-specific autophagy: microautophagy and macroautophagy 
(Fig. 1.1.2.). During microautophagy cytoplasm including organelles is taken up directly 
through invaginations of the lysosome or vacuole (Fig. 1.1.2) [77]. Macroautophagy on the 
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other hand sequesters cytoplasmic cargo with a de novo growing isolation membrane or 
phagophore (Fig. 1.1.1. and 1.1.2.). Closing of this double-membrane forms the 
autophagosomes that are delivered to the lysosome where they fuse. The inner membrane of 
the autophagosome and its content are then degraded [125]. Macroautophagy is the best 
studied autophagy pathway and will be described in more detail below. The cytoplasm-to-
vacuole targeting (Cvt) pathway and piecemeal microautophagy of the nucleus (PMN) in 
yeast and chaperone-mediated autophagy in mammalian cells are three examples for specific 
autophagic subtypes. The cytoplasm to vacuole targeting (Cvt) pathway is a biosynthetic 
process that uses the autophagy machinery. It delivers the hydrolases α-mannosidase (Ams1) 
and the precursor form of aminopeptidase I (preApe1) to the vacuole [80]. PMN is a 
starvation induced process that degrades small portions of the nucleus at nucleus-vacuole 
(NV) junctions [71, 117]. Chaperone-mediated autophagy (CMA) is a highly specific non-
vesicular form of autophagy. Heat shock cognate protein of 70 kDa (hsc70) recognizes a 
KFERQ related pentapeptide motif in substrates and delivers them to the lysosome, where 
they bind to the lysosome-associated membrane protein type 2A (LAMP-2A) receptor. 
Substrates are then translocated directly across the lysosomal membrane [62]. Other 
autophagic subtypes are known which specifically target organelles, for example peroxisomes 
(pexophagy), mitochondria (mitophagy), and the endoplasmic reticulum (ER-phagy), 





Figure 1.1.2.: Schematic overview of autophagy subtypes and their morphology. Macro- and 
microautophagy are two types of non-selective autophagy. During macroautophagy a portion of the 
cytoplasm is sequestered into a double-membraned vesicle, the autophagosome, which then fuses with 
the vacuole or lysosome. Selective autophagy subtypes include mitophagy, which takes up 
mitochondria, xenophagy for pathogens and the biosynthetic cytoplasm to vacuole targeting (Cvt) 
pathway that delivers hydrolases to the vacuole. During microautophagy cargo is taken up directly 
through invaginations of the vacuolar or lysosomal membrane and a similar selective subtype is 
micropexophagy that specifically targets peroxisomes. Piecemeal microautophagy of the nucleus 
(PMN) degrades portions of the nucleus. Both yeast and mammalian autophagic subtypes are shown in 
this figure. 
Macroautophagy, hereafter named autophagy, occurs at a low basal level constitutively under 
normal growing conditions [89] and is strongly upregulated under stress conditions like 
nutrient starvation. Importantly, autophagy degrades organelles and aggregated proteins that 
are too large for the ubiquitin-proteasome system. It encloses them in autophagosomes that 
have a size of 400-900 nm [135]. The double-membraned autophagosomes do not form by 
budding from other organelles but by de novo formation at the preautophagosomal assembly 
site (PAS). The cup-shaped initial sequestering compartment is called the isolation membrane 
or phagophore [133]. The phagophore grows by the addition of lipids, most likely via vesicle 
fusion mediated by SNAREs (soluble N-ethylmaleimide-sensitive fusion (NSF) attachment 
protein receptors) [142]. The membrane supply involves various sources at different stages 
and is still controversially discussed [112]. Different studies gave hints that lipid bilayers are 
either delivered from the ER [80], Golgi apparatus [43, 82] or other compartments including 
the plasma membrane [111] and mitochondria [47]. At the end the strongly bent phagophore 
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closes and forms the autophagosome [68]. Autophagosomes are trafficked to the lysosome or 
vacuole where their outer membranes fuse with the lysosome or vacuole [79]. The membrane 
of the remaining vesicle, the autophagic body in yeast, is lysed and the content is degraded by 
hydrolases and recycled [7]. 
Autophagy genes were discovered by pioneering yeast genetic screens performed 
independently by the groups of Yoshinori Ohsumi, Michael Thumm and Daniel Klionsky [51, 
137, 138] and are denoted as ATG (autophagy-related) genes. Currently, more than 40 Atg 
proteins are known [78]. The majority of autophagy related proteins assemble into complexes. 
Eighteen of them form the core autophagy machinery which is essential for the 
autophagosome formation [97]. Many aspects of autophagy are conserved from yeast to 
human and most yeast Atg proteins have orthologues in mammals (see Table 1.1.1. for 
comparison of the yeast and mammalian core autophagy machinery).  
 
Table 1.1.1.: Overview of name und function of autophagy core machinery proteins in yeast and 
mammals. Abbreviation: nd, no data. Modified from [13]. 
 Yeast Mammals Function 
Atg1 kinase 
complex 
Atg1 ULK1, 2 Serine/threonine protein kinase  
 
Atg13 ATG13 Target of the TOR signaling pathway 
Atg17 FIP200 Scaffold protein, regulatory subunit of the 
complex 
nd ATG101 Forms a complex with ULK, ATG13 and 
FIP200 in mammals, function unknown 
Atg29 Nd Forms a complex with Atg17 and Atg31 in 
yeast, that serves as scaffold for Atg1 
complex assembly  
Atg31 Nd Forms a complex with Atg17 and Atg29 in 




Vps34 PIK3C3/Vps34 Class III Phosphatidylinositol 3-kinase, 
produces PI(3)P 
Atg6/Vps30 Beclin1 Forms a complex with Vps34 and Atg14 
Atg14 ATG14L1 Forms a complex with Vps34 and Atg6 
Atg9 complex Atg9 mATG9 Transmembrane protein, carrier for 
membranes during phagophore expansion 
Atg2 ATG2A, B Forms a complex with Atg18, that recruits 
Atg9 






Atg3 ATG3 E2-like enzyme, involved in LC3 lipidation 
Atg4 ATG4A, B, C, 
D 
Cysteine protease, involved in LC3 activation 
and delipidation 
Atg5 ATG5 Part of the Atg12~Atg5/Atg16 complex, E3-
like enzyme, involved in LC3 lipidation 
Atg7 ATG7 E1-like enzyme, involved in LC3 and ATG12 
conjugation 
Atg8 LC3A, B, C;  
GABARAPs; 
GATE-16 
Ubiquitin-like proteins, that are conjugated to 
PE 
Atg10 ATG10 E2-like enzyme in Atg12 conjugation 
Atg12 ATG12 Ubiquitin-like protein, that conjugates to 
Atg5 
Atg16 ATG16L1, 2 Part of the Atg12~Atg5/Atg16 complex, 
specifies LC3 lipidation site 
 
1.2. Molecular mechanism of autophagy 
Autophagy initiation is an answer to nutrient starvation by inhibition of the TOR (target of 
rapamycin) kinase. Inhibition of TOR leads to Atg13 dephosphorylation, which then binds 
Atg1 kinase [60]. Activated Atg1 and Atg13 interact with the Atg17-Atg29-Atg31 complex at 
the preautophagosomal assembly site (PAS) [81]. The Atg1 complex recruits downstream Atg 
proteins to the PAS [106]. One of the first is the autophagy-specific phosphatidylinositol 3-
kinase complex (Vps30/Atg6, Atg14, Vps15, and Vps34) that is essential for autophagosome 
formation and produces phosphatidylinositol 3-phosphate (PI(3)P) (Fig. 1.2.1.) [123, 147]. 
PI(3)P is required for the autophagic pathway. It recruits effectors like PROPPINs (β-
propeller proteins that bind polyphosphoinositides) and anchors them to the membrane [18]. 
Atg18 is a PROPPIN that forms a complex with Atg2 and is involved in the cycling of Atg9 
[101]. Atg9 is the only membrane spanning Atg protein and is integrated into Golgi-derived 
vesicles that are proposed to deliver lipids to the growing isolation membrane [114]. Two 
ubiquitin-like conjugation systems are essential for autophagosome formation. The ubiquitin-
like protein Atg12 is conjugated to Atg5 by Atg7, an E1-like enzyme and Atg10, an E2-like 
enzyme that forms a bond between Atg12 and Atg5. The Atg12~Atg5 conjugate forms a 
stable complex with self-dimerizing Atg16, which binds to the outer side of the growing 
isolation membrane [139]. Binding of dimeric Atg12~Atg5/Atg16 to the PAS defines site of 
autophagosome formation and acts as a E3-like ligase second ubiquitin-like conjugation 
system [99]. Here, the ubiquitin-like Atg8, that is evenly distributed at the isolation membrane 
(Fig. 1.2.1.), is conjugated by Atg7 and Atg3 the respective E1-like and E2-like enzymes to 
phosphatidylethanolamine (PE). Atg8-PE is one of the major phospholipids that supports 
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membrane extension [96] and assembles with the Atg12~Atg5/Atg16 complex to form a 
scaffold at the outside of the isolation membrane (Fig. 1.2.1.) [61]. Lipidation of Atg8 is 
reversed by cleavage of the Atg4 protease during nutrient-rich conditions. Atg8–PE is able to 
facilitate membrane tethering and hemifusion and has an essential role in autophagosome 
formation [95, 96]. The closing of the isolation membrane, the autophagosome formation, is 
poorly understood. Shortly before or after autophagosome formation the Atg12~Atg5/Atg16 
complex dissociates from the surface and Atg8 is released through cleavage of Atg8-PE by 
Atg4 [63]. The autophagosome then fuses with the lysosome.  
 
 
Figure 1.2.1.: Schematic overview of the molecular mechanisms of autophagy. While the 
phagophore nucleates at the PAS, Atg9 and the PtdIns3K complex are recruited. Growing of the 
phagophore is organized by several autophagy complexes. The PtdIns3K complex produces PI(3)P 
and Atg9 cycles between the PAS and peripheral sites to deliver lipids. The Atg12~Atg5/Atg16 
complex binds to the outer side of the phagophore and conjugates the evenly distributed Atg8 to Atg8-
PE. Upon completion of the autophagosome, autophagy proteins are cleaved from the outer membrane 
and the mature vesicle can fuse with the vacuole. Figure from [146]. 
The structures of the components of the two ubiquitin-like conjugation systems are known 
(Fig.1.2.2). The Atg12~Atg5/Atg16 complex is homodimeric and consists of two 
Atg12~Atg5 conjugates that are bound to one chain of an Atg16 dimer respectively. The 
Atg12 structure reveals a C-terminal ubiquitin-fold including the typical conserved motif of 
five-stranded β-sheet and two α-helices, although Atg12 has no sequence homology to 
ubiquitin (Fig. 1.2.2. A) [42, 134]. Human Atg12 residue G140 is covalent linked to Atg5 
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K130 [99, 102]. Atg5 comprises two ubiquitin-like domains that flank a helix-rich domain 
[83]. It binds Atg12 on one side of the molecule whereas Atg16 is bound on the other site. 
Atg12 and Atg16 do not interact directly. Besides its N-terminal Atg5-binding domain, Atg16 
comprises a C-terminal coiled coil domain that facilitates homodimerization (Fig. 1.2.2. B) 
[37], mammalian Atg16L additional contains seven WD repeats at the C-terminus [90]. The 
Atg12~5 conjugate promotes the conjugation of Atg8 to phosphatidylethanolamine by direct 
interaction between Atg12 and Atg3 [36]. The Atg8 structure obtains an ubiquitin fold with a 
central five-stranded β-sheet, surrounded by two pair of α-helices [48, 67]. Before lipidation 
Atg8 is processed by Atg4 to expose a C-terminal Gly and activated by Atg7 [63].  
 
 
Figure 1.2.2.: Crystal structures of the ATG12~ATG5/ATG16N complex and the Atg16 coiled 
coil domain. A: Cartoon presentation of yeast Atg16 forming a parallel coiled-coil dimer (PDB code: 
3A7P). B: Cartoon representation of the human ATG12~ATG5 in complex with an N-terminal ATG 
construct (PDB code: 4GDL). ATG12 colored yellow, ATG16 colored red. ATG5 consists of two 
ubiquitin folds (UFD-1 in grey and UFD-2 in blue) and a α-helical bundle region (HBR in wheat). 
Atg12 G140 is covalent linked to Atg5 K130. C: Cartoon representation of S. cerevisiae Atg8 in dark 
turquoise (PDB code: 3VWX, [67]). Figure A from [37], B from [102]. 
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1.3. PROPPINs and the PROPPIN Atg21-Atg16 complex  
Seven natural PIs are known that are specifically recognized by PI effector proteins [8]. The 
PROPPINs (β-propellers that bind polyphosphoinositides) are PI effector proteins that 
specifically bind PI(3)P and PI(3,5)P2. The conserved FRRG motif is essential for PI binding 
of PROPPINs [29, 73, 95, 101]. In yeast there are three PROPPIN homologs Atg18, Atg21 
and Hsv2 (Homologous with swollen vacuole phenotype 2) [70]. In mammals four 
PROPPINs were discovered and named WIPI1 to WIPI4 (WD-40 repeat containing protein 
that interacts with PIs) [109]. WIPI1 and WIPI2 are postulated as Atg18 orthologues with 
different functions [108]. WIPI1 has similar functions like the yeast Atg18 and localizes to the 
autophagosomal membrane in a phosphoinositide dependent manner [110]. WIPI2 was often 
referred to be an orthologue of Atg21 but bioinformatic analyses show that Atg21 is yeast 
specific and has only distant ancestry with the WIPI family [108]. Still similar to yeast Atg21 
that binds Atg16, WIPI2B interacts with Atg16L1 and thereby recruits the 
Atg12~Atg5/Atg16L complex to facilitate LC3-lipidation in mammals [28, 108]. WIPI3 and 
WIPI4 feasible are orthologues of Hsv2.  
Yeast PROPPINs are highly homologous and structurally conserved. Crystal structures are 
available for KlHsv2 and KmHsv2 [9, 69, 143] and PaAtg18 [119]. Structural characterization 
revealed that the conserved FRRG motif is part of two phosphoinositide binding pockets. 
PROPPINs are WD-40 repeat proteins that fold into a seven-bladed  
β-propeller (Fig. 1.3.1. 1-7) [9, 69, 143]. Each blade is comprised of four antiparallel β-
strands (Fig. 1.3.1. A-D from inside to outside). Each β-strand is connected to the next β-
strand by a loop region. While the β-strands are conserved within the PROPPINs the loop 
regions are not conserved and differ in length [73].  
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Figure 1.3.1.: Structure of the PROPPIN Kluyveromyces lactis Hsv2. A: Top view of the KlHsv2 
structure. PROPPINS form a seven-bladed β-propeller scaffold (numbers 1-7) each blade consists of 
four antiparallel β-strands (letters A-D). B: Side view of the same structure showing the FRRG lipid 
binding motif (R219 and R220). Cartoon representation, colored in rainbow colors from N-terminal 
(blue) to C-terminal (red). (PDB: code 4AV9). Figure from [69]. 
Yeast PROPPINs play a role in different autophagy subtypes. Atg18 is a core autophagy 
protein and is involved in all autophagy types. In the early stage of autophagy it binds to 
PI(3)P at the PAS and interacts with Atg2 and is involved in mediating Atg9 vesicle cycling 
[115]. Furthermore Atg18 is essential for retrograde trafficking from the vacuole by binding 
of PI(3,5)P2 and maintaining vacuole homeostasis as part of the lipid kinase Fab1 complex 
[29, 32]. Hsv2 was so far only described to be involved in piecemeal autophagy of the nucleus 
(PMN) [70]. Atg21 functions in the selective Cvt pathway [95] and mitophagy [131] and 
regulates pexophagy in Pichia pastoris [136]. Atg21 binds via PI(3)P to the phagophore and 
recruits the Atg12~Atg5/Atg16 complex [58]. It has been suggested that Atg21 binds Atg8 at 
the top of the propeller and by recruiting of Atg8 determines the site of Atg8 lipidation [58]. 
The Atg21 binding sites for Atg8 and Atg16 are distinct. Residues E102 and especially D101 
of the Atg16 coiled coil domain are required for Atg21 binding [58]. The group of Michael 
Thumm proposed a model (Fig. 1.3.2.) where Atg21 binds via PI(3)P to the phagophore and 
recruits the Atg12~Atg5/Atg16 complex and Atg8 to the membrane in a distinct position. In 




Figure 1.3.2.: Model for the coordination of Atg8 lipidation. Atg21 localizes to the phagophore by 
PI(3)P binding, where it interacts with the dimeric Atg12~Atg5/Atg16L complex and thereby 
coordinates Atg8 lipidation by Atg3. Figure from [72]. 
 
1.4. The functions of Rab33B and Atg16L1 in autophagy 
Rab GTPases play a crucial role in membrane trafficking processes and several Rab proteins 
are involved in autophagy (Fig. 1.4.1.) [24, 124]. Rab proteins (Ras-related in brain) are small 
GTPases and form the largest family within the Ras superfamily of monomeric G proteins 
[45]. Rab proteins are present in yeast and mammals.  
 
Figure 1.4.1.: Schematic overview of Rab GTPases involvement in autophagy. Rab proteins Rab1, 
Rab5, Rab9A, Rab23 and Rab32 regulate autophagosome formation. Rab8B, Rab11, Rab24 and 
Rab33 promote autophagosome maturation. Rab7 regulates both autophagosome maturation and 
fusion with the lysosome. 
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More than 25 Rab proteins have been structurally characterized so far [31]. They share a fold 
that consists of a six stranded β-sheet with five parallel β-strands and one antiparallel β-
strand, surrounded by five α-helices (Fig. 1.4.2.). The amino acids of the active site are highly 
conserved within the entire Ras superfamily [144]. Five loops that connect the α-helices with 
the β-strands contain the elements for binding of guanine nucleotide exchange factors (GEFs) 
and Mg
2+
 and GTP hydrolysis [129]. Rab proteins shuttle between an active state (GTP-
bound) and an inactive state (GDP-bound). Two regions: switch I (effector domain G-2) and 
switch II (loop4/α-helix 2 after the G-3 region) undergo major conformational changes 
between the two states (Fig. 1.4.2.) [88, 122]. A third region encompass the phosphate-
binding loop (P-loop or Walker A motif) that is highly conserved through all ATP- or GTP-
binding proteins with consensus sequence of GXXXXGKT/S (where X is any amino acid) 
[118]. Mutating the catalytic important glutamine in the switch II region, that positions water 
for nucleophilic attack on the GTP γ-phosphate to a leucine results in a GTPase deficient 
mutant that traps the GTPase in a GTP-bound constitutive active form, for example Q92L in 
Rab33B. The T47N mutation in the P-loop region of Rab33B provides a dominant negative 




Figure 1.4.2.: Rab33B structures in the active and inactive state. A: Cartoon representation of 
GppNHp-bound Rab33 colored in grey (PDB code: 1Z06) and GDP-bound Rab33 in dark grey (PDB 
code 2G77). Switch region I colored in pink, P-loop in yellow and Switch II region in blue for 
GppNHp-bound Rab33 and light blue for GDP-bound Rab33. Stick representation of GppNHp and 
residue Q92 in green and GDP and residues T47 in smokey blue. B: Amino acid sequence of murine 
Rab33B with switch I, switch II and P-loop region colored according to A. Secondary structure 
elements are shown based on the structure of GppNHp-bound Rab33 (PDB code: 1Z06). 
 
Rab proteins function in all steps of autophagy (Fig. 1.4.1., for a review see [4]). Rab proteins 
Rab1, Rab5, Rab9A, Rab23 and Rab32 contribute to autophagosome formation. Rab7, 
Rab8B, Rab11 and Rab24 are required for autophagosome maturation. Rab7 and its effector 
the Vsp34 complex, play a key role in the regulation of autophagosome maturation and fusion 
with the lysosome [128]. Rab9 is needed in non-canonical autophagy, an Atg5/Atg7-
independent mode of autophagosome formation [98]. The exact role of Rab8A and Rab25 in 
autophagy is still unclear. Rab26 has recently been discovered to mediate the turnover of 
recycled synaptic vesicles by interaction with the Atg16L1-Atg5 complex via the autophagy 
pathway [14]. In addition, an even stronger direct interaction has been found between Rab33 
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and Atg16L1 that is linked to autophagosome formation [54]. Rab33 is a subclass within the 
Rab family consisting of the two homologous members Rab33A and Rab33B [150]. Rab33A 
is brain-specific [149] and Rab33B is ubiquitously expressed and localized at the medial 
Golgi cisternae [150]. Rab33 plays a role in intra-Golgi and Golgi-ER trafficking [127, 140]. 
Both Rab33B and to a lesser extent Rab33A interact with Atg16L1 in a GTP-dependent 
manner [54]. Atg16L is the mammalian orthologue of yeast Atg16.  
 
Figure 1.4.3.: Sequence alignment of murine Atg16L isoforms. Similar residues are colored black 
and yellow boxed, identical residues are colored white and red boxed. Alignment was done with 
Clustal W, Figure was made using ESPript 3.0 [116]. 
  
The yeast Atg5~Atg12/Atg16 complex has a size of ~350 kDa [75] and the mammalian 
complex has an estimated molecular weight of ~800 kDa [90]. Rab33B-Atg16L1 binding may 
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be enhanced by Atg16-Atg5 complex formation [21]. Atg16 contains an N-terminal Atg5-
binding region, a coiled-coil domain and unlike yeast, Atg16L has an additional C-terminal 
WD40 domain that forms a β-propeller that has been suggested to mediate protein-protein 
interactions. Yeast Atg16 forms a parallel dimeric coiled-coil [37]. Similarly, Atg16L homo-
dimerizes through its coiled coil domain [107]. The two mammalian isoforms Atg16L1 and 
Atg16L2 share a conserved Atg5-binding region and the WD40 domain but differ in the 
coiled-coil domain (Fig. 1.4.3.) [53]. Atg16L1 binding to Rab33B was located to the coiled 
coil domain residues 80-265 and not to the Atg5-binding site or the WD 40 domain (Fig. 
1.4.4. A) [54]. Both isoforms share the biochemical properties of homo-dimerization and 
Atg5~Atg12/Atg16L complex formation. Similar to Atg16L1, the coiled coil domain of 
Atg16L2 only binds Rab33A/B among 58 tested Rab proteins [53]. However, compared to 
Atg16L1 the Rab33B binding affinity of Atg16L2 is approx.100 times lower (Fig. 1.4.4. B) 
[53]. Atg16L2 is not located to the phagophore and its physiological role remains unclear 
[53]. The Atg5~Atg12/Atg16L1 complex localizes mainly at the outward edges of the 
growing isolation and acts as a novel E3 ligase on Atg3 and determines the LC3 lipidation site 
[49].  
 
Figure 1.4.4. Rab33B binding of Atg16L. A: Schematic representation of Atg16L1 constructs tested 
for FLAG-Rab33B and FLAG-Atg5 co-immunoprecipitation. Figure A modified from [54]. B: 
Binding curve of Atg16L1 and Atg16L2 binding to increasing concentrations of Rab33B. Figure B 
from [53]. 
Rab33B-Atg16L1 interaction may facilitate the recruitment of vesicles originating from Golgi 
apparatus to the growing isolation membrane (Fig. 1.4.5.) [54]. As the same study did find an 
effect on autophagosome formation when Rab33B was silenced by siRNA, the role of 
Rab33B in autophagy needs to be further investigated. A recent study shows that the Hepatitis 
B virus exploits this interaction and Rab33B together with the Atg5~Atg12/Atg16L1 complex 
assist in naked capsid formation and secretion of the virus [30]. 
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Figure 1.4.5.: Suggested role of Rab33B in autophagy. Rab33B-Atg16L1 binding delivers Golgi 
derived vesicles to the growing isolation membrane. Figure modified from [40]. 
 
1.5. The role of the autophagy related SCOC-FEZ1 complex 
The short coiled coil protein (SCOC or SCOCO) was identified as a positive regulator of 
autophagy in a genome-wide siRNA screen [86]. SCOC, a Golgi-protein, is widely expressed 
in human tissue, most abundant in the brain, heart and skeletal muscles [141]. SCOC is an 
effector of Arl1 [141] and Arl3 [105] and colocalizes with Golgi-associated proteins TGN46 
and mAtg9 [86], suggesting a function in Golgi transport. Four different isoforms produced 
by alternative splicing with a shared conserved coiled-coil domain were identified 
(Fig. 1.5.1.).  
 
Figure 1.5.1.: Sequence alignment of SCOC isoforms. Similar residues are colored black and 
yellow boxed, identical residues are colored white and red boxed. Alignment was done with Clustal 
W, Figure was made using ESPript 3.0 [116]. 
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SCOC forms a complex with fasciculation and elongation protein zeta 1 (FEZ1) [11]. FEZ1 is 
an adaptor for kinesin mediated axonal transport of the SNARE Syntaxin-1 and its function is 
regulated by phosphorylation [20, 25]. Human SCOC-FEZ1 complex formation is conserved 
because their orthologues in Caenorhabditis elegans interact as well [132]. UNC-69, the 
orthologue of SCOC interacts with UNC-76, a kinesin heavy chain adaptor and the orthologue 
of mammalian FEZ1 [15]. The UNC-69/UNC-76 complex is linked to axonal outgrowth and 
is required for normal presynaptic organization [132]. Besides its role in neuronal transport 
processes, the SCOC-FEZ1 complex is involved in the induction and regulation of autophagy 
upon starvation (Fig. 1.5.2.). FEZ1 interacts with the mammalian ULK1 kinase complex [57]. 
SCOC binding to FEZ1 disassembles the FEZ1-ULK1 complex and released ULK1 induces 
autophagy. SCOC-FEZ1 also forms a trimeric complex with UVRAG (UV radiation 
resistance associated gene) [86]. Starvation induces dissociation of the complex and UVRAG 
activates the autophagy promoting Vps34 kinase (Beclin 1-PI3K) complex. In vivo studies 
showed that siRNA knockdown of SCOC decreases LC3 lipidation, while overexpression 
increases LC3 lipidation upon starvation. Whereas FEZ1 knockdown increases and 
overexpression decreases LC3 lipidation [86]. Besides FEZ1 its paralog FEZ2 was identified 
[15]. Both proteins share the conserved coiled coil region [39]. Using a yeast two-hybrid 
system FEZ2 was shown to interact with the same interaction partners as FEZ1, like the 
interaction with SCOC, and 19 additional proteins [3]. However, until now no direct 





Figure 1.5.2.: Model for the possible SCOC-FEZ1 complex involvement in autophagy. Upon 
starvation SCOC binds to FEZ1 and releases the positive autophagy regulator ULK1. Under starvation 
conditions ULK1 may also regulate the release of UVRAG from a complex with SCOC-FEZ1. 
UVRAG binds to the Vsp34 kinase complex (BECN1 and PtdIns3K) that is part of the autophagy core 
machinery. Figure from [57]. 
 
The crystal structure of the SCOC coiled coil domain was published by our group [11]. SCOC 
forms a left handed parallel coiled coil dimer (Fig. 1.5.3.). Human FEZ1 is a mainly natively 
unfolded protein with a conserved coiled coil domain in the C-terminal half of the protein 
(Fig. 1.5.4.) [76]. SCOC-FEZ1 complex formation is mediated through the coiled coil 
domains of SCOC and FEZ1. FEZ1 coiled coil residues L254 and L260 are important for 
SCOC-FEZ1 complex formation [86] as well as the corresponding residues in UNC-76 for 
UNC-69/UNC-76 complex formation (Fig. 1.5.4.) [132]. Additionally, the SCOC surface 
residue R117 is important for FEZ1 binding (Fig. 1.5.4.) [11]. The minimal regions required 




Figure 1.5.3.: Crystal structure of the SCOC coiled coil domain. Cartoon representation of the two 
dimers AB and CC’. Molecule A is colored red, B blue, C green and C’ grey. Adapted from [11] 
 
 
Figure 1.5.4.: Domaine structure of human SCOC and FEZ1. Residues below coiled coil domains 
were shown to be important for SCOC-FEZ1 complex formation. 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals and media supplements 
Chemicals and media supplements used in this study are listed in table 2.1.1. 
Table 2.1.1.: Chemicals used in this study 
Chemicals Manufacturer 
6x DNA loading dye Thermo Scientific 
Agar BD 
Amino acids Sigma-Aldrich 
Ammonium persulfate (APS) Sigma-Aldrich 
complete EDTA-free, Protease inhibitor tablet Roche 
Coomassie R Brilliant blue R250 Fluka 
D-Glucose monohydrate Merck 
D-Lactose Fluka 
DMEM Lonza 
DMEM/F-12 Sigma Aldrich 
FCS PAA laboratories 
GelGreen Biotium 
GeneRulerTM 1 kb DNA Ladder Thermo Scientific 
GeneRulerTM 100 bp DNA Ladder Thermo Scientific 
GTPγS Jena Bioscience 
HEPES ultrapure GERBU Biotech 
Imidazole Sigma-Aldrich 
IPTG, Dioxane free ForMedium 
Lipofectamine TM 2000 Thermo Scientific 
NaF Sigma-Aldrich 
Ni-NTA Sepharose GE Healthcare 
N-Z-AmineAS Sigma-Aldrich 
Odyssey® One-Color Protein Molecular Weight Marker LI-COR 
PageRulerTM Prestained Protein Ladder Thermo Scientific 
Rotiphorese®Gel 30 (37.5:1) Roth 
Selenomethionine Tokyo Chemical Industry 
SpectraTM Multicolor Low Ranged Protein Ladder Thermo Scientific 
Tris(2-carboxyethyl)phosphine Sigma-Aldrich 
Tris-(hydroxymethyl)aminomethane VWR chemicals 
Triton-X-100 Sigma-Aldrich 
Tryptone/Peptone from Casein Roth 
Ultra-low Range Molecular Weight Marker Sigma-Aldrich 
Western Lightning® Plus-ECL PerkinElmer 
Yeast extract Roth 
Yeast extract-B QBiogene 
β-mercaptoethanol  Sigma-Aldrich 
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2.1.2. Buffers, media and antibiotics 
Buffers, media and antibiotics used in this study are listed in tables 2.1.2. to 2.1.4. 
Table 2.1.2.: Buffers used in this study 
Buffer Content 
Anode buffer for Schägger 
gel electrophoresis 
0.2M Tris to pH 8.9 with HCl 
 
Cathode Buffer Schägger gel 
electrophoresis 
0.1 M Tris, 0.1 M Tricine 
 
CD buffer 20 mM sodium phosphate pH 7.5, 150 mM NaF 
Coomassie Blue staining 
solutions 
A: 500 mg CoomassieR, 650 ml H2O, 250 ml isopropanol, 100 ml 
acetic acid 
B: 50 mg CoomassieR, 800 ml H2O, 100 ml isopropanol, 100 ml 
acetic acid 
C: 20 mg CoomassieR, 900 ml H2O, 100 ml acetic acid 
D: 900 ml H2O, 100 ml acetic acid 
Gel buffer for Schägger gel 
electrophoresis 
3 M Tris pH 8.45, 0.3 % SDS 
 
PBS 150 mM NaCl, 20 mM NaH2PO4 pH 7.4 
PBST 150 mM NaCl, 20 mM NaH2PO4 pH 7.4, 0,05 % (w/v) Tween 20 
Sample buffer for Schägger 
gel electrophoresis 
15 ml 0.5 M Tris pH 6.8, 6 g SDS, 15 mg Serva Blue, 4.33 g 
Glycerol, H2O to 50 ml 
make 10 ml aliquots, add 200 μl β-Mercaptoethanol 
TAE 40 mM Tris, 20 mM Acetate, 1 mM EDTA 
Western blot transfer buffer 25 mM Tris, 192 mM glycine, 0.04 % (w/v) SDS, 20 % (v/v) 
methanol 
 
Table 2.1.3.: Media used in this study 




ZY medium up to 1 L  
 
20 ml 50x5052  
 
20 ml 50xM  
 
 
200 μl 1000x trace 
metals mixture 
 
2 ml 1 M MgSO4 
10 g/l (w/v) N-Z-Amine AS, 5 g/L (w/v) yeast extract-B  
250 g/l (w/v) glycerol, 25 g/L (w/v) glucose, 100 g/l 
(w/v) galactose monohydrate 
222.5 g/l (w/v) Na2HPO4 x 2 H2O, 170 g/l (w/v) KH2PO4, 
134 g/l (w/v), NH4Cl, 35.5 g/L (w/v) Na2SO4  
 
50 mM Fe, 20 mM Ca, 10 mM Mn, 10 mM Zn, 2mM Co, 
2 mM Cu, 2 mM Ni, 2 mM Mo, 2 mM Se, 2 mM B 
 
D10 medium  DMEM, 10 % fetal bovine serum (FBS), 4 mM 
glutamine and 100 units/ml penicillin/streptomycin 
Luria Bertani 
medium (LB) 
 10 g/l (w/v) tryptone, 5 g/l (w/v) yeast extract, 10 g/l 
(w/v) NaCl 
18 g/l (w/v) of agar was added for plates 
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6 g/l (w/v) Na2HPO4, 3 g/l (w/v) KH2PO4, 1 g/l (w/v) 
NH4Cl, 0.5 g/l (w/v) NaCl, 4g/l (w/v) glucose, 1 mM 
MgSO4, 4.2 mg/l FeIISO4, 0.5 mg/ml thiamine vitamin 
100 mg/l (w/v) L-Lysine, 100 mg/l (w/v) L-
Phenylalanine, 100 mg/l (w/v) L-Threonine, 50 mg/l 
(w/v) L-Isoleucine, 50 mg/l (w/v) L-Leucine, 50 mg/l 
(w/v) L-Valine 
 
50 mg/l (w/v) L-Selenomethionine 
SOC medium  2 % (w/v) tryptone, 0.5 % (w/v) yeast extract, 10 mM 
NaCl, 2.5 mM KCl 




 12 g/L (w/v) tryptone, 24 g/L (w/v) yeast extract, 0.4 % 
(w/v) glycerol, 17 mM KH2PO4, 72 mM K2HPO4 
 
Table 2.1.4.: Antibiotics used in this study 
Antibiotic Concentration Manufacturer 
Ampicillin 100 µg/ml (w/v) Sigma-Aldrich 
Kanamycin 30 µg/ml (w/v) Sigma-Aldrich 
 
Antibiotics were prepared as 1000x stock solutions in deionized water. All solutions were 
filter sterilized and stored at -20 °C. 
2.1.3. Enzymes  
Enzymes used in this study are listed in table 2.1.5. 
Table 2.1.5.: Enzymes used in this study 
Enzyme   Manufacturer 
Alkaline Phosphatase NEB 
DNaseI AppliChem 
Lysozyme  Roth 
Restriction enzymes  NEB 
Substilisin Hampton Research 
T4 DNA Ligase NEB 
Thrombin MP Biomedical 
 
Thrombin was prepared in 10 mM Tris pH 7.4, 1 mM EDTA and 50 % glycerol. 
2.1.4. Kits 
Kits used in this study and suppliers are listed in table 2.1.6. 
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Table 2.1.6.: Kits used in this study 
Name Manufacturer 
NucleoSpin Plasmid kit Macherey & Nagel 
NucleoSpin Extract II kit Macherey & Nagel 
NucleoBond Xtra Macherey & Nagel 
Phusion High-Fidelity PCR Kit NEB 
Gibson Assembly® NEB 
QuickChange Lightning Site-Directed Mutagenesis Kit Agilent Technologies  
pENTR™/D-TOPO® Cloning Kit Thermo Scientific 
Western Lightening Plus-ECL Perkin Elmer 
Additive ScreenTM Hampton Research 
Additive ScreenTM-HT Hampton Research 
Silver BulletsTM Hampton Research 
CryoProtXTM Molecular Dimensions 
JBS Magic Triangle Jena Bioscience 
 
2.1.5. Columns for chromatography 
Columns for chromatography used in this study are listed in table 2.1.7. All columns were 
used in combination with an Äkta Purifier FPLC system (RT) or with the Äkta Prime FPLC 
(4 °C). The manufacturer’s recommendations were followed for handling of the columns, 
including storage, cleaning and equilibration. 
Table 2.1.7.: Columns for chromatography used in this study 
Column Manufacturer 
5 ml HisTrap FF column GE Healthcare 
5 ml Strep-Trap column GE Healthcare 
HiLoad 16/60 Superdex 200 prep grade GE Healthcare 
HiLoad 16/60 Superdex 75 prep grade GE Healthcare 
Superdex 200 10/300 GL GE Healthcare 
 
2.1.6. Antibodies 
Antibodies used in this study are listed in table 2.1.8. 
Table 2.1.8.: Antibodies used in this study 
Primary Antibody Clonality Host Manufacturer 
Anti-Atg16L pAb (PM040) Polyclonal Rabbit MBL Life Science 
GFP antibody (132002) Polyclonal Rabbit Synaptic Systems 
Hexa-Histidine tag (DIA900) Monoclonal Mouse Dianova 
LC3B Antibody (NB100-2220) Polyclonal Rabbit Novus Biologicals 
Strep-tag II antibody (ABIN3197820) Monoclonal Mouse IBA GmbH 
Penta His HRP conjugate (34460) Monoclonal Mouse Qiagen GmbH 
V5 tag antibody - ChIP Grade (ab9116) Polyclonal Rabbit Abcam 
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V5-Probe (sv5-pk) Antibody (sc-58052) Monoclonal Mouse Santa Cruz Biotechnology 
WIPI2 antibody (ab131271) Monoclonal Rabbit Abcam 
Secondary Antibody Clonality Host Manufacturer 
mouse IgG IR dye 800 Polyclonal Goat LI-COR 
mouse IgG (HRP labeled) Polyclonal Goat BioRad Laboratories  
mouse IgG light chain specific (HRP 
labeled) 
Polyclonal Goat BioRad Laboratories  
mouse IgG Cy3 Polyclonal Goat Jackson ImmunoResearch 
rabbit IgG IR dye 800 Polyclonal Goat LI-COR 
rabbit IgG (HRP labeled) Polyclonal Goat BioRad Laboratories 
 
2.1.7. Bacterial strains 
Bacterial strains used in this study are listed in table 2.1.9. 
Table 2.1.9.: Bacterial strains used in this study 
Strain  Manufacturer Usage 
E. coli XL1-blue Agilent Technologies Standard cloning 
E. coli XL10-Gold ultracompetent  Agilent Technologies Mutagenesis cloning 
E. coli NEB® 5-alpha competent 
(High Efficiency) 
NEB® GIBSON Assembly cloning 
E. coli BL21-Gold(DE3) competent Agilent Technologies Expression  
E. coli Rosetta™ 2(DE3)pLysS Novagen Expression  
 
2.1.8. DNA constructs 
DNA constructs produced and/or used in this study are listed in tables 2.1.10. to 2.1.12. 
Table 2.1.10.: DNA constructs in single cloning site vectors for bacterial expression. 
Abbreviation Restr. Sites: Restriction sites  
Gene Vector Tag Restr. sites Resistance Source 
mAtg16L1 (153-210) pET-28a 6x His NdeI / XhoI Kanamycin J.Groffmann 
KlAtg21  pET-28a 6x His NdeI / XhoI Kanamycin K. Kühnel 
KlAtg21 R103E pET-28a 6x His NdeI / XhoI Kanamycin J. Metje 
AgAtg16 (40-124) pET-28a 6x His NdeI / XhoI Kanamycin K. Kühnel 
AgAtg16 (70-124) pET-28a 6x His NdeI / XhoI Kanamycin K. Kühnel 
AgAtg16 (70-124) D78R pET-28a 6x His NdeI / XhoI Kanamycin J. Metje 
SCOC (78-159) pET-28a Strep II NcoI / XhoI Kanamycin C. Behrens 
SCOC (78-159) L105M pET-28a Strep II NcoI / XhoI Kanamycin C. Behrens 
FEZ1 (227-290) pET-22b 6x His NdeI / XhoI Ampicillin C. Behrens 
FEZ1 (225-295) pET-22b 6x His NdeI / XhoI Ampicillin C. Behrens 
FEZ1 (225-295) L251M pET-22b 6x His NdeI / XhoI Ampicillin J. Metje 




Table 2.1.11.: DNA constructs in pET-Duet1 vector for bacterial expression. All constructs were 
cloned with restriction sites BamHI / NotI for MCSI and NdeI / XhoI for MCS II. 
MCS I Tag MCS II Tag Resistance Source 
mRab33B cDNA (1-229) 
BC065076 
His - - Ampicillin A. Scacioc 
mRab33B (30-202) Q92L 6x His - - Ampicillin K. Kühnel 
mRab33B (30-202) Q92L 6x His mAtg16L1 (125-234) - Ampicillin M.Hellwig 
mRab33B (30-202) Q92L 6x His mAtg16L1 (127-210) - Ampicillin K. Kühnel 
mRab33B (30-202) Q92L 6x His mAtg16L1 (153-200) - Ampicillin K. Kühnel 
mRab33B (30-202) Q92L 6x His mAtg16L1 (153-210) - Ampicillin K. Kühnel 
mRab33B (30-202) Q92L 6x His mAtg16L1 (163-210) - Ampicillin K. Kühnel 
mRab33B (30-202) 6x His mAtg16L1 (153-210) - Ampicillin J. Metje 
mRab33B (30-202) T47N 6x His mAtg16L1 (153-210) - Ampicillin J. Metje 
mRab33B (30-202) Q92L, 
F70E 
6x His mAtg16L1 (153-210) - Ampicillin J. Metje 
mRab33B (30-202) Q92L, 
F70A 
6x His mAtg16L1 (153-210) - Ampicillin J. Metje 
mRab33B (30-202) Q92L, 
W87A 
6x His mAtg16L1 (153-210) - Ampicillin J. Metje 
mRab33B (30-202) Q92L 6x His mAtg16L1 (153-210) 
K198A 
- Ampicillin J. Metje 
mRab33B (30-202) Q92L 6x His mAtg16L1 (153-210) 
A202W 
- Ampicillin J. Metje 
mRab33B (30-202) Q92L 6x His mAtg16L1 (153-210) 
N206K 
- Ampicillin J. Metje 
 
Table 2.1.12.: DNA constructs in Gateway vectors for mammalian expression 
Gene Vector Tag Resistance Source 
mRab33B cDNA (1-229) BC065076 pET-Duet1 His Ampicillin A. Scacioc 
mRab33B (1-229) WT pENTR™/D-TOPO® - Ampicillin J. Metje 
mRab33B (1-229) WT pcDNA3.1/nV5 V5 Ampicillin J. Metje 
mRab33B (1-229) Q92L pcDNA3.1/nV5 V5 Ampicillin J. Metje 
mRab33B (1-229) T47N pcDNA3.1/nV5 V5 Ampicillin J. Metje 
mRab33B (1-229) Q92L F70A pcDNA3.1/nV5 V5 Ampicillin J. Metje 
mRab33B (1-229) Q92L F70E pcDNA3.1/nV5 V5 Ampicillin J. Metje 
mRab33B (1-229) Q92L W87A pcDNA3.1/nV5 V5 Ampicillin J. Metje 
mAtg16L1 (1-632) WT pcDNA6.1/C-EmGFP EmGFP Ampicillin A. Scacioc 
mAtg16L1 (1-632) K198A pcDNA6.1/C-EmGFP EmGFP Ampicillin J. Metje 
mAtg16L1 (1-632) A202W pcDNA6.1/C-EmGFP EmGFP Ampicillin J. Metje 
mAtg16L1 (1-632) N206K pcDNA6.1/C-EmGFP EmGFP Ampicillin J. Metje 
 
2.1.9. Oligonucleotides 
Oligonucleotides used in this study are listed in table 2.1.13. Oligonucleotides were ordered 
from Eurofins Genomics GmbH 
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Table 2.1.13.: Oligonucleotides strains used in this study 
Name Usage Sequence 5`to 3` 
mRab33Bfl_TOPO_fw Gateway Cloning caccacttcggagatggagtcgtc 
mRab33Bfl_TOPO_rev Gateway Cloning tcagcaccagcaagtcacc 
mRab33B_L92Q_fw Mutagenesis ctgaaccgctcctgccctgccgtgt 
mRab33B_L92Q_rev Mutagenesis acacggcagggcaggagcggttcag 
mRab33B_Q92L_fw Mutagenesis ctgaaccgctccagccctgccgtgt 
mRab33B_Q92L_rev Mutagenesis acacggcagggctggagcggttcag 
mRab33B_T47N_fw Mutagenesis tcgaacgtgggcaagaactgcctgacttaccgc 
mRab33B_T47N_rev Mutagenesis gcggtaagtcaggcagttcttgcccacgttcga 
mRab33B_F70E_fw Mutagenesis cacggctcgctctcgttcgtccaccccgatcgt 
mRab33B_F70E_rev Mutagenesis acgatcggggtggacgaacgagagcgagccgtg 
mRab33B_F70A_fw Mutagenesis cggctcgctctcgggcgtccaccccgatc 
mRab33B_F70A_rev Mutagenesis gatcggggtggacgcccgagagcgagccg 
mRab33B_W87A_fw Mutagenesis cagccctgccgtgtccgccaactggatcttgat 
mRab33B_W87A_rev Mutagenesis atcaagatccagttggcggacacggcagggctg 
mAtg16L1_153_GA_fw Gibson Assembly 
Cloning 
gccgcgcggcagccatatgcaggacctcgaggtagcc 
mAtg16L1_210_GA_rev Gibson Assembly 
Cloning 
cagtggtggtggtggtggtgctcgagctcattctctgcattgagg 
mAtg16 L1_K198E_fw Mutagenesis ttggcttcttgggcctcctcagccatccatc 
mAtg16 L1_K198E_rev Mutagenesis gatggatggctgaggaggcccaagaagccaa 
mAtg16 L1_A202W_fw Mutagenesis ctctgcattgaggcgattccattcttgggccttctcagc 
mAtg16 L1_A202W_re Mutagenesis gctgagaaggcccaagaatggaatcgcctcaatgcagag 
mAtg16 L1_N206K_fw Mutagenesis accctcattctctgctttgaggcgattggcttc  
mAtg16 L1_N206K_fw Mutagenesis gaagccaatcgcctcaaagcagagaatgagggt 
AgAtg16_I81M_fw Mutagenesis cgatgttcagggacatgatctcgtcattcagtttctct 
AgAtg16_I81M_rev Mutagenesis agagaaactgaatgacgagatcatgtccctgaacatcg 
AgAtg16_D78R_fw Mutagenesis gggaaatgatctcgcgattcagtttctctgcgtctttactcat 
AgAtg16_D78R_rev Mutagenesis atgagtaaagacgcagagaaactgaatcgcgagatcatttccc 
KlAtg21_R103E_fw Mutagenesis tttcagcaccacacagatgattttttcgttcataatcacgtccatgatctc 
KlAtg21_R103E_re Mutagenesis gagatcatggacgtgattatgaacgaaaaaatcatctgtgtggtgctgaaa 
Fez1_L251M_fwd Mutagenesis tggtgcagcagatggcccgccgg 
Fez1_L251M_rev Mutagenesis ccggcgggccatctgctgcacca 
Fez1_L273M_fwd Mutagenesis aagaactcctttatcacggtgatgattgaggttcagaacaagcag 
Fez1_L273M_rev Mutagenesis ctgcttgttctgaacctcaatcatcaccgtgataaaggagttctt 
M13_fwd Sequencing cgccagggttttcccagtcacgac 
M13_rev Sequencing tcacacaggaaacagctatgac 
T7_promoter Sequencing taatacgactcactataggg 
T7_terminator Sequencing ctagttattgctcagcggtg 
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2.2. Methods 
2.2.1. Molecular Cloning 
2.2.1.1. Standard Cloning 
For standard cloning inserts were duplicated by PCR, cut from an agarose gel and purified. 
Inserts and vectors were restriction digested and ligated with T7 polymerase prior to 
transformation.  
PCR 
For PCR Phusion High-Fidelity PCR kit and primers flanking the insert were used. All 
reaction components (see Table 2.2.1.) were assembled on ice, mixed and collected to the 
bottom of the tube by a quick spin prior to PCR. 






PCRs were done in a Biometra T-Personal Combi Thermocycler and comprised the following 
steps (Table 2.2.2.). For standard procedure, steps 2–4 were repeated for 35 cycles. 
Table 2.2.2.: Standard PCR reaction steps 
Step Temperature Time 
1. Initial denaturation 95 °C 30 sec 
2. Denaturation 95 °C 10 sec 
3. Annealing According to NEB Tm calculator 20 sec 
4. Elongation 72 °C 15 sec per kb 
5. Final extension 72 °C 5 min 
6. Hold 12 °C  
 
DNA agarose gel electrophoresis and gel extraction purification 
PCR products and DNA plasmids were visualized by 0.7-1 % agarose gel electrophoresis. 
Samples for electrophoresis were mixed with 6 x loading dye. TAE buffer was used as 
Component Volume 
H2O To 50 µl 
5 x Phusion HF Buffer 10 µl 
10 mM dNTPS 1 µl 
10 µM forward primer 2,5 µl 
10 µM reverse primer 2,5  µl 
Template DNA Variable (50-100 ng) 
Phusion DNA Polymerase 0.5 µl 
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running buffer. Agarose gels were stained with GelGreen™ Nucleic Acid Gel Stain and sizes 
of DNA products were estimated with DNA ladders. Gel extraction was done with the 
NucleoSpin Extract II kit according to the manufacturer’s instructions. 
Restriction digestion  
Restriction digest reactions were carried out for one hour at 37 °C with restriction enzymes in 
40 μl reactions and heat inactivated when needed according to the manufacturer’s instructions 
(see Table 2.2.3.). 
Table 2.2.3.: Restriction digestion reaction assembly 
Component Volume 
H2O Up to 40 µl 
PCR product or vector Variable (up to 1 µg) 
10x CutSmart® Buffer 4 µl 
Enzyme 1 1 µl 
Enzyme 2 (if double digestion) 1 µl 
BSA (if required) 0,4 µl 
 
Ligation 
Ligations were performed with 50-100 ng of restriction digested vector combined with 
restriction digested insert in a ratio of 1:3. A final reaction volume of 10 μl was set up with 
1 μl of T4 DNA Ligase and 1 μl of 10 x buffer. Ligation was conducted at room temperature 
for 60 min. 
2.2.1.2. Gibson Assembly® Cloning and Gateway® Cloning 
Gibson Assembly® Cloning was performed according to the manufacturer’s instructions 
using the Gibson Assembly Kit from NEB.  
2.2.1.3. Gateway® Cloning  
Gibson Assembly® Cloning was performed according to the manufacturer’s instructions 
using the pENTR™/D-TOPO® Cloning Kit and the Gateway™ LR Clonase™ II Enzyme 
Mix from Thermo Scientific. 
2.2.1.4. Site-Directed Mutagenesis 
Mutations were introduced by the QuikChange Lightning Multi Site-Directed Mutagenesis 
Kit according to the manufacturer’s instructions. 
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2.2.2. Transformation 
2.2.2.1. Heat shock transformation  
50 µl chemically competent E. coli (XL1-blue or BL21 (DE3)) cells were thawed on ice. 
Incubated on ice with 1.42 mM β-Mercaptoethanol for 10 min and 5-10 ng DNA for 30 min. 
Cells were heat shocked at 42 °C for 45 sec, cooled for 1 min on ice, then 800 µl prewarmed 
SOC medium was added. Bacteria recovered for 60 min at 37 °C while shacking, before they 
were plated on LB agar plates containing appropriate antibiotics. 
2.2.2.2. Cotransformation 
20 µl chemically competent E. coli Rosetta 2 (DE3) cells were thawed on ice. Incubated on 
ice with 5 ng of each plasmid for 5 min. Cells were heat shocked at 42 °C for 30 sec, cooled 
for 2 min on ice, then 100 µl prewarmed SOC medium was added. Bacteria recovered for 
60 min at 37 °C while shacking, before they were plated on LB agar plates containing 
appropriate antibiotics. 
2.2.2.3. Transformation for GIBSON Assembly and mutagenesis 
Transformation for GIBSON Assembly and mutagenesis was performed with competent cells 
provided with the kits according to the manufacturer’s instructions. 45 µl ultracompetent 
E. coli (XL10-gold) cells provided with the QuikChange Lightning Multi Site-Directed 
Mutagenesis Kit or 45 µl NEB® 5-alpha Competent E. coli provided with the Gibson 
Assembly® Cloning Kit were thawed on ice. Incubated on ice with 2 µl of provided β-
Mercaptoethanol for 2 min and 2 µl of reaction for 30 min. Cells were heat shocked at 42 °C 
for 30 sec, cooled for 2 min on ice, then 500 µl prewarmed SOC medium was added. Bacteria 
recovered for 60 min at 37 °C while shaking, before they were plated on LB agar plates 
containing appropriate antibiotics. 
2.2.3. Sequencing of plasmids 
To verify the correct sequence plasmids were sent for single tube sequencing to Eurofins 
Genomics or SEQLAB Sequence Laboratories Göttingen GmbH using appropriate primers. 
2.2.4. Gel electrophoresis 
Schägger gel electrophoresis  
Almost all proteins used in this study are smaller than 40 kDa. Therefore, Schägger gel 
electrophoresis which has an optimal resolution for proteins smaller than 30 kDa was used 
instead of normal SDS gel electrophoresis [120]. Schägger gels are two-phase polyacrylamide 
gels made of a stacking (25 % stacking gel buffer, 61.4 % water, 12.5 % acrylamide, 
29 
1 % APS, TEMED) and a resolving gel (25 % resolving gel buffer, 34 % water, 40 % 
acrylamide, 1 % APS, TEMED). Before electrophoresis, protein samples were mixed with 
Sample buffer for Schägger gel electrophoresis and incubated for 5 min at 95 °C. Anode and 
cathode buffer for Schägger gel electrophoresis were used. Electrophoretic separation was 
done at 70 V until the sample buffer dye reached the stacking gel. Voltage was switched to 
140 V until the sample buffer dye reached to very bottom of the gel. 
Gels were stained with Coomassie staining and destaining solutions heated in microwave for 
1 min according to table 2.2.4. and stored in H2O. 
Table 2.2.4.: Coomassie staining protocol 
Step Solution Incubation time 
1 Coomassie staining solution A 20 min 
2 Coomassie staining solution B 1 min 
3 Coomassie staining solution C 1 min 
4 Coomassie destaining solution D 30 min 
 
SDS PAGE 
To separate lager proteins precasted NuPAGE™ 4-12 % Bis-Tris Protein Gels with NuPAGE 
MOPS SDS Running Buffer (Thermo Scientific) were used according to the manufacturer's 
instructions. 
Native gel electrophoresis 
To analyze cross-linking results native gel electrophoresis was done using precasted RunBlue 
Native Mini Protein Gels 10 % (Expedeon) according to the manufacturer's instructions. 
2.2.5. Western blot 
For Western Blotting analysis resolved gels were blotted to nitrocellulose membranes by 
semidry transfer. Gels, membranes and Whatman filter papers were moistened in western blot 
transfer buffer before assembly. Blotting was performed for 60 min at a constant voltage of 
25 V. After blotting membranes were washed with PBS for 10 min. Next membranes were 
blocked with 3 % BSA or 1 % skimmed milk in PBS for 1 hour at RT. Membranes were 
washed with two times PBST and once PBS for 10 min each and incubated with primary 
antibody in 3 % BSA or 1 % skimmed milk in PBS for 1 hour at RT. Washing was repeated 
and membranes were incubated with secondary antibody in 3 % BSA or 1 % skimmed milk in 
PBS for 1 hour at RT. After another round of washing Western Lightening Plus-ECL solution 
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was added and the chemiluminiscence signal was detected with Imageready LAS-1000 CCD 
camera (Fujifilm). 
2.2.6. Protein expression and purification 
Specific expression purification protocols were developed for each complex individually. 
2.2.6.1. Selenomethionine labeling of proteins 
Proteins were labeled with selenomethionine by expression in M9 minimal medium. M9 
medium was mixed by recipe in table 2.1.3., supplemented with appropriate antibiotics and 
prewarmed at 37 °C. For inoculation 15 ml of an LB overnight culture was spun down at 
3 000 rpm at 4 °C to remove LB medium and resuspended in minimal medium. The culture 
was grown at 37 °C until OD600 of 0.3. At this time the temperature was switched to 25 °C 
and the amino acid mixture and solid selenomethionine was added. 15 min later expression 
was induced with 1 mM IPTG and cultures were grown over night at 25 °C. Cells were 
harvested by centrifugation with a JS-4.2 rotor in a Beckman J6-MI centrifuge at 4 000 rpm, 
4 °C for 20 min. Pellets were resuspended in appropriate buffer and stored frozen at -20 °C. 
Selenomethionine labeled proteins were purified as described for native proteins but all 
buffers were supplemented with 1 mM β-mercaptoethanol 
2.2.6.2. Rab33B-Atg16L1 E. coli expression and purification 
pETDuet-1 mRab33B or mRab33B-mAtg16L1 constructs or pET28a mAtg16L1 constructs 
were transformed in E. coli BL21 competent cells. Single cell colonies were picked and 
transferred to LB medium with appropriate antibiotics and grown over night at 37 °C. For 
pETDuet-1 Rab33B or Rab33B-mAtg16L1 constructs auto induction medium (see table 
2.1.3.) with ampicillin was induced with 1:100 overnight culture and grown at 37 °C until 
OD600 0.3. Then temperature was switched to 25 °C and cells let grown over night. For 
pET28a mAtg16L1 constructs TB medium was induced with 1:100 ml overnight culture and 
grown at 37 °C. At OD600 0.3 cultures were induced with 1 mM IPTG for 4 h of expression. 
All cells were harvested by centrifugation with a JS-4.2 rotor in a Beckman J6-MI centrifuge 
at 4,000 rpm, 4 °C for 20 min. Pellets were resuspended in 50 mM HEPES pH 7.5, 250 mM 
NaCl, 30 mM imidazole, 5 mM MgCl2, 1 mM TCEP and stored frozen at -20 °C. 
For large scale purification cell pellets were thawed and supplemented with a PI tablet, 
DNaseI, lysozyme and 1 mM MgCl2. Cell suspension was stirred for 15 min at room 
temperature. Cell suspension was homogenized with a homogenizer and lysed with three 
repetitions in a microfluidizer M-110L (Microfluidics Corporation) according to 
manufacturer’s instructions. Cell debris was pelleted at 16 000 rpm and 4 °C by 45 min 
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centrifugation with a SS-34 rotor in a Du Pont Sorvall centrifuge. The supernatant was filtered 
with 0.45 mm filter and filled in a 150 ml Superloop (GE Healthcare) and applied to a 5 ml 
HisTrap column (GE Healthcare) connected to the Äkta Prime FPLC system at 4 °C using 
50 mM HEPES pH 7.5, 250 mM NaCl, 30 mM imidazole, 5 mM MgCl2, 1 mM TCEP. 
Supernatant was loaded onto the column at a flow rate of 1 mL/min, then the column was 
washed with 13 CV buffer at 1.5 ml/min. His tagged protein complexes were eluted with a 
gradient at 1 ml/min with over 12 CV to 100 % 50 mM HEPES pH 7.5, 250 mM NaCl, 
400 mM imidazole, 5 mM MgCl2, 1 mM TCEP. Elution fractions containing the protein were 
collected and concentrated to 5 ml in a 10 000 MWCO concentrator. Concentrated elution 
fractions were filled in a 5 ml loop (GE Healthcare) and applied to a Superdex 200 16/60 
HiLoad column connected to the Äkta Prime FPLC system at 4 °C. Size exclusion 
chromatography was run at a flow rate of 1 ml/min with 30 mM HEPES pH 7.5, 150 mM 
NaCl, 2 mM MgCl2, and 1 mM TCEP. Fractions containing the desired proteins were 
collected and concentrated in a 3 000 MWCO concentrator to 30-45 mg/ml. Purified proteins 
were aliquoted, flash cooled with liquid nitrogen and stored at -80 °C until usage. 
2.2.6.3. Rab33B-Atg16L1 HEK 293T cell expression and transfection 
The mammalian cell lines HEK 293T cells and COS-7 cells were cultured in DMEM 
(Dulbecco's Modified Eagle Medium, Lonza) supplemented with 10 % Fetal bovine serum 
(FBS), 2 mM L-glutamine and 100 units/ml penicillin/streptomycin. ARPE-19 cells were 
grown in DMEM/F-12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12, Sigma 
Aldrich) with the same supplements. Cells were maintained in 10-cm petri dishes for 2-3 days 
at 37 °C and 90 % humidity in 5 % CO2 . When cells reached the confluence of 80 %-90 % 
they were passaged and diluted. Mammalian cells were transiently transfected using 
LipofectaminTM 2000 (Invitrogen) according to the manufacturer's instructions. 50 µl of 
Lipofectamine was diluted in 1.5 ml DMEM without supplement for 5 min at RT and then 
combined with 12 µg of DNA diluted in 1.5 ml of DMEM without supplement. This 
transfection mix was then incubated for an additional 20 min at room temperature. 
Subsequently the mixture was added onto the cells and then incubated for 24 h in the cell 
incubator. After 24 h, transfected cells were lysed using 600 µl of lysis buffer containing 
50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 1 % Triton-X-100) for 15 min at 4 °C. 
The lysate was collected using scraper and transferred into 2 ml Eppendorf tube and 
centrifuged at 10.000 g for 10 min. The supernatant was used for co-immunoprecipitation. 
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To examine the expression levels transfected cells were lysed and the supernatant was 
submitted to SDS PAGE electrophoresis and western blotting. Membranes were probed with 
rabbit anti-GFP (1:10 000) or mouse anti-V5 (1:1 000) primary antibody and goat anti rabbit 
or goat anti mouse IR dye 800 (1:15 000) secondary antibody for Odyssey fluorescence 
detection (LI-COR Odyssey CLx Infrared Imaging System). Rab33B-Atg16L1 HEK 293T 
cell expression and transfection were done by Dr. Beyenech Binnotti (Department for 
Neurobiology). 
2.2.6.4. KlAtg21-AgAtg16 expression and purification 
pET28a KlAtg21 or pET28a AgAtg16 constructs were transformed in E. coli BL21 competent 
cells. Single cell colonies were picked and transferred to LB medium with appropriate 
antibiotics and grown over night at 37 °C. Auto induction medium (see table 2.1.3.) with 
appropriate medium was induced with 1:100 overnight culture and grown at 37 °C until 
OD600 0.3. Then temperature was switched to 25 °C and cells let grown over night. Cells were 
harvested by centrifugation with a JS-4.2 rotor in a Beckman J6-MI centrifuge at 4 000 rpm, 
4 °C for 20 min. Pellets were resuspended in 50 mM HEPES pH 7.5, 250 mM NaCl, 30 mM 
imidazole, 1 mM TCEP and stored frozen at -20 °C. 
For purification cell pellets were thawed and supplemented with a PI tablet, DNaseI, 
lysozyme and 1 mM MgCl2. For complex purification cell pellets of KlAtg21 and AgAtg16 
were mixed in a 2:1 ratio. Cell suspension was stirred for 15 min at room temperature. Cell 
suspension was homogenized with a homogenizer and lysed with three repetitions in a 
microfluidizer M-110L (Microfluidics Corporation) according to manufacturer’s instructions. 
Cell debris was pelleted at 16 000 rpm and 4 °C by 45 min centrifugation with a SS-34 rotor 
in a Du Pont Sorvall centrifuge. The supernatant was filtered with 0.45 mm filter and filled in 
a 150 ml Superloop (GE Healthcare) and applied to a 5 ml HisTrap column (GE Healthcare) 
connected to the Äkta Prime FPLC system at 4 °C using 50 mM HEPES pH 7.5, 250 mM 
NaCl, 30 mM imidazole, 1 mM TCEP. Supernatant was loaded onto the column at a flow rate 
of 1 ml/min, then the column was washed with 12 CV buffer at 1.5 ml/min. His tagged 
protein complexes were eluted with a gradient at 1 ml/min with 10 CV of using 50 mM 
HEPES pH 7.5, 250 mM NaCl, 400 mM imidazole, 1 mM TCEP. Elution fractions containing 
the desired protein were collected and concentrated to 5ml in a 10 000 MWCO concentrator. 
Concentrated elution fractions were filled in a 5 ml loop (GE Healthcare) and applied to a 
Superdex 200 16/60 HiLoad column connected to the Äkta Prime FPLC system at 4 °C. Size 
exclusion chromatography was run at a flow rate of 1 ml/min with 30 mM HEPES pH 7.5, 
150 mM NaCl, 1 mM TCEP. Fractions containing the desired proteins were collected and 
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concentrated in a 3 000 MWCO concentrator to 10-30 mg/ml. Purified proteins were 
aliquoted, flash cooled with liquid nitrogen and stored at -80 °C until usage. 
2.2.6.5. SCOC-FEZ1 co-expression and co-purification 
pET28a SCOC and pET22b FEZ1 were co-transformed in E. coli Rosetta™ 2(DE3)pLysS 
competent cells. Single cell colonies were picked and transferred to LB medium with 
appropriate antibiotics and grown over night at 37 °C. LB expression cultures were induced 
with 1:100 ml overnight culture and grown at 37 °C. At OD600 0.3 cultures were induced with 
1 mM IPTG. After 3 to 4 h of expression cells were harvested by centrifugation with a JS-4.2 
rotor in a Beckman J6-MI centrifuge at 4 000 rpm, 4 °C for 20 min. Pellets were resuspended 
in 50 mM HEPES pH 7.5, 250 mM NaCl and stored frozen at -20 °C. 
For co-purification of Strep-tagged SCOC with His-tagged FEZ1, cell pellets were thawed 
and supplemented with a PI tablet, DNaseI, lysozyme and 1 mM MgCl2. Cell suspension was 
stirred for 15 min at room temperature. Cell suspension was homogenized with a 
homogenizer and lysed with three repetitions in a microfluidizer M-110L (Microfluidics 
Corporation) according to the manufacturer’s instructions. Cell debris was pelleted at 
16 000 rpm and 4 °C by 45 min centrifugation with a SS-34 rotor in a Du Pont Sorvall 
centrifuge. The supernatant was filtered with 0.45 mm filter and imidazole concentration 
adjusted to 30 mM. The supernatant was incubated with 0.5 ml Ni-NTA Sepharose per 10 ml 
supernatant for 1 h at 4 °C under rotation. Ni-NTA Sepharose was washed three times with 5 
times sepharose volume of 50 mM HEPES pH 7.5, 250 mM NaCl, 30 mM imidazole. His 
tagged protein was eluted with 3 times sepharose volume of 50 mM HEPES pH 7.5, 250 mM 
NaCl, 400 mM imidazole. Elution was immediately filled in a 50 ml Superloop (GE 
Healthcare) and applied to a 5 ml StrepTrap column (GE Healthcare) connected to the Äkta 
Prime FPLC system at 4 °C using 50 mM HEPES pH 7.5, 250 mM NaCl. Supernatant was 
loaded onto the column at a flow rate of 1 ml/min, then the column was washed with 7 CV 
buffer at 1.5 ml/min. Strep tagged protein complexes were eluted at 1 ml/min with 6 CV of 
buffer supplemented with 2.5 mM desthiobiotin. Elution fractions containing the protein were 
collected and concentrated to 5 ml in a 3 000 MWCO concentrator. Concentrated elution 
fractions were filled in a 5 ml loop (GE Healthcare) and applied to a Superdex 75 16/60 
HiLoad column connected to the Äkta Prime FPLC system at 4 °C. Size exclusion 
chromatography was run at a flow rate of 1 ml/min with 30 mM HEPES pH 7.5, 150 mM 
NaCl. Fractions containing the protein complex were collected and concentrated in a 3 000 
MWCO concentrator to 10-15 mg/ml. Purified proteins were aliquoted, flash cooled with 
liquid nitrogen and stored at -80 °C until usage. 
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2.2.7. His-tag cleavage by thrombin  
Cloning of SCOC in the pET28a and FEZ1 in the pET22b vector included a thrombin 
cleavage site between protein sequence and the tag [56]. After gel filtration both tags were 
cleaved for one purification batch. Pooled fractions were dialyzed at 4 °C overnight in a 
Spectra/Pore dialysis membrane (Spectrumlabs.com) with gel filtration buffer containing 
10 U of thrombin (MP Biomedicals) per mg of protein. After dialysis, thrombin was inhibited 
by adding 4 mM Pefabloc SC (Roche), a serine protease inhibitor. 
2.2.8. Measurement of protein concentration 
For SCOC-FEZ1 complex and Rab33B-mAtg16L1 complex protein concentrations were 
usually determined using the Bradford assay [17]. Protein solution was diluted to appropriate 
concentrations with H2O to a final volume of 200 µl. 800 µl  Bradford working solution 
(500 ml contained: 425 ml H2O, 15 ml 95 % ethanol, 30 ml 88 % phosphoric acid) was added 
and the absorbance was measured at 595 nm on a Genesys 6 spectrophotometer (Thermo 
Spectronic). The concentration was determined from a BSA standard curve using 1 to 10 µg 
BSA. 
In the case of KlAtg21 and AgAtg16 the protein concentration was spectroscopically 
measured using an ND-1000 spectrophotometer (NanoDrop Technologies Inc.) which uses a 
path length of 0.2 mm and measured the absorbance of aromatic amino acid residues at 
280 nm wavelength using the molecular weight and extinction coefficient of the protein 
2.2.9. Analytic gel filtration 
To analyze complex formation size exclusion chromatography with a Superdex™ 200 10/300 
GL column (analytic gel filtration) connected to a Äkta Purifier FPLC system at RT was 
performed. The column was equilibrated with gel filtration buffer used for protein 
purification. Proteins were incubated alone or together with the potential complex partner 
prior analysis for 30 min at 4 °C in a total volume of 400 µl. Proteins were injected in a 
500 µl loop and loaded on the column at a flowrate of 0.5 ml/min. The column was run with 
1.25 CV gel filtration buffer at a flowrate of 0.5 ml/min and 0.5 ml fractions were collected. 
Chromatograms of single proteins and proteins mixtures were compared and fractions were 
analyzed by Schägger gel electrophoresis. 
2.2.10. Limited proteolysis 
Limited proteolysis was performed using the Proti-Ace I + II (Hampton Research) Kits 
following the manufacturer’s instructions. Proteins were mixed with 1:1000 proteases 
(Proteinase-K, Clostripain, Pepsin, Thermolysin, Bromelain, Actinase E, α-Chymotrypsin, 
35 
Trypsin, Elastase, Papain, Substilisin or Endoproteinase Glu-C). The degradation process was 
followed by taking samples at different time points. Reactions were stopped by adding 
Schägger gel sample buffer and heating to 95 °C for 5 min. Limited proteolysis was analyzed 
by Schägger gel electrophoresis. 
2.2.11. Circular dichroism spectroscopy  
Circular dichroism spectra were recorded with a Chirascan Circular Dichroism spectrometer 
(AppliedPhotophysics) using Hellma quartz cuvettes with a path length of 0.1 cm. Samples 
were buffer exchanged to CD buffer before measurements. Far UV CD spectra of 1 mg/ml 
protein were recorded from 180 to 260 nm with a step size of 0.5 nm, a bandwidth of 0.5 nm 
and 3 sec time per point at 20 °C. Thermal melts were determined from 20 to 90 °C in 0.2 °C 
steps with a heating rate of 0.5 °C/min at 222 nm for α-helix and 215 nm for β-sheet 
containing proteins. Data were analyzed with the manufacturer’s ProView Software.  
2.2.12. ProteoPlex assay  
ProteoPlex [23] is a stabilizing assay method for macromolecular complexes based on the 
thermal shift assay (ThermoFluor) [34]. To find optimal stabilizing conditions proteins are 
heated in 96 different buffer conditions by a high-throughput system. Unfolding events are 
monitored with SYPRO Orange dye. ProteoPlex measurements were conducted by Dr. David 
Haselbach in the lab of Prof. Holger Stark (Department for Structural Dynamics, MPI for 
Biophysical Chemistry, Göttingen). 
2.2.13. SEC-MALLS  
The stoichiometry of complexes can be analyzed by size exclusion chromatography coupled 
to a Multi Angle Laser Light Scatterer (SEC-MALLS). For SEC-MALLS measurements 
purified proteins were loaded on a Superdex 10/300 GL column connected to an Äkta Purifier 
FPLC system. The instrument was equilibrated with gel filtration buffer used during 
purification. The size exclusion column is connected to a miniDAWN Treos multi-angle light 
scattering detector and an Optilab T-rEX refractive index concentration detector (Wyatt 
Technologies). Results were evaluated with the program ASTRA® 6 by Wyatt Technologies. 
SEC-MALLS measurements were conducted by Johannes Arens and Dr. Achim Dickmanns 




2.2.14. Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) measurements were accompanied using the MicroCal 
iTC200 (GE Healthcare Life Sciences) set up. Prior to ITC measurements proteins were 
dialyzed overnight in the same buffer, spun down at 10 000 rpm for 10 min at 4 °C and 
concentrations were adjusted. 25 total injections of 2 μl were performed with 120 s delay. 
Temperature was set to 20 °C, stirring speed to 300 rpm and reference power to 7 μcal/s. ITC 
measurements were conducted by Dr. Angel Perez Lara (Department for Neurobiology, MPI 
for Biophysical Chemistry, Göttingen) with an instrument in the group of Prof. Marina 
Rodnina (Department for Physical Biochemistry, MPI for Biophysical Chemistry, Göttingen).  
2.2.15. Cross-linking and analysis by mass spectrometry 
Protein complexes were cross-linked with bis(sulfosuccinimidyl) suberate (BS3). 200 µl 
purified protein complexes (5 mg/ml) were incubated with 0, 0.25, 0.5, 1, 2 and 4 mM BS3 
for 30 min at RT under constant rotation. The reaction was stopped by the addition of 1 µL of 
1 M Tris-HCl, pH 8. Samples were run on a NativePAGE™ Bis-Tris Gel (Thermo Scientific). 
Gels were sent to the Bioanalytical Mass Spectrometry Facility. Bands of interest were cut 
from the gels and redissolved in 50 mM NH4HCO3, 4 M urea, pH 8.0. Proteins were digested 
with trypsin of 1/20 complex amount (w/w) overnight. Subsequently, the peptide fragments 
were desalted and fractionated by a Superdex Peptide 10/300 GL size exclusion column (GE 
Healthcare) using a solvent system containing 30% acetonitrile (ACN), 0.1%  trifluoroacetic 
acid (TFA) (v/v). The fragments were collected in 50 µL fractions, lyophilized, reconstituted 
in 20-30 µL of 5 % ACN, 0.1 % formic acid (FA), and subjected to Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) analysis.   
Six microliters of the cross-linking sample was injected onto a nano-liquid chromatography 
system (UltiMateTM 3000 RSLCnano system) including a 3 cm × 150 µm inner diameter 
C18 trapping column in-line with a 30 cm × 75 µm inner diameter  C18 analytical column 
(both in-house packed  with 1.9- µm C18 material, Dr. Maisch GmbH). Peptides were loaded 
on the trapping column, desalted for 3 min at a flow rate of 10 µL/min in 95% of mobile 
phase A (0.1 % FA in H2O, (v/v)) and 5 % of mobile phase B (80 % ACN and 0.05 % FA in 
H2O, (v/v)). After desalting, peptides were eluted and separated on the analytical column 
using a 43-min linear gradient of 15-46 % mobile phase B at a flow rate of 300 nl/min. 
Separated peptides were analyzed on-line on an Orbitrap Fusion mass spectrometer (Thermo 
Scientific). A top-20 method was employed were the 20 most intense precursor ions with 
charge states 3-8 in the survey scan (380-1580 m/z scan range) were isolated in the 
quadrupole mass filter (isolation window 1.6 m/z) and fragmented in the higher energy 
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collisional dissociation (HCD) cell with normalized energy 30. A dynamic exclusion of 20 s 
was used. Both the survey scan (MS1) and the product ion scan (MS2) were performed in the 
Orbitrap at 120,000 and 30,000 resolution, respectively. Spray voltage was set at 2.3 kV and 
60% of S-lens RF level was used. Automatic gain control (AGC) targets were set at 5×105 
(MS1) and 5×104 (MS2). The raw data were converted to mgf files by Proteome Discoverer 
2.0.0.802 software (Thermo Scientific). The mgf files were searched against a FASTA 
database containing the sequences protein complex components by pLink 1.22 software using 
a target-decoy strategy. Database search parameters included mass accuracies of MS1<10 
ppm and MS2<20 ppm, carbamidomethylation on cysteine as a fixed modification, oxidation 
on methionine as variable modification. Number of residues of each peptide on a cross-link 
pair was set between 4 and 40. A maximal of two trypsin missed-cleavage sites was allowed. 
The results were obtained with 1 % false discovery rate. Visualization of cross-links was 
made with xiNET [26]. To overcome false positive cross-links the threshold for the maximal 
score was set to 5.1. 
This work was done in collaboration with Dr. Momchil Ninov (Department of Neurobiology, 
MPI for Biophysical Chemistry, Göttingen) and Dr. Chung-Tien Lee with technical support of 
Monika Raabe in the group of Prof. Henning Urlaub (Bioanalytical Mass Spectrometry, MPI 
for Biophysical Chemistry, Göttingen).  
2.2.16. Ni-Sepharose pulldown 
To analyze complex formation of Rab33B-Atg16L1 by Ni-Sepharose pulldown the complex 
was expressed in E. coli cells and solubilized as described before (2.2.5.2.). In the meantime 
Ni-NTA Sepharose beads (GE Healthcare) were washed with H2O and buffer A (50 mM 
HEPES pH 7.5, 250 mM NaCl, 30 mM imidazole, 5 mM MgCl2, 1 mM TCEP). 10 ml 
supernatant from E. coli expression was incubated with 1 ml Ni-Sepharose beads for one hour 
under constant rotation at 4 °C. Beads were centrifuged at 3 000 rpm for 5 min at 4 °C and the 
flow trough was removed. Beads were washed three times with 5 ml buffer A. Finally 
proteins were eluted two times with 1.5 ml buffer B (50 mM HEPES pH 7.5, 250 mM NaCl, 
400 mM imidazole, 5 mM MgCl2, 1 mM TCEP). Samples were taken from cell pellet (P), 
supernatant (S), flow through (ft), wash steps 1-3 (W1-3) and elution (E1-2) mixed with 3x 
Schägger gel buffer and boiled for 5 min at 95 °C. Purification steps were analyzed by 
Schägger gel electrophoresis and stained with Coomassie. Elution fractions were pooled and 
analyzed by Schägger gel electrophoresis followed by western blot. Membranes were blocked 
in 3 % BSA and probed with Penta His HRP conjugate antibody (1:1500) to detect His-tagged 
Rab33B or blocked in 5 % skimmed milk and probed with rabbit anti-Atg16L primary 
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antibody (1:2000) and goat anti-rabbit IgG (HRP labeled) (1:1000) secondary antibody to 
detect Atg16L1. 
2.2.17. Mammalian cell line culture 
The mammalian cell lines HEK 293T cells and COS-7 cells were cultured in DMEM 
(Dulbecco's Modified Eagle Medium, Lonza) supplemented with 10 % Fetal bovine serum 
(FBS), 2 mM L-glutamine and 100 units/ml penicillin/streptomycin. ARPE-19 cells were 
grown in DMEM/F-12 (Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12, Sigma 
Aldrich) with the same supplements. Cells were maintained in 10-cm petri dishes for 2-3 days 
at 37 °C and 90 % humidity in 5 % CO2. When cells reached the confluence of 80 %-90 % 
they were passaged and diluted. 
2.2.18. Co-immunoprecipitation 
The precleared supernatant from transiently transfected HEK 293T cells (2.2.6.3.) was used 
for co-immunoprecipitation. 30 µl of supernatant was used as input fraction. The rest of the 
sample was incubated with specific antibody (anti V5 or anti GFP) for 2 h under constant 
rotation at 4 °C. In the meantime protein A dynabeads (Thermo Scientific) were washed once 
with lysis buffer and then kept in the lysis buffer under constant rotation. The supernatant was 
transferred in the prewashed beads and incubated for an additional hour under constant 
rotation at 4 °C. The beads were washed three times with 1 ml lysis buffer, transferred to a 
new tube and washed again two times. Finally proteins were eluted from the beads using 4x 
NuPAGE LDS Sample Buffer (Thermo Scientific) in presence of 10 % of beta-mercapto-
ethanol. Samples were boiled for 10 min at 70 °C. 5 µl of the input and 10 µl of the elution 
(IP) sample were separated by SDS-Page gel electrophoresis. Proteins were transferred on a 
PDVF membrane by western blotting. Membranes were cut, blocked with 10 % skimmed 
milk in PBST and probed with specific primary antibodies rabbit GFP (1:10 000), mouse V5 
(1:1000) or rabbit LC3B (1:1000). For GFP-pulldowns a mouse anti rabbit light chain specific 
HRP labeled secondary antibody (1:2000) was used to detect the GFP antibody. For all other 
probes and V5 pull downs either goat anti mouse HRP labeled (1:2000) or goat anti rabbit 
HRP labeled (1:2000) secondary antibody was used. Co-immunoprecipitation was done with 
Dr. Beyenech Binnotti (Department for Neurobiology). 
2.2.19. Fluorescence microscopy 
Transiently transfected COS-7 or ARPE-19 cells were washed once with PBS to remove 
serum. The cells were fixed using 4 % paraformaldehyde for 15 min at RT. The fixative was 
removed and the cells were washed 3 times 5 min each with PBS. Afterward the cells were 
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blocked with 10 % normal goat serum and 0.2 % Triton-X-100 in PBS for 1 h. The coverslips 
were inverted on top of a drop of 45-50 μl of mouse anti-V5 primary antibody (1:2000) 
diluted in blocking buffer. The incubation was performed in a dark and humidified chamber 
for 1 to 2 hours at RT or o/n at 4 °C. The coverslips were washed 3 times for 5 min each with 
PBS and incubated again following the same procedure with goat anti mouse Cy3 (1:600) 
secondary antibody for 1 hour at RT. Additional, cells were incubated with DAPI (Thermo 
Scientific). Finally the cells were washed as previously described and mounted on a 
microscope slides using a mounting media (Fluoro-Gel, Electron Microscopy Sciences, or 
VECTASHIELD HardSet Mounting Medium with DAPI, Vector Laboratory). The mounting 
media was let dry o/n at 4 °C. 
Images were acquired using an epifluorescence microscope (Axioverter 200M, ZEISS). 
ImageJ was used to convert and merge pictures. Fluorescence microscopy was done with Dr. 
Beyenech Binnotti (Department for Neurobiology). 
2.2.20. MAP1LC3 Lipidation assay 
Transiently transfected HEK 293T cells (2.2.6.3.) were used for the MAP1LC3 Lipidation 
assay. 24 hours after transfection cells were treated for 4 hours with 20 mM NH4Cl to block 
the autophagic flux. For control cells were maintained in normal nutrient rich medium. After 
4 hours cells were washed once with ice cold PBS, and then lysed for 10 min with lysis buffer 
(50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM MgCl2, 2% TX-100 and complete protease 
inhibitor (Roche)).  Lysates were collected and precleared by centrifugation at 10 000 rpm for 
10 min at 4°C. Protein concentrations were measured with Pierce BCA reagent (Thermo 
Scientific). 10 µg total protein was separated by 12 % Schägger gel electrophoresis. Proteins 
were transferred on a PDVF membrane by western blotting. Membranes were cut, blocked 
with 10 % skimmed milk in PBST and probed with specific primary antibodies rabbit GFP 
(1:5000), mouse V5 (1:1000), mouse Tubulin (1:2000) or rabbit LC3B (1:1000). Either goat 
anti mouse IgG IR dye 800 (1:15 000) or goat anti rabbit IgG IR dye 800 (1:15 000) 
secondary antibody was used for Odyssey fluorescence detection (LI-COR Odyssey CLx 
Infrared Imaging System). The MAP1LC3 Lipidation assay was done by Dr. Beyenech 
Binnotti (Department for Neurobiology). 
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2.2.21. Crystallization and structure determination 
2.2.21.1. Crystallization screen setup 
96-well sitting drop plates 
Initial crystallization screening experiments were set up in 96-well sitting drop plates (MRC 2 
Well Crystallization Plate (Swissci) UVP, Hampton research or MRC 96 well Crystallization 
Plate™ UV, Molecular Dimensions) with commercial available crystallization screens. 
Commercial crystallization screens were purchased from Hampton Research (SaltRx), Qiagen 
(AmSO4, Anions, Cations, ClassicLite, Classics I+II, ComPAS, JCSG
+
, PACT, PEG I+II, 
pHclear I+II, Protein Complex) or Emerald Biosystems (Wiz1+2, Wiz3+4 screens).Two 
drops of different protein concentrations were pipetted for each well. The Cartesian robot was 
used for setting 60 nl drops of crystallization solution and adding 60 nl protein solution. The 
Gryphon robot was used for setting100 nl drops of crystallization solution and adding 1000 nl 
protein solution. Plates were covered with a transparent sealing tape and stored at 20 or 4 °C 
in an automated Formulatrix crystallization imager which imaged the plate on a pre-set 
schedule at the Crystallization Facility of the MPI for Biophysical Chemistry, Göttingen. 
Images were checked with the Rockmaker main Application software (Formulatrix). 
24-well Linbro hanging drop plates 
When crystallization hits from initial screening were found optimization was done using 24-
well Linbro hanging drop plates. The original crystallization solution was self-made, 1 ml for 
every reservoir. For optimization pH, precipitant or salt concentration was differed along row 
and axis in a grid screen.  1-3 µl protein and 1-3 µl reservoir solution (mother liquor) were 
pipetted without mixing a siliconized cover slip with up to 4 drops on one slide. The cover 
slip was flipped upside down onto the greased well and sealed air tight. All chemicals used in 
the optimization screens were from Sigma, Fluka, or Sigma-Aldrich and were analytical grade 
with ≥99.0 % purity. 
Additive and Silver Bullets screen  
Additive screen (HR2-428, Hampton Research) or Silver Bullets (HR2-096) was used for 
optimization. For 96-well screens 70 µl of crystallization solution was filled in every well and 
mixed with 7 µl of additive or Silver Bullets. For 24-well plate screens 1.5 µl protein and 
1.5 µl reservoir solution were pipetted on a cover slip followed by 0.3 µl additive before 
placing on the pregreased Linbro plate.  
 
41 
Streak seeding  
Streak seeding was performed in 24-well plates to provide nucleation sites. Therefore an 
existing crystal was crushed with an acupuncture needle. A fresh needle was then streaked 
first through the crashed crystal and then through the pre-pipetted crystallization drop. 
Heavy metal soaking 
Heavy metal soaking was done using the JBS Magic Triangle Phasing Kit (Jena Bioscience). 
According to the manufacturer’s instructions 5-Amino-2,4,6-triiodoiso-phthalic acid (I3C) 
was incorporated by soaking and co-crystallization. For co-crystallization different 
concentrations of IC3 (5, 10 and 15 mM) were added to the crystallization solution prior to 
crystallization. For soaking native crystals were transferred for 10 – 60 second to a fresh drop 
of crystallization solution supplemented with 100, 250 or 500 mM IC3. 
2.2.21.2. Flash cooling of crystals 
Prior to flash cooling crystals were cryoprotected to prevent ice formation around the crystal. 
For this 20-30 % of the water content of the respective mother liquor was substituted by 
cryoprotectants like ethylene glycol, xylitol, sucrose or PEG 400 or mixtures (Cryoprotectant 
screen). Crystals were fished with mounted round LithopLoops (Molecular Dimensions) and 
put in fresh mother liquor, then transferred to a mixture of 1:1 mother liquor and cryosolution 
and finally in pure cryosolution. Crystals were fished out of the cryosolution and quickly flash 
cooled in liquid nitrogen. 
2.2.21.3. X-ray diffraction data collection and processing 
X-ray diffraction data were collected at 100 K on a PILATUS M6 detector at beamline 
X10SA or on an EIGER 16M detector at beamline X06SA at the Swiss Light Source (Paul 
Scherrer Institute, Villigen, Switzerland). Diffraction data were processed and scaled with the 
XDS software package consisting of three programs XDS, XDSSCALE and XDSCONV [59]. 
XDS is the main program that performs eight subroutines in order to produce a list of 
corrected, integrated intensities. XYCORR, INIT and COLSPOT determine and correct the 
collected spots versus the background.  Determined spots are used for indexing by IDXREF to 
determine orientation, dimensions, and symmetry of the crystal lattice and integrated by 
INTEGRATE. The final CORRECT step applies correction factors to the measured 
intensities, refines the unit cell parameters and reports statistics of data completeness and 
quality. XSCALE is used for scaling and merging of data. XDSCONV converts to specific 
output formats needed for structure determination programs. Processed data were converted to 
.mtz file format. 
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2.2.21.4. Xtriage analysis 
Processed datasets were subjected for analysis by the program Xtriage from the Phenix 
program suite [1]. Xtriage determines the quality of datasets by analyzing the Matthews 
coefficient [84] to estimate the number of molecules in the asymmetric unit of a crystal and the 
intensity of anomalous signal if present. Furthermore it automatically identifies ice rings and 
twinning. 
2.2.21.5. Molecular replacement 
For structure determination an electron density map must be calculated by Fourier synthesis. 
Both structure factors and phases are needed for the calculation. Structure factor amplitudes 
are directly derived by the measured intensities of the reflection spots. Phases cannot be 
obtained directly from experimental data. Phases can be directly derived by de novo phasing 
suitable for high resolution structures or by indirect methods like experimental phasing or 
molecular replacement. Experimental phasing can be done by single or multiple anomalous 
diffraction (SAD/ MAD), if an anomalous scatterer is present. Therefore proteins can be 
labeled with selenomethionine or crystals can be soaked with heavy metals. SAD or MAD 
data are obtained at wavelengths where anomalous diffraction occurs. Differences between 
Friedel pairs are measured and used to calculate the position of the anomalous atoms by 
Patterson methods. To obtain an electron density map by SAD or MAD the anomalous signal 
must obtain certain intensity.  
Structure determination by molecular replacement (MR) requires a search model. Structures 
with a sequence identity of at least 30 % are potentially suitable for molecular replacement. 
To minimize the variance of a search model flexible domains or side chains can be truncated. 
For MR Patterson functions are calculated from both the measured structure factors and the 
search model. Because the anomalous signal strength was low for AgAtg16 and homologues 
structures were available for KlAtg21, AgAtg16, mRab33B and mAtg16L1 molecular 
replacement was used to obtain phases in this study. For AgAtg16 Phaser-MR from the CCP4 
program suite and for KlAtg21-AgAtg16 and Rab33B-Atg16L1 Phaser-MR from the Phenix 
program suite was used [85]. Molecular replacement requires knowledge about the expected 
number of molecules per asymmetric unit. Multiple search models can be used at the same 
time or Phaser-MR can search for an additional model in a fixed partial solution. Phaser-MR 
performs an anisotropy correction to overcome anisotropy, a translational non-
crystallographic symmetry (tNCS) correction, a rotation function to determine the orientation 
and a translational function to calculate the absolute position of the model in the unit cell. 
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Fitting of the model is evaluated by a packing analysis that calculates the rotation function Z-
score (TFZ) based on the number of clashes between atoms. Phaser-MR performs a simple 
rigid-body refinement and calculates phases for the electron density map from the positions of 
the molecules in the asymmetric unit. Finally the log-likelihood gain (LLG) is calculated to 
evaluate the success of MR. The final TFZ should be above 8, and LLG should be positive 
and as high as possible for successful molecular replacement [85]. Electron density maps and 
models were examined with Coot [33]. 
2.2.21.6. Refinement  
Phenix.refine from the phenix program suite was used for KlAtg21-AgAtg16 and Rab33B-
Atg16L1 structure refinement [2]. For the AgAtg16 structure a first round of refinement by 
Refmac5 [94] from the CCP4 program suite was followed by phenix.refine. Initial cycles of 
rigid-body refinement were done for all structures followed by restrained refinement with 
alternating manual model building with Coot for the Rab33B-Atg16L1 and AgAtg16 
structures. Rotamer and Ramachandran outliers of side chains and other geometric constraints 
were detected by phenix.refine output and manually corrected in Coot. Disagreements or 
increments with the model were identified by observation of the omit electron density map 
and correct by manual rebuilding in Coot. Coot ligand finder was used to place ligands in the 
Rab33B-Atg16L1 structure [33]. Refinement and manual corrections were repeated until the 
R-Factor and geometrical values were satisfying for the resolution limit of the structures.  
2.2.21.7. Generation of figures 





3.1. Structural characterization of the murine Rab33B-Atg16L1 complex 
 
Rab33B was the first GTPase described to directly interact with an autophagy protein. The 
precise role of the Rab33B-Atg16L1 complex in autophagy needs further investigation. My 
goal was to determine the crystal structure of the Rab33B-Atg16L1 complex in order to 
understand how these proteins interact on a molecular level. This might help to understand 
how Golgi-derived vesicles are recruited to the phagophore. Itoh et al. [54] showed that that 
the Atg16L1 construct comprising residues 141-265 binds Rab33B and suggest that Atg16L1 
is an effector of Rab33B. First steps for the characterization of the mRab33B 
Q92L~mAtg16L1 complex were done before in our lab by Dr. Amanda Schalk [121], 
Michaela Hellwig and Dr. Karin Kühnel (personal communication). Dr. Amanda Schalk 
showed that full-length Rab33BQ92L is not soluble but the truncated Rab33B(30-202)Q92L 
is highly soluble and stable so this construct was used for expression [121]. Because Atg16L1 
Rab33B interaction is GTP-dependent [54], Rab33B Q92L, a GTPase deficient mutant was 
used for in vitro experiments. A. Schalk purified the Rab33B(30-202)Q92L/ 
Atg5~Atg16L1(1-265) complex. However, attempts to crystallize this complex did not give 
crystals. With the goal to determine the structure of the Rab33B-Atg16L1 complex an optimal 
minimal construct of Atg16L1, which still binds Rab33B was tried to be identified. Fragments 
of the Atg16L1 coiled coil domain with variable length were tested for complex formation. 
Previous work by Dr. Amanda Schalk [121], Michaela Hellwig and Dr. Karin Kühnel showed 
that the minimal Atg16L1 binding region compromises residues 153-210, but the Atg16L1 





Figure 3.1.1.: Various truncated mAtg16L1 ccd constructs tested for Rab33B (30-202)Q92L 
binding. Yes or No indicates if complex formation was observed. Construct mAtg16L1(163-210) was 
cloned but not yet analyzed. (Modified figure from Dr. Karin Kühnel) 
 
3.1.1 Recombinant expression and purification of Rab33B, Atg16L1 and Rab33B-
Atg16L1 complexes  
 
For expression and purification of the complex the already available construct of 
mRab33Q92L(30-202) as an N-terminal His-tagged protein in the MCSI and untagged 
mAtg16L1 variants in the MCSII of the pETDuet-1 vector were used. For large scale 
purification the complex was purified by HisTrap affinity chromatography followed by a 
polishing step with size exclusion chromatography using a HiLoad 16/60Superdex 200 
column (Fig. 3.1.2.). Schägger gel analysis shows that the mRab33B-mAtg16L1 complex 
eluted first from the gel filtration column followed by mRab33B alone (Fig. 3.1.2. D). Due to 
the small size of Atg16L1 and the large amounts of protein only one peak is visible in the 
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chromatogram for Rab33B and Rab33B-Atg16L1 complex. Only fractions containing the 
complex were used for further experiments. The mRab33B(30-202)Q92L-mAtg16L1(153-
210) (Fig. 3.1.2.) and mRab33B(30-202)Q92L-mAtg16L1 (163-210) complex (Fig. 3.1.3.) 
were both purified, identifying mAtg16L1(163-210) as the minimal Atg16L1 coiled coil 
domain required for Rab33B binding. Both complexes were used for crystallization studies. 
The mRab33B-mAtg16L1(153-210) complex was more stable than the mRab33B-
mAtg16L1(163-210) and was used for all further studies. 
 
Figure 3.1.2.: Purification of the Rab33B(30-202)Q92L-Atg16L1(153-210) complex. 
Chromatograms of HisTrap affinity A: and size exclusion chromatography B: using a HiLoad 16/60 
Superdex 200 column. C, D: Schägger gels of purification steps A and B, respectively. M: Marker, 
Start: Input for SEC. 
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Figure 3.1.3.: Purification of the Rab33B(30-202)Q92L-Atg16L1(163-210) complex. 
Chromatograms of HisTrap affinity A: and size exclusion chromatography B: using a HiLoad 16/60 
Superdex 200 column. C, D: Schägger gels of purification steps A and B, respectively. M: Marker, 
Start: Input for SEC. 
 
For expression and purification of the individual proteins mRab33Q92L(30-202) was used as 
an N-terminal His-tagged protein in the MCSI of the pETDuet-1 vector. mAtg16L1(153-210) 
was cloned as an N-terminal His-tagged protein in the pET28b vector using full length 
mAtg16L1 as a template. Distinct proteins were purified as described before for the complex. 
3.1.2. Biochemical and biophysical characterization of Rab33B-Atg16L1 complex 
formation 
3.1.2.1. ProteoPlex assay for the Rab33B-Atg16L1 complex 
With the aim to optimize buffer conditions and thereby enhance the chance for crystallizing 
the purified Rab33B(30-202)Q92L-mAtg16L1(153-210) complex was sent for an 
fluorescence-based thermal-shift assay (ProteoPlex) using the automated set-up in the 
laboratory of Prof. Dr. Holger Stark [22]. With this method one can analyze the influence of 
diverse factors like pH, ionic strength and additives on the stability of a protein. 96 buffers 
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were tested in an automated assay by Dr. David Haselbach (Department for Structural 
Dynamics). Results show that HEPES pH 7.4 buffer is among the most stabilizing buffers 
(Fig. 3.1.4.). An additive screen revealed that magnesium improved protein stability as well 
(data not shown), but this was not surprising because GTPases contain magnesium as a co-
factor. Buffer conditions for subsequent purification were not changed, because a buffer 
consisting of 30 mM HEPES pH 7.5, 150 mM NaCl and 2 mM MgCl2 buffer was already 
being used. 
 
Figure 3.1.4.: ProteoPlex unfolding curves of the Rab33B(30-202)Q92L-Atg16L1(153-210) 
complex 
 
3.1.2.2. Limited proteolysis of the Rab33B-Atg16L1 complex 
Flexible domains and residues can hamper crystallization and limited proteolysis can be used 
to crop flexible elements and enhance crystallization. The mRab33(30-202)Q92L-
mAtg16L1(153-210) complex was digested with twelve different proteases from the Proti-
Ace Kit 1&2 (Hampton Research) and DNaseI. DNaseI was chosen because purifications 
with too much DNaseI resulted in a partially degraded complex, possible due to a protease 
contamination in the DNaseI batch (Fig. 3.1.5.).  
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Figure 3.1.5.: Comparison of Rab33B(30-202)Q92L-Atg16L1(153-210) complex purification with 
different DNaseI concentrations. Schägger gel electrophoresis of size exclusion chromatography 
using a HiLoad 16/60 Superdex 200 column. A: Cells were lysed with a small amount of DNaseI (~1 
small spatula tip/ pellet from 1.5L expression culture). B: Cells were lysed with a small amount of 
DNaseI (~2 spatula tip/ pellet from 1.5L expression culture).  M: Marker, Start: Input for SEC. 
The purified complex (4 mg/ml) was mixed with 1:500 protease or DNaseI and incubated at 
37 °C. As a control the complex was incubated without protease. Samples were taken at 
different time points during protease incubation. Analysis by Schägger gels (Fig. 3.1.6.) 
showed that most proteases (α-C, TR, P-K, CL, EL, PA and SU) did not degrade the complex. 
Using Thrombin, PE, BR however resulted in the complete degradation of Atg16L1, whereas 
Rab33B remained mostly intact. Only for A-E and DNaseI after 60 min and EG-C after 30 
min a promising partial digestion pattern was observed. For in-situ crystallization the 
Rab33(30-202)Q92L-Atg16L1(153-210) (45 mg/ml) complex was mixed with either 1:500   
A-E, EG-C or DNaseI and incubated for 15 min at 37 °C prior to setting drops for 
crystallization. Digested proteins were screened in commercial crystallization screens but no 
crystallization hit was found. 
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Figure 3.1.6.: Limited proteolysis of the Rab33B-Atg16L1 complex. Purified Rab33B(30-
202)Q92L-mAtg16L1(153-210) complex (4 mg/ml) was incubated with 1:500 proteases or DNaseI. 
Proteases used are TH: Thermolysin, A-E: Actinase, α-C: α-Chymotrypsin, TR: Trypsin, P-K: 
Proteinase-K, CL: Clostripain, PE: Pepsin,  BR: Bromelain, EL: Elastase, PA: Papain, SU: Substilisin, 
EG-C: Endoproteinase Glu-C. M: Marker. Numbers indicate incubation time at 37 °C. 
 
3.1.2.3. Isothermal titration calorimetry measurements of the Rab33B-Atg16L1 complex 
In order to characterize the thermodynamic parameters of the interaction between 
mRab33B(30-202)Q92L and mAtg16L1(153-210) isothermal titration calorimetry (ITC) 
measurements were conducted together with Dr. Ángel Pérez-Lara (Department of 
Neurobiology). 200 µM mRab33B(30-202)Q92L was titrated in the cell containing 15 µM 
mAtg16L1(153-210) (Fig. 3.1.7.). Binding is exothermic and proteins interact with high 
affinity with a Kd of 0.21 ±0.02 µM. The stoichiometric analysis showed that two 
mRab33B(30-202)Q92L molecules bind to one Atg16L1 (153-210) dimer.  
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Figure 3.1.7.: Isothermal titration calorimetry titration curves of mRab33B(30-202)Q92L and 
mAtg16L1(153-210). 200 µM mRab33B(30-202)Q92L was titrated into 15 µM mAtg16L1 (153-210). 
Data was fitted with a One Set of Sites fitting model. Top panel shows raw ITC data after subtraction 
of dilution enthalpies. Bottom panel shows integrated heat. 
 
3.1.3. Structure determination of the Rab33B(30-202)Q92L-Atg16L1(153-210) complex   
3.1.3.1. Crystallization of the Rab33B-Atg16L1 complex 
With the aim of determining the x-ray crystallographic structure of a mRab33B(30-
202)Q92L-mAtg16L1 complex commercial 96-well crystallization screens were set up using 
a pipetting robot and monitored with a Formulatrix imager. Both, mRab33B(30-202)Q92L-
mAtg16L1(153-210) and mRab33B(30-202)Q92L-mAtg16L1(163-210) were used for 
crystallization trials but the complex with the shorter Atg16L1 construct did not gave crystals. 
For mRab33B(30-202)Q92L-mAtg16L1(153-210) needle crystals were found initially after 5-
10 days in a Qiagen Protein Complex 96-well screen. 60 nl of 42 mg/ml protein and 60 nl 
crystallization screen solution were pipetted in sitting drops and stored at 20 °C (Fig.3.1.8.). 
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Figure 3.1.8.: Initial needle like crystals from Rab33B(30-202)Q92L-Atg16L1(153-210). Letters 
A-D correspond to the crystallization conditions stated in table 3.1.1. 
Table 3.1.1.: Initial crystallization conditions for Rab33B(30-202)Q92L-Atg16L1(153-210) from 
96-well plate screening 
Condition Buffer composition 
A 0.1 M MES monohydrate pH 6.5, 0.2 M sodium chloride, 10 % (w/v) PEG 4 000 
B 0.1 M MES monohydrate pH 6, 0.2 M sodium chloride, 20 % (w/v) PEG MME 
C 0.1 M Sodium cacodylate pH 6, 0.2 M sodium chloride, 8 % (w/v) PEG 8 000 
D 0.1 M sodium acetate anhydrous pH 5, 15 % (v/v) (+/-)-2-methyl-2,4-pentanediol,  
2 % (w/v) PEG 4 000 
 
Since crystals could not be reproduced on 24-well hanging drop plates optimization was also 
performed in 96-well sitting drops using the Gryphon 8-channel robot. Crystallization 
solutions from initial crystals were reproduced according to the manufacturer’s protocol. 
70 µl of crystallization solution was pipetted in the reservoir of a 96-well plate and mixed 
with 7 µl of Hampton Additive Screen. An improvement was found using Qiagen 
ProteinComplex crystallization solution 91 with the addition of 0.1 M  




Figure 3.1.9.: Rab33B(30-202)Q92L-Atg16L1(153-210) crystals using the Hampton Additive 
Screen. Precipitant contained 0.1 M MES monohydrate pH 6.5, 0.2 M sodium chloride, 10 % (w/v) 
PEG 4000, 10 mM TCEP hydrochloride. Arrows indicate crystals. The scale bar corresponds to 50 
µm.  
 
Because TCEP hydrochloride improved crystallization, 1 mM TCEP hydrochloride was then 
added to all protein purification buffers. mRab33B(30-202)Q92L-mAtg16L1(153-210) was 
purified with buffers containing TCEP and used for further optimization attempts. Several 
additives were found that also enhanced crystallization. Crystals from these conditions were 
reproduced in 24-well plates using 1.5 µl protein + 1.5 µl precipitant hanging drops. pH and 
precipitant concentrations for crystallization solution A (see Table 3.1.1.) were varied using a 
grid screen but only reproduction of the original commercial solution gave crystals. All 
further crystallization attempts were done with this solution. Crystals were equilibrated in the 
precipitant supplemented with 25 % ethylene glycol and then fished out with a loop and flash 
cooled in liquid nitrogen. Crystals diffracted to ~9 Å at beamline PXII at the Swiss Light 
Source (Switzerland). 
To ensure that mRab33B is bound to GTP and not GDP and to further optimize crystallization 
GTPγS (Guanosine 5'-O-[γ-thio]triphosphate) an artificial non-hydrolyzable form of GTP was 
added to the lysed bacteria during protein purification and to the pooled size exclusion 
chromatography fractions. Unfrozen protein (48 mg/ml) was used for crystallization with 
optimized conditions in 24-well plates. Crystals were equilibrated in crystallization solution 
supplemented with 25 % ethylene glycol and flash cooled in liquid nitrogen. Diffraction was 




3.1.3.2. X-ray data collection and processing for the Rab33B(30-202)Q92L-Atg16L1(153-
210) complex 
Data for structure determination of the mRab33B(30-202)Q92L-mAtg16L1(153-210) were 
collected from a crystal grown in a 24-well hanging drop plate. Protein buffer consisted of 
20 mM HEPES pH 7.5, 150 mM NaCl, 2 mM MgCl2, 1 mM TCEP hydrochloride, 10 µM 
GTPγS. The crystal grew in a drop composed of 3 µl protein (48 mg/ml), 2 µl crystallization 
solution A and 0.5 µl 1 M spermine. Crystal was soaked in crystallization solution 
supplemented with 25 % ethylene glycol (EG) before flash cooling in liquid nitrogen. Data 
were collected at 100 K at beamline X06SA (Swiss Light Source, Paul Scherrer Institute, 
Villigen, Switzerland). After mounting of the crystal a grid screen was performed to find the 
best diffracting region of the crystal (Fig. 3.1.10.) Four test shots were taken at the best 
position for indexing of the crystal unit cell and the optimal collection strategy was 
determined with go.com (local software written by Dr. M. Wang, SLS). 
 
 
Figure 3.1.10.: Rab33B(30-202)Q92L-Atg16L1(153-210) crystal mounted at the Swiss Light 
Source. Pink squares define zone for grid screening. Each square has a size of 10 x 20 µm. 
 
A complete native dataset with 360 ° oscillation was collected at 1 Å wavelength (for details 
see table 3.1.2.). Data were processed with input values specific for the EIGER 16M detector 
using the XDS software package. XDS defined the space group as monoclinic P1211 and this 
was confirmed by the expected absences of reflections along the screw axis (0,2n,0). The 
diffraction data were converted to unmerged CCP4F format with XDSCONV. 
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Table 3.1.2.: Data collection for Rab33B(30-202)Q92L-Atg16L1(153-210) crystal 
Beamline X06SA, Swiss Light Source (Switzerland) 
Detector EIGER 16M (Dectris) 
Detector distance 500 mm 
φ/Δφ 0.2/ 360 ° 
Exposure time 0.1 sec 
Beam intensity 0.1 
λ 1 Å 
Number of frames 1800 
Spacegroup P1211 
 
3.1.3.3. Matthew´s coefficient for the Rab33B-Atg16L1 complex 
The Matthew´s coefficient [84] was calculated to estimate the number of macromolecules in 
the asymmetric unit. This number is important to search for the correct number of molecules 
during structure determination. The molecular weight of one molecule Rab33B(30-202)Q92L 
(20583 Da) and one molecule Atg16L1(153-210) (6779 Da) was combined giving 27632 Da 
as input value for a 1:1 complex. The calculated Matthew´s coefficient (Table 3.1.3.) did not 
gave a distinct value for molecules per asymmetric unit. 7, 8 or 9 molecules per asymmetric 
unit are most likely, corresponding to a water content of 43 - 56 % in the crystal. 
Table 3.1.3.: Matthews coefficient for Rab33B(30-202)Q92L-Atg16L1(153-210) crystals 
For estimated molecular weight of 27362 Da. 
Nmol/asym  Matthews Coeff  % solvent          P(3.47)     P(tot) 
_____________________________________________________________ 
   1        19.41           93.67          0.00         0.00 
2          9.70             87.33          0.00         0.00 
3           6.47             81.00          0.00         0.00 
  4           4.85             74.66          0.01         0.00 
  5           3.88             68.33          0.03         0.02 
  6           3.23             62.00          0.10         0.07 
  7           2.77             55.66          0.22         0.19 
   8           2.43             49.33          0.32         0.32 
  9           2.16             42.99          0.24         0.29 
  10         1.94             36.66          0.06         0.10 
  11         1.76             30.33          0.00         0.01 
  12         1.62             23.99          0.00         0.00 
  13         1.49             17.66          0.00         0.00 
  14         1.39             11.32        0.00         0.00 
  15         1.29               4.99        0.00         0.00 
 
3.1.3.4. Molecular replacement for the Rab33B-mAtg16L1 complex 
The structure was determined by molecular replacement using the PHENIX program suite at 
3.5 Å resolution. The .mtz-file and a .fasta-file with the mRab33B(30-202)Q92L sequence 
were given as input for Phaser_MR, lacking the nucleotide and magnesium. The known 
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structure of GppNHp-Bound Rab33 GTPase (PDB code: 1Z06) was used as search model. 
Analyzing the cell content did not give a clear indication of the number of molecules per 
asymmetric unit. Therefore, molecular replacement was tried with four to eight Rab33B 
molecules. The best solution was found for six Rab33B molecules per asymmetric unit 
(Table 3.1.4.). This solution revealed three additional regions with helical shape in the 
electron density map. The complete structure was determined by a second round of molecular 
replacement using the coiled coil domain of ScAtg16 (PDB code: 3A7O) as a search model. 
The coiled coil domain of mammalian and yeast Atg16 is evolutionary conserved 
(Fig. 3.1.11.). Heptad positions are identical in the coiled coil domain of lower and higher 
eukaryotes. Three Atg16 dimers were found in the asymmetric unit (Table 3.1.5.). Additional 
electron density was observed in switch I and II regions of Rab33B. GTP and Mg
2+ 
were 
found in all six Rab33B molecules using Coot Ligand Finder giving further proof for the 
correctness of the molecular replacement solution. 
Table 3.1.4.: Results of first round of molecular replacement with Phaser_MR for the Rab33B-
Atg16L1 complex structure. Using 1Z06 as a search model for Rab33B. 
Component copies Number of MR solutions Top LLG Top TFZ 
4 12 2001.339 5.8 
5 1 1539.257 28 
6 1 2236.042 34.2 
7 6 2174.428 6.2 
8 6 2118.417 5.9 
 
 
Figure 3.1.11.: Sequence alignment of yeast and mouse Atg16. Alignment was done with a 
structure based sequence alignment using T-Coffee Expresso [5]. Coiled coil heptad positions were 
assigned with TWISTER [130]. Alignment was truncated and the WD40 repeat of Atg16L1, not 
present in the yeast homologues is not shown. Colors indicate fitting score from blue (bad) to red 
(good). 
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Table 3.1.5.: Result of second round of molecular replacement with Phaser_MR for the Rab33B-
Atg16L1 complex structure. Using six Rab33B molecules (Table 3.1.4.) as fixed partial solution and 
yeast Atg16 ccd 3A7O as a search model for Atg16L1. 
Component copies Number of MR solutions Top LLG Top TFZ 
3 1 2457.713 10.5 
 
3.1.3.5. Refinement and structure validation for the Rab33B-Atg16L1 complex 
The initial model contained six Rab33B molecules and three Atg16L1 dimers. Manual model 
building was done with Coot and included rebuilding of Atg16L1 residues, addition of 
residues at the C- and N-termini and side chain corrections. Rotamer outliers of side chains 
and geometric constraints were checked and corrected with Coot. Disordered side chains were 
deleted and residues were modelled as alanines (Table 3.1.6.). Manual model building and 
several cycles of refinement with Phenix were performed and resulted in the final structure 
with a Rwork/Rfree of 20/24.6 %. Detailed data refinement statistics are listed in Table 3.1.7. 
The structure was validated using Phenix Polygon plot that compares the refinement statistics 
to structures in the PDB with a similar resolution cut-off (Fig. 3.1.12. A). All values lie within 
the permitted range. The Ramachandran plot was used to analyze the geometry of the model 
(Fig. 3.1.12. B). 95 % of the residues are within the preferred regions, 4.6 % in the allowed 
regions and no outliers were found. 
Table 3.1.6.: Rab33B(30-202)Q92L-Atg16L1(153-210) residues modeled as alanine in the crystal 
structure. 
Chain Residues Chain Residues 
A; mRab33B R61, K97, L137, N139 I; mAtg16L1 N159, K163, E197, 
K198 
B; mRab33B E63, K97, N181, N139, 
R153, K165 
J; mAtg16L1 K163, R181 
C; mRab33B R61, K133, L137, D184, 
K198 
K; mAtg16L1 K163, E197 
D; mRab33B R57, R61, E63, D69, 
K133, D140, K165, 
N185, H187, K198, L199, 
K200 
L; mAtg16L1 K163, D167 
E; mRab33B D69, E80, R81, K97, 
K133, N183, D184, 
K198, K200 
M; mAtg16L1 N159, Q160, K163, 
K179 
F; mRab33B R61, D69, K97, K133, 
N181, D186 
N; mAtg16L1 Q160, K163 
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Table 3.1.7.: Data collection and refinement statistics of Rab33B(30-202)Q92L-Atg16L1(153-
210) complex. Values in parentheses refer to the highest resolution shell, Ramachandran statistics 
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Figure 3.1.12.: Refinement statistic plots for the Rab33B(30-202)Q92L-Atg16L1(153-210) 
structure. A: Polyglon plot. Structure statistics (black numbers) are compared to PDB entries with 
similar resolution (red numbers). B: Ramachandran plot of all non Pro/Gly residues. Plots were made 
by Phenix refine. 
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3.1.3.6. Structure analysis for the Rab33B-Atg16L1 complex 
In total twelve molecules are observed in the asymmetric unit of the crystal structure 
(Fig.3.1.13). They form three mRab33B(30-202)Q92L-mAtg16L1(153-210) complexes. Two 
mRab33 molecules form a complex with the C-terminal region of a parallel mAtg16L1 dimer 
(Fig.3.1.14). 
 
Figure 3.1.13.: Three Rab33B(30-202)Q92L-Atg16L1(153-210) complexes are present in the 
asymmetric unit. Two mRab33 molecules interact with one mAtg16L1 dimer. Rab33B molecules A 
and B are colored blue, C and D red, E and F green. mAtg16L1 dimer composed of chains I and J is 
colored light blue, the KL dimer light red and the MN dimer light green. 
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Figure 3.1.14.: Structure of the Rab33B(30-202)Q92L-Atg16L1(153-210) complex. The complex 
consists of two Rab33B molecules that bind to the diverging C-termini of the Atg16L1 dimer 
respectively. The Atg16L1 binding site is nearby the Rab33 GTP binding site. Rab33B (dark blue) and 
Atg16L1 (light blue) are in cartoon representation. The GTP as sticks in green and orange and the 
Mg2+ ion as yellow sphere. 
 
 Rab33B chains A/F and B/C are very close due to crystal packing. Crystal packing is loose 
and there are large solvent filled channels between symmetry-related molecules (Fig. 3.2.15). 
The three individual complexes align with a root-mean-square deviation of atomic positions 
(RMSD) of 0.602. Rab33B molecules are quite similar, whereas the Atg16L1 molecules are 






Figure 3.1.15.: Crystal packing of the Rab33B(30-202)Q92L-Atg16L1(153-210) crystal. Twelve 
molecules forming three Rab33-Atg16L1 complexes are present in the asymmetric unit are shown in 
color and symmetry-related molecules are colored grey. 
 
Figure 3.1.16.: Alignment of the three Rab33B(30-202)Q92L-Atg16L1(153-210) complexes found 
in the asymmetric unit. Cartoon representation of complexes ABIJ in blue, CDKL in red and EFMN 
in green. The complexes align with a RMSD of 0.602 
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The Atg16L1 bound Rab33B structure is very similar to the known Rab33B structures [31, 
103] mRab33B(30-202)Q92L exhibits the typical GTPase fold (Fig. 3.1.17 A). It consists of a 
central six-stranded β-sheet made of five parallel strands and an antiparallel strand, 
surrounded by five α-helices. The GTPase fold is conserved for Rab proteins (Fig. 3.1.18. and 
Fig. 3.1.19.) Binding of Atg16L1 takes place at switch I, switch II and the interswitch region 
(Fig. 3.1.17. B). Ligands GTP and Mg
2+
 bind as expected in the switch I and II regions and 
the 5´-posphate arm of GTP is flanked by the P-loop (Walker A motif) (Fig. 3.1.17 A). 
Binding of GTP and Mg
2+
 is consistent with ligand binding observed in other GTP bound Rab 
crystal structures (Fig. 3.1.18.).  
 
Figure 3.1.17.: Typical GTPase fold of Rab33B(30-202)Q92L. A: Overview of Rab33B structure. 
Cartoon representation of mRab33B in dark turquoise. Bound ligands GTP is shown as a stick model 
and magnesium as a yellow sphere. Switch I is colored pink, Switch II dark blue and the P loop lemon. 
B: Details of Atg16L1 binding site. Atg16L1 chain is colored in light pink.  
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Figure 3.1.18.: Overlay of GTP bound Rab33B and Rab1a structures. Cartoon representation of 
mRab33B in dark turquoise with GTP shown as green carbon stick model and magnesium as a yellow 
sphere superimposed with Rab1a (PDB code 3TKL) in light pink with bound ligands GTP as pink 
carbon stick model and magnesium as pink sphere. 
 
Figure 3.1.19.: Sequence alignment of murine Rab proteins. Arrows and helices on top of the 
alignment present structural elements of Rab33B. Similar residues are colored black and yellow 
boxed, identical residues are colored white and red boxed. Alignment is truncated at the C-terminus of 
Rab33B. Alignment was done with T-Coffee Expresso [5], Figure was made using ESPript 3.0 [116]. 
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Although the overall Atg16L1-bound Rab33B structure is very similar to GppNHp-bound 
Rab33B (PDB code 1Z06) and GDP bound Rab33B (PDB code 2G77, [103]) significant 
conformational differences are observed in the switch regions and the site of Atg16L1 
interaction. GDP bound Rab33B (PDB code 2G77) shows different switch region 
conformations due to GDP binding in comparison with the GTP bound Rab33B structure 
(Fig. 3.1.20.).  
 
Figure 3.1.20.: Overlay of Rab33B structures in different nucleotide bound states. Cartoon 
representation of mRab33B in dark turquoise with bound GTP as green stick model and Mg2+ as a 
yellow sphere superimposed with GppNHp-bound Rab33 (PDB code 1Z06) in blue and GDP-bound 
Rab33 (PDB code 2G77) in pink. Black box marks the Switch II region. 
 
Although GppNHp-bound Rab33B and Rab33B bound to Atg16L1 are both in the active state 
a different conformation of the F70 side chain is observed (Fig. 3.1.21.). Interestingly residue 
F70 was later shown to be essential for Atg16L1 binding both in vivo and in vitro. Two 
Rab33B molecules interact with the diverging C-termini of an Atg16L1 dimer. Atg16L1 
residues 191 to 208 interact with Rab33B, which is consistent with the results of the co-
expression experiments to find the minimal interacting coiled coil domain of Atg16L1. Here, 
truncating the Atg16L1 C-terminal end from 210 to 200 abolished Rab33B binding. 
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Figure 3.1.21.: Overlay of Rab33B structures in the active state. Cartoon representation of Atg16 
bound mRab33B in light blue superimposed with GppNHp-bound Rab33 (PDB code 1Z06) shown in 
blue. Residue F70 is shown as stick in dark blue for Rab33B and light blue for GppNHp-bound 
Rab33. Omit map of F70 from Atg16L1 bound Rab33B is countered at 2σ in green and clearly 
demonstrate the different side chain conformation of F70 in both structures. 
 
The geometry of the Atg16L1 coiled coil domain was analyzed using the program TWISTER 
[130]. The program calculates the local coiled-coil radius in Å (cc_rad) along the coiled coil 
axis as a function of residue number. Poly-alanine coordinate files of the three Atg16L1 
dimers were used for calculations. The results show a normal coiled-coil radius until residue 
189 and from this residue onwards the C-termini are constantly diverging (Fig. 3.1.22).  
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Figure 3.1.22.: Twister analysis of Atg16L1 dimers. The local coiled-coil radius in Å (cc_rad) along 
the coiled coil axis is shown as a function of residue number. Analysis shows the divergence of the C-
termini starting at residue 189. Calculations were done with TWISTER [130]. 
Additionally, an ideal mAtg16L1(153-210) coiled coil dimer was modeled using CCBuilder 
Version 1.0 [145] and superimposed with the actual Atg16L1 ccd in complex with Rab33B 
(Fig. 3.1.23). The diverging C-terminus is clearly visible. Analyzing the heptad repeat pattern 
of Atg16L1 reveals the typical repeating pattern “hxxhcxc” of hydrophobic (h) amino acids at 
position a and d and charged (c) amino acids at position e and g for the first four heptad 
repeats (Fig. 3.1.24.). The four heptad repeats (residues 187-208) at the C-terminus do not 
completely obey this pattern with mainly polar and acidic residues at position a (residues 187, 
201, 208) and d (residues 183, 204) and hydrophobic residues at position e (residues 191, 198, 
205). 
 
Figure 3.1.23.: Overlay of the Atg16L1 structure and an ideal Atg16L1 model. Cartoon 
representation of Rab33B bound Atg16L1 dimer IJ in blue superimposed with an ideal Atg16L1 coiled 
coil dimer model in yellow. Ideal Atg16L1 coiled coil dimer model was made using CCBuilder 





Figure 3.1.24.: Helical wheel projection of the residues in the Atg16L1 dimer IJ. Black: 
hydrophobic residues, Yellow: polar residues, Red: acidic residues, Blue: basic residues. Numbers 
indicate residue number. Helical wheel was made using DrawCoil 1.0 [46]. 
 
3.1.4. Cross-linking of the Rab33B-Atg16L1 complex and analysis by mass spectrometry 
Protein cross-linking and analysis by mass spectrometry gives further insights into protein-
protein interactions. Here, the mRab33(30-202)Q92L-mAtg16L1(153-210) complex was 
cross-linked using the amine-reactive bis(sulfosuccinimidyl) suberate (BS3) at different 
concentrations. The amount of cross-linking was analyzed by native gel electrophoresis (Fig. 
3.1.25.). Without cross-linker only the two bands of Rab33B and Atg16L1 were observed. 
After the addition of BS3 more bands with a higher molecular weight appeared. The amount 
of high molecular weight bands increased with the cross-linker concentration. Two bands, 
marked with black arrows (Fig. 3.1.6.) were chosen and sent for mass spectrometry analysis. 
This work was done in collaboration with Dr. Momchil Ninov (Department of Neurobiology) 
and Dr. Chung-Tien Lee (Bioanalytical Mass Spectrometry). 
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Figure 3.1.25.: Cross-linking of the Rab33B-Atg16L1 complex. Native gel electrophoresis of the 
Rab33B-Atg16L1 complex (5 mg/ml), cross-linked with 0, 0.25, 0.5, 1, 2 and 4 mM BS3. Arrows 
mark bands that were analyzed by mass spectrometry. Left arrow flags band1, right arrow band2. M: 
Marker.  
Bands were cut from the gel, digested with trypsin and subjected to LC-MS/MS analysis. 
Each sample measured in two technical replicates. Raw data were searched against a FASTA 
database containing the full length sequences of mRab33B and mAtg16L1 using the target-
decoy strategy of pLink. Results are shown with the count of spectrum and the maximum 
score for each cross-link (Table 3.1.8.). Cross-links were visualized by web-based xiNET [26] 
(Fig. 3.1.26.). To exclude false positive cross-links the threshold for the maximal score was 
set to 5.1. The cross-linker used in this study BS3
 
has a length of 11.4 Å and it preferentially 
cross-links the zeta nitrogen atom of lysines (NZ). Since lysine sidechains are often 
conformational flexible and proteins are dynamic in solution a maximum distance of ~24-30 
Å between Cα atoms of two cross-linked lysines is feasible. Moreover, maximum Cα- Cα 
distances of ~40 Å were observed [87].  
The cross-linked lysine residues were mapped onto the Rab33B, Atg16L1 and Rab33B-
Atg16L1 structure and Cα-Cα distances were measured using PyMol to visualize and analyze 
the cross-links (Fig. 3.1.27 – 3.1.29). Rab33B K97 localized in the switch II (89-98) region 
was the prominent intra molecular cross-linking site (Table 3.1.8., Fig. 3.1.27.). Inter 
molecular cross-links for mAtg16L1 support that the protein forms a parallel coiled coil dimer 
(Table 3.1.8., Fig. 3.1.28.). Seven intermolecular cross-links were found between Rab33B and 
Atg16L1 (Table 3.1.8., Fig. 3.1.29.). The most prominent cross-links occurred between 
Rab33B K97 and Atg16L1 K179 and K182. Interestingly Atg16L1 K198 that is important for 
70 
complex formation was cross-linked to three Rab33B residues namely K35, K97 and K149. 
Rab33B residues K46, K165 and K198 that formed intra molecularly cross-links but lay in 
distance to the Atg16L1 binding site were not cross-linked with Atg16L1. 
 
Figure 3.1.26.: Visualization of the mass spectrometry analysis of the cross-linking of the 
Rab33B-Atg16L1 complex. A: shows analysis of band1, B: shows analysis of band2 from Fig 3.1.6. 
Samples were run in two technical replicates. Threshold was set to 5.1. Turquoise lines inter cross-
links between Rab33B and Atg16L1. Purple lines inter- or intra molecular cross-links, Red line: Inter-









Table 3.1.8.: Data of the mass spectrometry analysis of the cross-linking of the Rab33B-Atg16L1 
complex. Samples were run in two technical replicates. Threshold was set to 5.1.  
    Band1 Band2 








Rab33B 97 Atg16L1 182 3 12.82   9 22.46 
 97  179 3 15.52 8 18.28 
 97  198   1 13.11 
 35  182   5 14.77 
 35  198   4 8.46 
 149  182   4 13.01 
 149  198   2 7.45 
        
Atg16L1 182 Atg16L1 198   5 20.26 
 179  182 2 15.7 5 14.03 
 198  198   4 10.4 
 182  182   2 6.98 
        
Rab33B 97 Rab33B 35 10 16.36 57 21.56 
 97  46 6 18.34 6 20.57 
 97  149 7 9.59 15 14.03 
 97  198 6 17.76 2 13.54 
 97  165 8 12.86 7 12.93 
 97  97 2 5.8 23 10.63 
 149  46   2 11.03 
 149  165 3 7.3 4 7.83 
 149  198 2 5.23 2 5.51 
 35  149   5 7.9 





Figure 3.1.27.: Intra molecular cross-links of Rab33B K97. Cartoon representation of Rab33B in 
dark blue. Lysines are presented as sticks in green. Cα-Cα distances (Å) between K97 and intra 
molecular cross-links to other lysine residues are shown as dashed lines. Figure was made with Pymol. 
 
Figure 3.1.28.: Intra molecular cross-links of Atg16L1. Cartoon representation of Atg16L1 in blue. 
Lysines are presented as sticks in green. Cα-Cα distances (Å) between intra molecular cross-links are 
shown as dashed lines. Figure was made with Pymol. 
73 
 
Figure 3.1.29.: Cross-links between Rab33B and Atg16L1. Cartoon representation of Rab33B in 
dark blue and Atg16L1 in blue. Lysines are presented as sticks in green. Cα-Cα distances (Å) between 
intra molecular cross links are shown as dashed lines. Figure was made with Pymol. 
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3.1.5. Analyzing complex formation of Rab33B and Atg16L1 mutants in vitro 
Based on the structure of the Rab33B(30-202)Q92L-Atg16L1(153-210) complex and 
literature search for residues that were mutated in other Rab proteins [148, 151], mutants were 
designed to interrupt complex formation of Rab33B and Atg16L1. Three mutations were 
selected for each protein at positions that are likely to contribute to complex formation (Fig. 
3.1.30.). For Rab33B aromatic residues F70 and W87 were mutated. Both residues are 
strongly conserved in Rab GTPases (Fig. 3.1.19.). Residue F70, that is part of the switch I 
region, was chosen because it undergoes a conformational change upon binding to Atg16L1 
(Fig. 3.1.21.). Two mutations were selected for Rab33B residue F70. The F70A mutation 
removes the aromatic side chain and thus gives insights on the importance of the phenyl-side 
chain for complex formation. The F70E mutation changes this amino acid position from 
neutral to a negative charge.  
Tryptophan is the largest amino acid with aromatic and nonpolar characteristics; mutation 
W87A changes this position to a small hydrophobic amino acid. For Atg16L1 mutation 
K198A changes the flexible amino acid with a positive charged ε-amino group to a small 
hydrophobic amino acid. For A202W a steric clash would be expected that inhibits complex 
formation. With mutation N206K the neutral amino acid is changed to positively charged 
residue. Only residue N206 is conserved between mammalian and yeast Atg16 (Fig. 3.1.11.) 
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Figure 3.1.30.: Rab33B-Atg16L1 mutations. Transparent cartoon representation of in light turquoise 
bound ligands GTP as green carbon stick model and magnesium as yellow sphere and Atg16L1 in 
light pink. Residues selected for mutagenesis F70, W87 (Rab33B) and Atg16L1 residues K198, A202 
and N206 are shown in stick representation in dark blue. 
Rab33B(30-202)Q92L-Atg16L1(153-210) mutants were also co-expressed in pETDuet1 
vector with a His-tagged Rab33B and untagged Atg16 as described previously. A pull-down 
assay with Ni-sepharose beads was performed to examine complex formation. Schägger gel 
electrophoresis was performed for all pull down steps in order to verify expression of both 
proteins and to track proteins. As an example the pull down of Rab33B(30-202)Q92L-
Atg16L1(153-210)K198A is shown (Figure 3.1.31.). Both proteins are expressed as seen in 
the supernatant fraction. After binding to Ni-sepharose beads the Atg16L1 band is visible in 
the flow through and the amount of Atg16L1 decreases with every washing step when 
unbound protein is washed from the beads. Finally, Rab33B elutes alone indicating that no 
complex was formed between Rab33B(30-202)Q92L and Atg16L1(153-210)K198A.  
 
Figure 3.1.31.: Ni-sepharose pulldown of Rab33B(30-202)Q92L and Atg16L1(153-210) K198A. 
Schägger gel electrophoresis of samples from all purification steps. Arrows indicate bands for 
Rab33B(30-202)Q92L and mAtg16L1(153-210) K198A. M: Marker, P: Pellet, S: Supernatant, ft: flow 
through, W1-3: Wash 1-3, E1-2: Elution 1-2.  
Ni-Sepharose elution fractions of all mutants were separated by Schägger gel electrophoresis 
and subjected to western blotting. One membrane was probed with anti-His Tag antibody to 
detect Rab33B and the other was probed with anti-Atg16L1 antibody (Fig. 3.1.32.). Complex 
formation of Atg16L1(153-210)WT was also tested with Rab33B(30-202)WT, GTP-bound 
Rab33B(30-202)Q92L and GDP-bound Rab33B(30-202)T47N. Immunodetection revealed 
that Rab33B(30-202)WT and Q92L bound Atg16L1(153-210) in similar amounts, whereas 
the Rab33B(30-202)T47N did not bind Atg16L1 in vitro. This observation confirms that 
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Atg16L1 is an effector of Rab33B. Additionally, it can be concluded that Rab33B(30-202) 
WT is predominantly present in the GTP-bound form. Importantly, all single point mutations 
that were introduced in either Rab33B or Atg16L1 disrupted complex formation in vitro. 
 
 
Figure 3.1.32.: Ni-Sepharose pulldown of Rab33B(30-202) and Atg16L1(153-210). Ni-Sepharose 
elution fractions were used for Schägger gel electrophoresis and blotted on two nitrocellulose 
membranes. Membranes were probed with A: Penta His HRP conjugate antibody or B: rabbit anti-
Atg16L primary antibody and goat anti-rabbit IgG (HRP labeled) secondary antibody. M: Marker. 
Rab33B mutations WT and T47N did not contain the Q92L mutation, whereas F70E/A and W87A 
were mutated additional to Q92L. 
 
3.1.6. In vivo characterization of the Rab33B-Atg16L1 complex 
To further investigate complex formation of Rab33B and Atg16L1 and examine the influence 
of the Rab33B-Atg16L1 complex on autophagy in vivo studies were conducted with Dr. 
Beyenech Binnotti (Department for Neurobiology).   
3.1.6.1. Expression of full length Rab33B and Atg16L1 in HEK293 cells 
For in vivo expression full length mRab33B Q92L and WT were cloned into mammalian 
expression vector pcDNA3.1/nV5. F70A/E and W87A mutations were additional introduced 
for mRab33B Q92L and mRab33B WT was altered to the GDP-trapped mutant T47N. For 
full length mAtg16L1 in mammalian expression vector pcDNA6.1/C-EmGFP mutations 
K198A, A202W and N206K were prepared. 
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pcDNA3.1/nV5 Rab33B Q92L was co-transfected with pcDNA6.1/C-EmGFP mAtg16L1 
WT, K198A, A202W and N206K for overexpression in HEK293 cells. To test the effect of 
the Rab33B mutants pcDNA6.1/C-EmGFP mAtg16L1 WT was co-transfected with 
pcDNA3.1/nV5 Rab33B WT, T47N or Q92L F70A/E and Q92L W87A. Overexpression 
levels were tested by western blotting, membranes were probed with anti-GFP or anti-V5 
primary antibody and IR dye 800 secondary antibody. All Atg16L1 variants were 
overexpressed at equivalent levels and the same was observed for all Rab33B variants (Fig. 
3.1.33.). 
 
Figure 3.1.33.: Western blot analysis to characterize the overexpression of Atg16L1-EmGFP and 
V5-Rab33B. Overexpression was done in HEK cells. Western blot membranes were probed 
Membranes were probed with rabbit anti-GFP or mouse anti-V5 primary antibody and IR dye 
800 (green) secondary antibody for Odyssey fluorescence detection. Marker in red.  
 
3.1.6.2. Immunoprecipitation and pull down assays  
Co-immunoprecipitation experiments were conducted to evaluate complex formation of 
Rab33B and Atg16L1 in vivo. HEK293 cells overexpressing full length mRab33B and 
mAtg16L1 constructs were lysed and incubated with a GFP-antibody. The GFP-antibody was 
immobilized with protein A dynabeads. GFP-antibody-beads capture GFP-tagged Atg16L1 
and all proteins that form a direct or indirect complex with Atg16L1. After GFP-pull down 
proteins were eluted and submitted to SDS gel electrophoresis followed by western blotting. 
Success of the immunocoprecipitation was verified by Atg16L1 staining with a GFP antibody. 
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Rab33B bound to Atg16L1 was detected with a V5-antibody. To test for lipidation 
membranes were also probed with specific antibodies for endogenous LC3B (Fig. 3.1.34.).  
Analysis of the western blot revealed that Atg16L1 WT, A202W and N206K were efficiently 
and equally extracted by the anti GFP-antibody. Only Atg16K1 K198A was extracted in 
lower amounts but repetition of the experiment showed similar amounts of all Atg16L1 
variants (data not shown). In the presence of Atg16L1, both WT Rab33B WT and Q92L co-
precipitated in similar high amounts. When Atg16L1 WT was co-expressed with the GDP-
bound Rab33B T47N a significantly lower amount of Rab33B T47N co-precipitated. In 
contrast, no complex formation was observed in pull down experiments with the Rab33B(30-
202) T47N mutant and WT mAtg16L1(153-210) in vitro. Complex formation of Rab33B 
Q92L with Atg16L1 was disrupted for all mutants expect for Atg16L1 WT and Rab33B 
Q92L F70E which showed a significantly reduced level of complex formation compared to 
Rab33B Q92L with Atg16L1 WT.  
The lipidation state of LC3 was analyzed with a LC3B specific antibody. The antibody detects 
a band of approximately 17 kDa for the PE-modified LC3-II form and a 19 kDa band for 
unlipidated LC3-I. Both LC3 forms were only detected in the input demonstrating that no 
direct binding to Atg16L1 occurred as expected. Interestingly, the level of LC3-II was 
increased when the constantly active Rab33B Q92L was overexpressed as observed before 




Figure 3.1.34.: GFP co-immunoprecipitation of Atg16L1-EmGFP and V5-Rab33B variants. 
Overexpression was done in HEK293 cells. Western blots were probed with either anti-GFP, anti-V5 
or anti-LC3B antibodies. 
Additionally to the GFP pulldown a V5 pulldown was performed to validate these findings 
(Fig. 3.1.35.). The experiment was conducted as before, but an anti V5-antibody was used for 
immobilization. Co-immunoprecipitation using the V5-antibody demonstrated the same 
complex formation pattern for the Rab33B and AtgL1 constructs. The highest amount of 
Atg16L1 WT pull down was observed for Rab33B WT and its Q92L mutant. The GDP-
trapped Rab33B T47N mutant did not co-precipitated Atg16L1 WT. A low amount of co-
immunoprecipitation was observed for Rab33B Q92L F70E with Atg16L1 WT and for 
Rab33B WT with Atg16L1 K198A or N206K. However, no complex formation was observed 




Figure 3.1.35.: V5 co-immunoprecipitation of Atg16L1-EmGFP and V5-Rab33B variants. 
Overexpression was done in HEK293 cells. Western blots were probed with either anti-GFP, anti-V5 
or anti-LC3B antibodies. 
 
3.1.6.3. MAP1LC3 Lipidation assay 
To further verify the finding of increased LC3-II levels when the constantly active Rab33B 
Q92L mutant was overexpressed a MAP1LC3 lipidation assay was performed. Microtubule-
associated proteins 1A/1B light chain 3B (MAP1LC3), hereafter named LC3, was detected 
with a LC3B specific antibody. The antibody detects a band of approximately 17 kDa for the 
PE-modified LC3-II form and a 19 kDa band for unlipidated LC3-I. Tubulin was detected for 
quantification of protein levels. Cells were maintained under nutrient conditions or treated 
with 20 mM NH4Cl to block the autophagic flux [92]. Results are in agreement with the 
observations made in co-immunoprecipitation experiments. Under nutrient conditions LC3-II 
levels were enhanced for Rab33B Q92L with Atg16L1 WT compared to Rab33B WT or 
T47N with Atg16L1 WT. Additionally increased LC3-II levels were observed for Rab33B 
Q92L F70E with Atg16L1 WT and Rab33B Q92L with Atg16L1 mutants. Results show that 
the effect of Rab33B Q92L on LC3 levels in nutrient rich conditions is independent of 
complex formation with Atg16L1 like observed before. 
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Figure 3.1.36.: MAP1LC3 Lipidation assay. Overexpression was done in HEK293 cells. Cells were 
maintained under nutrient conditions or 20 mM NH4Cl. Western blots were probed with either anti-
GFP, anti-V5, anti-Tubulin or anti-LC3B antibodies. 
 
3.1.6.4. Fluorescence microscopy 
In order to study the intracellular distribution and function of the Rab33B-Atg16L1 complex 
fluorescence microscopy was performed in Cos-7 cells, a fibroblast-like cell line derived from 
monkey kidney tissue, which was co-transfected with the Rab33B and Atg16L1 variants used 
for co-immunoprecipitation. In cells co-transfected with Atg16L1 and either Rab33B Q92L or 
WT punctate structures positive for both proteins were observed in the cytoplasm, 
demonstrating co-localization (Fig. 3.1.37. A). Expression of GTP-bound Rab33B Q92L with 
Atg16L1 lead to the observation of enlarged punctuate structures (Fig. 3.1.37. B), whereas the 
expression of GDP-bound Rab33B T47N with Atg16L1 clearly reduced the amount of 
punctuate structures compared to Rab33B WT. Furthermore Rab33B T47N is located mostly 
to the perinuclear area (Fig 3.1.37. C). A dramatic loss of punctuate structures was observed 
upon expression of the Rab33B Q92L F70A/F70E/W87A mutants with Atg16 L1 or Rab33B 
Q92L with Atg16L1 K198A, A202W or N206K mutants, respectively (Fig. 3.1.38. D-F and 
Fig. 3.1.39. G-I). Only few punctuate Atg16L1 positive structures were observed in some of 
the cells but do not localize with Rab33B. No difference between cells that lack the Rab33B-
Atg16L1 complex (Fig. 3.1.38. E, F and Fig. 3.1.39. G) and cells with a decreased amount of 





Figure 3.1.37.: Intracellular distribution of EmGFP-Atg16L1 and V5-Rab33B WT/ Q92L or T47N. EmGFP-Atg16L1 and V5-Rab33B 










Figure 3.1.38.: Intracellular distribution of EmGFP-Atg16L1 and V5-Rab33B Q92L F70A/ F70E or W87A. EmGFP-Atg16L1 and V5-




Figure 3.1.39.: Intracellular distribution of EmGFP-Atg16L1 K198A/ A202W or N206K and V5-Rab33B Q92L. EmGFP-Atg16L1 variants 
and V5-Rab33B Q92L transiently expressed in Cos-7 cells. Scale bar, 10 µm. 
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3.2. Characterization of the KlAtg21-AgAtg16 complex 
The Atg21-Atg16 complex coordinates the lipidation of Atg8 by organizing the ubiquitin-like 
conjugation system at the expanding isolation membrane. Atg16 coiled coil domain residues 
E102 and D101 are important for Atg21 binding [58]. Further insights into the interaction 
between Atg21 and Atg16 will help to understand its molecular function.  
3.2.1. Expression and purification of KlAtg21, AgAtg16 and KlAtg21-AgAtg16 
complexes 
For expression and purification of the Atg21-Atg16 complex full length Atg21 from yeast 
Kluyveromyces lactis was chosen. Dr. Andreea Scacioc showed that Saccharomyces 
cerevisiae Atg21 is insoluble when expressed by E. coli. [119]. K. lactis Atg21 was 
previously purified in our group [19]. S. cerevisiae and K. lactis Atg21 are conserved and 
share 40.2 % identity (SIM Expasy). The coiled coil domain of Ashbya gossypii Atg16 
interacts with KlAtg21 and was used for further studies because AgAtg21 could not be 
expressed (K. Kühnel, personal communication). Both KlAtg21 and AgAtg16 were 
individually expressed in E. coli from a pET28a vector. For purification of the complex 
expression pellets of KlAtg21 and AgAtg16 were mixed in a ratio of 2:1. Each protein was 
purified either individually or together for complex isolation with a two-step protocol. The 
first step was HisTrap chromatography followed by a polishing step with size exclusion 
chromatography using a HiLoad 16/60 Superdex 200 column (Fig. 3.2.1.). Purification of the 




Figure 3.2.1.: Purification of KlAtg21 and AgAtg16 (70-124). Schägger gel analysis of purification 
steps. A, B: Purification of AgAtg16(70-124). A: HisTrap, B: size exclusion chromatography 
Superdex 200. C, D: Purification of KlAtg21. C: HisTrap, D: size exclusion chromatography 
Superdex 200. Of notice, KlAtg21 eluted as double band due to degradation of the protein. M: Marker, 
Start: Input for SEC. Numbers corresponds to fractions. 
 
3.2.2. Biochemical characterization of the KlAtg21-AgAtg16 complex 
3.2.2.1. Analysis of complex formation by analytical gel filtration 
To minimize the KlAtg21-AgAtg16 complex for crystallization the minimal binding domain 
of AgAtg16 was searched for. Construct design and initial experiments were conducted by Dr. 
Karin Kühnel. These preliminary results needed further confirmation. To identify the minimal 
binding domain of AgAtg16 for complex formation the interaction of full length KlAtg21 
with different AgAtg16 constructs was analyzed by analytical gel filtration. Here, 100 nmol 
KlAtg21 was mixed with 50 nmol AgAtg16, incubated for 30 min on ice and loaded on a 
Superdex 200 10/300 GL analytical gel filtration column with 30 mM HEPES pH 7.5, 150 
mM NaCl, 1 mM TCEP gel filtration buffer. The chromatogram was compared to individual 
runs of KlAtg21 and AgAtg16. A peak shift indicates complex formation. Complex formation 
was observed between full-length KlAtg21 and AgAtg16 (40-124) (Fig. 3.2.2.) and AgAtg16 
(70-124) (Fig. 3.2.3.). For KlAtg21-AgAtg16 (40-124) almost all protein formed a complex, 
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whereas for the KlAtg21-AgAtg16(70-124) run two peaks representing the complex and 
unbound protein were observed. Thus, KlAtg21 and AgAtg16(40-124) seemed to form a more 
stable complex. Only a small peak shift was observed for KlAtg21 with C-terminal truncated 
AgAtg16 (47-103) (Fig. 3.2.4.) and AgAtg16 (47-103) eluted between fractions 26-32 
indicating a weak interaction.  
 
 
Figure 3.2.2.: Analytic gel filtration of KlAtg21 and AgAtg16 (40-124). Chromatograms of size 
exclusion chromatography using a Superdex 200 10/300 GL column. Red curve: KlAtg21, green 
curve: AgAtg16 (40-124), blue curve: KlAtg21 and AgAtg16 (40-124). Schägger gel electrophoresis 
of elution fractions are shown on the right side. M=Marker, Numbers refer to elution fractions. Bands 






Figure 3.2.3.: Analytic gel filtration of KlAtg21 and AgAtg16 (70-124). Chromatograms of size 
exclusion chromatography using a Superdex 200 10/300 GL column. Red curve: KlAtg21, green 
curve: AgAtg16 (70-124), blue curve: KlAtg21 and AgAtg16 (70-124). Schägger gel electrophoresis 
of elution fractions are shown on the right side. M=Marker, Numbers refer to elution fractions. Bands 






Figure 3.2.4.: Analytic gel filtration of KlAtg21 and AgAtg16 (47-103). Chromatograms of size 
exclusion chromatography using a Superdex 200 10/300 GL column. Red curve: KlAtg21, green 
curve: AgAtg16 (47-103), blue curve: KlAtg21 and AgAtg16 (47-103). Schägger gel electrophoresis 
of elution fractions are shown on the right side. Bands were colored according to chromatogram color. 
Arrows indicate KlAtg21 or AgAtg16 (47-103) respectively. 
 
3.2.2.2. Analysis of the KlAtg21-AgAtg16 complex stoichiometry by SEC-MALLS 
measurements 
The stoichiometry of the KlAtg21-AgAtg16 (70-124) complex was investigated by SEC-
MALLS measurements in collaboration with Johannes Arens and Dr. Achim Dickmanns 
(Department for Molecular Structural Biology, University of Göttingen). After separation on a 
Superdex 200 10/300 GL column samples were run through a MALLS detector. MALLS 
measurements allow the molecular weight determination of a protein independent of its shape 
and can therefore be used for the determination of molecular weights of non-globular 
proteins, for example coiled-coil proteins. Measurements were done for the KlAtg21-
AgAtg16 complex, KlAtg21 and AgAtg16 individually to analyze the stoichiometry of the 
complex.  
Chromatograms of the size exclusion prior to MALLS measurements showed that the 
KlAtg21-AgAtg16 (70-124) complex was formed (Fig. 3.2.5.) SEC-MALLS measurements 
(Fig. 3.2.6. and Table 3.2.1.) of KlAtg21 gave a molecular weight of 43 kDa, which is 
consistent with the calculated molecular weight of 45.7 kDa including the His Tag. For 
AgAtg16 (70-124) 15 kDa were measured and 15.4 kDa were calculated for an Atg16 dimer 
including the His Tag. Results also confirm that AgAtg16 is dimeric. Measurements of the 
molecular weight of the KlAtg21-AgAtg16 (70-124) complex gave a molecular weight of 
67 kDa. The measured value corresponds to one KlAtg21 molecule in the complex. Because 
the Atg16 coiled coil domain is most likely to form a dimer it is likely that one KlAtg21 
molecule forms a complex with one AgAtg16 dimer, giving a theoretical molecular weight of 





Figure 3.2.5.: SEC of KlAtg21, AgAtg16 (70-124) alone and KlAtg21-AgAtg16 (70-124) complex. 
Chromatograms of size exclusion chromatography using a Superdex 200 10/300 GL column prior to 
MALLS measurements. Green curve: KlAtg21, Red curve: AgAtg16 (70-124), blue curve: KlAtg21-
AgAtg16 (70-124) complex.  
 
 
Figure 3.2.6.: MALLS measurements of KlAtg21, AgAtg16 (70-124) and KlAtg21-AgAtg16 (70-
124) complex. Peaks correspond to size exclusion chromatography elution volume (x-axis). 




Table 3.2.1.: Molecular weights of KlAtg21, AgAtg16 (70-124) and KlAtg21-AgAtg16 (70-124) 
complex. Listed are the average molar mass measured by SEC-MALLS and the theoretical mass 
calculated from the protein sequence including Tags. 







1.574 x 104 (±0.043 %) 4.314 x 104 (±0.009 %) 6.767 x 104 (±0.009 %) 
Theoretical molecular 
weight (g/mol) 
1.54 x 104 4.57x104 unknown 
 
3.2.2.3. Isothermal calorimetry measurements of the KlAtg21-AgAtg16 complex 
In order to investigate the thermodynamic parameters of the KlAtg21- AgAtg16 complex 
formation isothermal titration calorimetry (ITC) measurements were done together with Dr. 
Ángel Pérez-Lara (Department for Neurobiology). 200 µM AgAtg16(40-124) or (70-124) 
were titrated in the cell containing 20 µM KlAtg21. An exothermic reaction indicating 
binding was not observed. 
 
Figure 3.2.7.: Isothermal titration calorimetry titration curves of KlAtg21 with AgAtg16(40-
124). 200 µM AgAtg16 (40-124) was titrated into 20 µM KlAtg21. Data was fitted with a One Set of 
Sites fitting model. Top panel shows raw ITC data. Bottom panel shows integrated heat. 
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3.2.3. Structure determination of the KlAtg21-AgAtg16 complex 
Structure determination of the Atg21-Atg16 complex was a main goal in our group. Dr. Karin 
Kühnel crystallized the KlAtg21-AgAtg16 (40-124) complex by in-situ proteolysis with 
1:1000 Clostripain and a precipitant composed of 15 % (w/v) PEG 4000 and 0.1 M HEPES 
pH 7.0. Crystals were optimized but their diffraction did not improve. Structure determination 
of the KlAtg21-AgAtg16 complex was performed by me from the point of data collection. 
3.2.3.1. X-ray data collection and processing for the KlAtg21-AgAtg16 complex 
Data were collected at 100 K at beamline X06SA (Swiss Light Source, Paul Scherrer 
Institute, Villigen, Switzerland). Because KlAtg21-AgAtg16(40-124) crystals had an 
elongated shape a grid screening was performed for every crystals tested. Grid screen analysis 
revealed that all crystals displayed different diffraction properties sidelong (Fig. 3.2.8.). The 
best diffracting region was chosen to collect data.  
 
Figure 3.2.8.: Grid screen of a KlAtg21-AgAtg16 (40-124) crystal. A: Crystal mounted at PXI at 
the Swiss Light Source. Pink squares define zone for grid screen. Each square has the size of 10 x 40 
µm. B: Results of grid screening. Colors indicate the diffraction intensity from low (dark blue) to high 
(red). 
 
Four test shots were taken at the best position to index the crystal. A data collection strategy 
was determined with go.com (local software written by Dr. M. Wang, SLS). A complete 
native data set at 4.0 Å resolution was recorded with an oscillation angle of 0.5 over 360° 




Table 3.2.2.: Data collection for the KlAtg21-AgAtg16(40-124) complex  
Beamline X06SA, Swiss Light Source (Switzerland) 
Detector EIGER 16M (Dectris) 
Detector distance 600 mm 
φ/Δφ 0.2/ 360 ° 
Exposure time 0.1 sec 
Beam intensity 0.1 
λ 1 Å 
Number of frames 1800 
 
Data were processed with input values specific for the EIGER 16M detector using the XDS 
software package. KlAtg21-AgAtg16 crystals belong to space group P3221 (154) with unit 
cell dimensions of a = 123.5 Å, b = 123.5 Å, c = 185.22 Å, α = 90 °, β = 90 °, γ = 120 °. 
XDSCONV was used to convert scaled data to unmerged CCP4F format. 
 
3.2.3.2. Molecular replacement for the KlAtg21-AgAtg16 complex 
The Phenix program suite was used for molecular replacement and refinement. The first step 
of structure solution was to try molecular replacement (MR) with the known PROPPIN 
structures of Kluyveromyces marxianus Hsv2 (PDB code: 4EXV, [9]), Kluyveromyces lactis 
Hsv2 (PDB code: 4V16, [19]) and Pichia angusta Atg18 (PDB code: 5LTD and 5LTG, 
[119]). Flexible loop regions were truncated from the search models first. Loop 318-229 was 
removed for KlHsv2 (14-338) and the corresponding loop 330-339 was deleted in KmHsv2 
(19-350). The two available structures of PaAtg18 were superimposed and loop 91-97 was 
truncated. Additionally, side chains were deleted for all models. Molecular replacement with 
truncated PaAtg18 and KmHsv2 was successful (Table 3.2.3.). Two PROPPIN molecules 
were placed and the same orientation of the β-propellers was observed for PaAtg18 and 
KmHsv2 (Fig. 3.2.9.). However, MR with KlHsv2 did not give a solution. Using PaAtg18 as 






Figure 3.2.9.: First round in the molecular replacement structure determination of KlAtg21-
AgAtg16. Two PROPPIN molecules were placed in the asymmetric unit. Overlay of cartoon 
representations. A: Blue: MR solution with PaAtg18 as search model (Superimposition of PDB codes 
5LTD and 5LTG), Grey: MR solution using KmHsv2 as a search model (PDB code: 4EXV). B: Both 
solutions rainbow colored from blue at the N-terminus to red at the C-terminus. Numbers indicate 
propeller. 
Table 3.2.3.: Result of first round of molecular replacement with Phaser_MR for the KlAtg21-
AgAtg16 complex structure. Using PaAtg18 (superimposed and truncated) or KmHsv2 (truncated) as 
polyalanine search models for KlAtg21.  
Search model Component copies Number of MR solutions Top LLG Top TFZ 
PaAtg18 2 1 1268.2 37.7 
KmHsv2 2 1 547.6 23.7 
 
Once the two PROPPIN molecules were placed in the electron density a first round of 
refinement clearly revealed additional electron density between the two molecules with a 
helical shape and a length of around 48 Å (Fig. 3.2.10 A). A second step of molecular 
replacement with the short dimeric coiled coil domain of ScAtg16 (PDB code: 3A7P) and the 
dimeric coiled coil domain of AgAtg16 (see section 3.2.6.) was then performed. Both 
molecules gave good solutions for both solutions from the first round of MR (Table 3.2.4.). 
Both Atg16 dimer gave a perfect fit in the additional electron density (Fig. 3.2.10 B). 
Conserved residues were placed at the same position for both Atg16 structures. The Atg16 
models were truncated at both ends to the length of accessible electron density. Because 
AgAtg16 (40-124) was used for crystallization the coiled coil domain of AgAtg16 was used 
for the final KlAtg21-AgAtg16 model. Due to the low resolution of the data (only 4.0 Å) side 
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chains are not visible, so the sequence of KlAtg21 was not built in and proteins were included 
as polyalanine models. One cycle of refinement was performed for the polyalanine KlAtg21-
AgAtg16 model after molecular replacement to evaluate the solution. The Rwork/Rfree values of 
0.38/0.39 show that the molecular replacement solution is correct. Data collection and 
refinement statistics are listed in Table 3.2.5 and a comparison with structures with a similar 
resolution limit is shown in (Fig. 3.2.11.).  
 
 
Figure 3.2.10.: First round of molecular replacement for Atg21 reveals additional electron 
density. Cartoon representation of two PROPPIN molecules in grey. A: Omit Fo-Fc electron density 
map contoured at 2 σ in green showed an additional helical shaped electron density.  B: Superimposed 
Atg16 coiled coil domain (blue ribbon presentation). 
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Table 3.2.4.: Result of second round of molecular replacement with Phaser_MR for the 
KlAtg21-AgAtg16 complex structure. Using truncated ScAtg16 dimer (PDB code: 3A7O) or 













PaAtg18 ScAtg16 1 13 1291.7 14.7 
PaAtg18 AgAtg16 1 11 1308.9 15.7 
KmHsv2 ScAtg16 1 15 622.8 13.9 
KmHsv2 AgAtg16 1 10 628.7 14.2 
 
Table 3.2.5.: Data collection and refinement statistics for the KlAtg21-AgAtg16(40-124) complex. 
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Figure 3.2.11.: Refinement statistic plots for the KlAtg21-AgAtg16(40-124) complex. Polyglon 
plot. Structure statistics (black numbers) are compared to PDB entries with similar resolution (red 
numbers). Plot was made with phenix.refine. 
3.2.3.3. Structure based comparison of yeast PROPPINs 
Although molecular replacement for KlAtg21-AgAtg16 gave consistent models with 
reasonable refinement statistics using all combinations of PaAtg18, KmHsv2, ScAtg16 (60-
118) and AgAtg16 (43-108) as search models, further proof of the model was done due to the 
low resolution of the structure. The protein sequence of KlAtg21 was aligned with other yeast 
PROPPINs, incorporating the known PaAtg18, KmHsv2 and KlHsv2 structures using T 




Figure 3.2.12.: Superimposition of PaAtg18, KlHsv2 and KmHsv2. Cartoon representation of 
PaAtg18 in light turquoise, KlHsv2 in light pink and KmHsv2 in light yellow. A: Overview of 
superimposed PROPPIN structures. Numbers represent propeller blades one to seven. B: Close 
up view of the phosphoinositide binding motif “FRRG”. Residues FRRG presented as sticks. 
C: KlAtg21-AgAtg16 2mFo-DFc electron density map countered at σ=1 around the FRRG 
motif. 
The blades in all three PROPPIN structures are conserved; only blade seven is less conserved. 
Especially, blades one to three, five and six are highly conserved, which includes the 
connecting loops (Fig. 3.2.13.). Superimposition of the structures verifies the alignment (Fig. 
3.2.14. A). Functionally important regions like the phosphoinositide binding “FRRG” motif 
are conserved and the three structures are very similar in this region (Fig. 3.2.14. B).  
To gain insights into the evolutionary conservation of amino acid positions based on the 
phylogenetic relations between homologous sequences in respect to the PaAtg18 and 
KmHsv2 structures ConSurf [44] was used. Yeast Atg21 sequences were aligned with either 
PaAtg18 or KmHsv2 using T Coffee Expresso. Multiple sequence alignments were done to 
calculate the amino acid conservation score. Of notice, besides a good overall conservation 
score the binding region of Atg16 at blade two and three is highly conserved (Fig. 3.2.13. and 
Fig. 3.2.14.). Especially, residues PaAtg18 R128 and KmHsv2 R105 that are homologous to 








Figure 3.2.13.: Structure based sequence alignment of yeast PROPPINs. Similar residues are 
shown bold and yellow boxed, identical residues are colored white and red boxed. Secondary structure 
elements are marked. PROPPINS form a seven-bladed β-propeller scaffold (numbers 1-7) each blade 
consists of four antiparallel β-strands (letters A-D). Alignment was done with T-Coffee Expresso [5], 





Figure 3.2.14.: ConSurf analysis of PaAtg18 and KmHsv2 for conserved Atg21 residues. Surface 
representation of A: PaAtg18 and B: KmHsv2. Cartoon representation of C: PaAtg18 and D: 
KmHsv2. Overview of superimposed PROPPIN structures. The amino acids are colored by their 
conservation grades as shown in the color-coding bar with turquoise-through-maroon indicating 
variable-through-conserved. An arginine important for Atg16 binding is presented as sticks in the 





3.2.3.4. Structure analysis of the KlAtg21-AgAtg16 complex 
Crystal packing of the KlAtg21-AgAtg16 complex is very loose, which might explain the 
weak diffraction of the crystals (Fig. 3.2.15.). 
  
Figure 3.2.15.: Crystal packing in the KlAtg21-AgAtg16 crystal. One PROPPIN-Atg16 complex in 
the asymmetric unit is shown in color. Crystallographic symmetry-related molecules are shown in 
grey. 
 
The crystal structure clearly shows the formation of a complex with two KlAtg21 molecules 
binding one AgAtg16 dimer, however molecular details of interaction cannot be observed due 
to the low resolution (4.0 Å) of the electron density map (Fig.3.1.16.). The residues of the 
Atg16 molecule cannot build in with confidence because no side chains are visible at this low 
resolution, but molecular replacement localized both ScAtg16 and AgAtg16 structures in the 
same manner. Of notice, no SeMet crystals were obtained from the complex, which would 
have aided the sequence assignment. Nevertheless, important conclusions can be made about 






Figure 3.1.16.: Electron density map of the KlAtg21-AgAtg16 complex crystals. The 4.0 Å 
resolution 2mFo-DFc electron density map contoured at σ=1 in grey. The refined molecular 
replacement solution with the PaAtg18 and AgAtg16 structures are shown as poly-alanine models in 
stick representation. 
 
KlAtg21 adopts the typical PROPPIN fold as seen in the electron density map (Fig. 3.2.16.). 
AgAtg16 binds to KlAtg21 blades two and three (Fig. 3.1.17.), which is opposite to the 
membrane binding motif FRRG on strand 5D and the loop connecting it with strand 6A. The 
two Atg21 molecules adopt a reversed V conformation to each other and give the impression 
to bend from the membrane towards the Atg16 dimer. According to this model residues 
KlAtg21 R103 and AgAg16 D78 come in close contact (Fig. 3.2.18.). The group of Prof. 
Michael Thumm recently proposed that ScAtg16 D101 and E102 of the coiled coil domain 
directly interact with Atg21 [58]. AgAtg16 D78 is syngeneic to ScAtg16 D101. To deepen the 
understanding of the interaction of Atg21 and Atg16 and to confirm the model presented here 






Figure 3.1.17.: Overview of the KlAtg21-AgAtg16 crystal structure. Two KlAtg21 molecules form 
a complex with the C-terminal part of the Atg16 coiled coil dimer. Interaction takes places between 
blade two and three of the KlAtg21 PROPPIN structure. Cartoon representation of KlAtg21 rainbow 
colored from blue at the N-terminus to red at the C-terminus and AgAtg16 in grey. Numbers (1-7) 
correspond to the KlAtg21 PROPPIN blades.  
 
 
Figure 3.1.18.: Proposed model for KlAtg21-AgAtg16 interaction. Interaction of KlAtg21-
AgAtg16 probably occurs between residue AgAtg16 D78 and KlAtg21 R103 that is located opposite 





3.2.4. Identification of the KlAtg21 – AgAtg16 binding site by charge modification and 
analytic gel filtration analysis 
Upon structure determination of the KlAtg21-AgAtg16 complex and prior observations of the 
importance of ScAtg16 E102 and D101 for complex formation [58], Prof. Michael Thumm 
suggested the following KlAtg21 and AgAtg16 mutants to get further insights into Atg21-
Atg16 binding (Fig. 3.2.19.). Mutations reverse the charge of the residues that are likely to 
contribute to complex formation. Upon charge reversal, complex formation is probably 
restored. The KlAtg21 R103E and AgAtg16 (70-124) D78R mutants were purified and 
complex formation was studied by analytical gel filtration. As shown before complex 
formation was observed for KlAtg21 WT with AgAtg16 (70-124) WT (Fig. 3.2.20). No 
complex was formed using KlAtg21 WT and the mutant AgAtg16 (70-124) D78R (Fig. 
3.2.21.) or the mutant KlAtg21 R103E and AgAtg16 WT (Fig. 3.2.22.), indicating their 
importance for complex formation. However, complex formation was not restored for Atg16 
(70-124) D78R with KlAtg21 R103E in vitro (Fig. 3.2.23.). 
 




Figure 3.2.20.: Analytic gel filtration of KlAtg21 and AgAtg16 (70-124). Chromatograms of size 
exclusion chromatography using a Superdex 200 10/300 GL column. Red curve: KlAtg21, green 
curve: AgAtg16 (70-124), blue curve: KlAtg21 and AgAtg16 (70-124). Schägger gel electrophoresis 
of elution fractions are shown on the right side. M=Marker, Numbers refer to elution fractions. Bands 





Figure 3.2.21.: Analytic gel filtration of KlAtg21 R103E and AgAtg16 (70-124). Chromatograms 
of size exclusion chromatography using a Superdex 200 10/300 GL column. Red curve: KlAtg21 
R103E, green curve: AgAtg16 (70-124), blue curve: KlAtg21 R103 E and AgAtg16 (70-124). 
Schägger gel electrophoresis of elution fractions are shown on the right side. M=Marker, Numbers 
refer to elution fractions. Bands were colored according to chromatogram color.  
 
 
Figure 3.2.22.: Analytic gel filtration of KlAtg21 and AgAtg16 (70-124) D78R. Chromatograms of 
size exclusion chromatography using a Superdex 200 10/300 GL column. Red curve: KlAtg21, green 
curve: AgAtg16 (70-124) D78R, blue curve: KlAtg21 and AgAtg16 (70-124) D78R. Schägger gel 
electrophoresis of elution fractions are shown on the right side. M=Marker, Numbers refer to elution 





Figure 3.2.23.: Analytic gel filtration of KlAtg21 R103E and AgAtg16 (70-124) D78R. 
Chromatograms of size exclusion chromatography using a Superdex 200 10/300 GL column. Red 
curve: KlAtg21 R103E, green curve: AgAtg16 (70-124) D78R, blue curve: KlAtg21 R103E and 
AgAtg16 (70-124) D78R. Schägger gel electrophoresis of elution fractions are shown on the right 
side. M=Marker, Numbers refer to elution fractions. Bands were colored according to chromatogram 
color.  
3.2.5. Hypothetical model for the coordination of Atg21 and the Atg12~Atg5/Atg16 
complex 
Solving the crystal structure of the KlAtg21-AgAtg16 complex reveals a new structural piece 
how the Atg12~Atg5/Atg16 complex is recruited to the membrane and thereby defines the 
Atg8 lipidation site. With superimposition of the new Atg21-Atg16 complex structure and the 
known crystal structures of ScAtg16 (PDB code: 3A7P) and human Atg12~Atg5 conjugate in 
complex with an N-terminal fragment of Atg16L1 and a fragment of Atg3 (PDB code: 
4NAW) and ScAtg18 (PDB code: 3VWX) in complex with a fragment of PfAtg3 (PDB code: 
4EOY), I propose a model of the Atg21 bound Atg12~Atg5/Atg16 complex and how it 
interacts with Atg8 (Fig. 3.2.24.). Atg16 binds the Atg12~Atg5 conjugate at the N-terminal 
part. Atg12~Atg5 conjugate functions as an E3-like enzyme for Atg8 lipidation. Atg12 
recruits Atg3 by direct interaction and rearranges its catalytic site. The C-terminus of Atg8 is 
processed by the cysteine protease Atg4 to expose a glycine. Atg8 is then activated by E1-like 
activating enzyme Atg7. Direct binding at the top of the Atg21 propeller opposite to Atg16 
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localizes Atg8 to a pool of phosphatidylethanolamine. Atg3 acts as an E2 enzyme for Atg8 
and conjugates Atg8-PE. 
 
 
Figure 3.2.24.: Hypothetical model of Atg21 bound Atg12~Atg5/Atg16 complex 
interacting with Atg8 and Atg3. Cartoon representation of the complex. Model was made by 
superimposition and manual arrangement. KlAtg21 in dark blue, stick representation of the FRRG 
motif in red, Atg8 binding site in wheat, corresponding residue ScAtg21 D146 in pink. Atg16 
(Superimposition of KlAtg21-AgAtg16/ C-terminal truncated coiled coil domain of ScAtg16, PDB 
code: 3A7P) in grey and human Atg12~Atg5/Atg16N with a fragment of Atg3 (PDB code: 4NAW), 
colored in red, green, grey and yellow respectively. Unknown linker between Atg16 coiled coil and 
Atg5-binding domain are marked with arrows. A fragment of PfAtg3 (PfAtg8-PfAtg3 complex, PDB 
code: 4EOY) in yellow defines the site of Atg8 interaction. PfAtg8 is replaced by ScAtg8 (ScAtg8-










3.2.6. Structure of the AgAtg16 coiled coil domain  
3.2.6.1. Crystallization of AgAtg16 
During screening of crystallization conditions for KlAtg21-AgAtg16 (40-124) by Dr. Karin 
Kühnel crystals appeared after 30 days in one condition of the Hampton SaltRX screen 
(Fig. 3.2.25.). Crystallization took place under in-situ proteolysis with 1:500 Clostripain (CL) 
at 20 °C and could only be reproduced with this one purification batch.  
 
Figure 3.2.25.: Initial AgAtg16 (40-124) crystals. Crystals growing on a 96-well sitting drop plate. 
Crystals appeared after 30 days in SaltRX screen. Crystallization condition: 0.1 M Bis-Tris propane 
pH 7, 1 M Ammonium citrate tribasic. AgAtg16 (40-124) was mixed with 1:500 Clostripain. 
 
These crystals appeared to have the same space group and very similar cell dimensions to 
SCOC-FEZ1 crystals observed from PEG 20000 conditions (Table 3.2.6.). Because of the 
very similar appearance and cell dimensions to SCOC-FEZ1 crystals, I took over all further 
experiments with these crystals.  
Crystals were then identified as partially proteolytic digested AgAtg16 crystals by Schägger 
gel electrophoresis (Fig. 3.2.26.). The average purification batch of KlAtg21-AgAtg16(40-
124) contains a similar ratio of Atg21 to Atg16. In comparison, the purification batch which 
yielded AgAtg16 crystal did contain only a very small amount of Atg21. Clostripain digestion 





Table 3.2.6.: Comparison of space group and cell dimensions of the AgAtg16 (40-124) and SCOC-
FEZ1 (grown in PEG 20.000 conditions) crystals 
 AgAtg16(40-124) crystal SCOC-FEZ1 crystal 
Space group P6522 P6122 or P6522 
Cell dimensions 
a, b, c (Å) 
α, β, γ (°) 
 
106.15, 106.15, 148.94 
  90.0,     90.0, 120.0 
 
~104, ~104, ~148 
  90.0,  90.0, 120.0 
 
 
Figure 3.2.26.: Schägger gel electrophoresis of different KlAtg21-AgAtg16 (40-124) purification 
batches.  M: Marker. 1. line shows the purification batch that gave the AgAtg16 crystals, 2. line same 
purification batch incubated with 1:500 Clostripain (CL), 3. lane: AgAtg16 crystals were fished and 
solubilized in gel filtration buffer, 4. lane: purification batch that was used for growing KlAtg21-
AgAtg16 crystals. 
 
Crystallization conditions were optimized on 24-well hanging drop plates. Optimal 
crystallization conditions were found for drops composed of 3 µl 6.8 mg/ml AgAtg16 (40-
124) proteolysed with 1:1000 CL, 2 µl crystallization solution made of 0.6 M Bis-Tris 
propane pH 6.5 and 0.6 M ammonium citrate tribasic and 0.5 µl 30 % (w/v) 1,5-
diaminopentane dihydrochloride. Huge hexagonal crystals started growing after 7 days 




Figure 3.2.27.: Optimized AgAtg16 (40-124) crystals. Crystals appeared after 7 days in 0.1 M Bis-
Tris propane pH 6.5, 0.6 M Ammonium citrate tribasic on 24-well Linbro plate. 
 
3.2.6.2. Mutagenesis of AgAtg16 for selenomethionine labeling 
Since the first low resolution datasets collected for AgAtg16 crystals were not sufficient for 
molecular replacement, structure determination was attempted by single-wavelength 
anomalous diffraction (SAD). Methionines in the protein can be labelled with Selenium by 
minimal expression with selenomethionine. AgAtg16(40-124) contains only two methionines 
at the C- and N-terminus that might be flexible. To obtain a stronger anomalous signal a 
mutant was created that introduces an additional methionine. Isoleucine 81 was chosen 
because of its outer position in the heptad repeat, meaning that a mutation is very likely not to 
interfere with dimer formation. AgAtg16 (40-124) I81M was expressed and purified like the 
native protein (Fig. 3.2.28.). Functionality of AgAtg16 (40-124) I81M was tested by 
analyzing the complex formation with KlAtg21 by analytic gel filtration (Fig. 3.2.29.). 




Figure 3.2.28.: Purification of AgAtg16 (40-124) I81M. A, C: HisTrap affinity chromatography. 
Schägger gel and corresponding chromatogram. B, D: Size exclusion chromatography using a HiLoad 
16/60 Superdex 200 column. Schägger gel and corresponding chromatogram. M: Marker, Start: Input 
for SEC. 
 
Figure 3.2.29.: Analytic gel filtration of KlAtg21 and AgAtg16 (40-124) I81M. Chromatograms of 
size exclusion chromatography using a Superdex 200 10/300 GL column. Red curve: KlAtg21, green 
curve: AgAtg16 (40-124) I81M, blue curve: KlAtg21 and AgAtg16 (40-124) I81M.  
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3.2.6.3. Heavy metal soaking with magic triangle 
Another option to obtain phase information is the heavy-atom derivatization. With this 
technique anomalous scatterers like heavy atoms are incorporated into the protein crystal. 
Because heavy atom handling is risky the JBS Magic Triangle Phasing Kit was the first 
choice. The “Magic Triangle” 5-Amino-2,4,6-triiodoiso-phthalic acid (I3C) consists of three 
covalently bound iodine atoms forming an equilateral triangle with a side length of 6.0 Å [10]. 
Compared to many heavy metal compounds IC3 has only low toxicity. IC3 was incorporated 
into AgAtg16(40-124) crystals by soaking and co-crystallization. For co-crystallization 
different concentrations of IC3 (5, 10 and 15 mM) were added to the crystallization solution. 
Crystals grew in the same manner as native crystals. For soaking native crystals were 
transferred to a fresh drop of crystallization solution supplemented with 100, 250 or 500 mM 
IC3. Data for crystals with incorporated IC3 were collected at the same wavelength as an in-
house Cu Kα beamline (1.54 Å) as suggested [10]. Crystal diffracted weaker than native 
crystals and the strength of the anomalous signal was not suitable for SAD phasing. 
3.2.6.4. X-ray data collection and processing for AgAtg16 
Data for structure determination of the AgAtg16 (40-124) were collected from a crystal 
growing in a 24-well hanging drop plate. Crystal was soaked in a solution of 1:1 
crystallization solution and 30 % ethylene glycol before flash cooling in liquid nitrogen. Data 
were collected at 100 K at beamline X10SA (Swiss Light Source, Paul Scherrer Institute, 
Villigen, Switzerland) (Fig. 3.2.30.). Four test shots were taken at the best position for 
indexing of the crystal Unit cell and collection strategies were determined with go.com (local 
software written by Dr. M. Wang). 
 
Figure 3.2.30.: AgAtg16 (40-124) crystal mounted at the Swiss Light Source. The yellow square 
has the size of 10 x 50 µm. 
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A native dataset of 360 degrees was collected at 0.979 Å wavelength (for details see table 
3.2.7.). Data were processed with input values specific for the PILATUS 6M detector using 
the XDS software package. XDS defined the space group as P6522, which was confirmed by 
the absences of reflections along the screw axis (0,0,6n).  
Table 3.2.7.: Data collection for AgAtg16(40-124) crystal 
Beamline X10SA, Swiss Light Source (Switzerland) 
Detector PILATUS 6M (Dectris) 
Detector distance 300 mm 
φ/Δφ 0.25/ 360 ° 
Exposure time 0.25 sec 
Beam intensity 0.3 
Λ 0.979 Å 
Number of frames 1440 
 
3.2.6.5. Matthews coefficient for the AgAtg16(40-124) crystal 
The Matthews coefficient [84] was calculated using the CCP4 program suite to estimate the 
number of macromolecules in the asymmetric unit. This number is important to search for the 
correct number of molecules during structure determination. The molecular weight of a 
AgAtg16(40-124) dimer 19125 Da was used as input. With 74 % probability the calculated 
Matthew coefficient (Table 3.2.8.) assumed two dimers per asymmetric unit with 41.77 % 
solvent content. The demanding solvent content fits well with the relatively low diffraction of 
the crystals. 
 
Table 3.2.8.: Matthews coefficient for AgAtg16(40-124) crystals. For estimated molecular weight   
of 19125 Da  
Nmol/asym  Matthews Coeff  %solvent       P(3.20)     P(tot) 
_____________________________________________________________ 
  1         6.33           80.59          0.00         0.00 
  2           3.17             61.18          0.35         0.25 
  3          2.11             41.77          0.64         0.74 
  4           1.58             22.36          0.00         0.00 
  5          1.27             2.95          0.00         0.00 
   
 
3.2.6.6. Molecular replacement for AgAtg16 
Since selenomethionine labeled protein did not crystallize and soaking of the crystals in IC3 
for phasing gave no significant anomalous signal, the structure was determined by molecular 
replacement. Phaser_MR in the CCP4 program suite was used to successfully search for two 
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dimers with the structure of yeast Atg16 (PDB code 3A7O) as search model. ScAtg16 and 
AgAtg16 are highly conserved in the coiled coil domain (Fig. 3.2.31.). After one cycle of 
refinement with Refmac5 the initial model of AgAtg16 was build using arp_warp_classic.  
 
Figure 3.2.31.: Alignment of ScAtg16 and AgAtg16. Alignment was done using Clustal omega. 
Shading indicate level of conservation.  
 
3.2.6.7. Refinement and structure validation for AgAtg16 
The AgAtg16 structure was refined with Phenix and manual model building in Coot. The final 
round of refinement gave Rwork/Rfree values of 0.27/0.33 % (for complete data statistic for 
refinement see table 3.2.9.). The final model of AgAtg16 (40-124) contains four molecules in 
the asymmetric unit forming two coiled coil dimers with chains AB and CD. The model 
includes residues 43-108 for the dimer with chains A and B and 52-108 for the dimer with 
chains C and D. The structure was validated using Phenix polygon plot that compares the 
refinement statistics to structures in the PDB with a similar resolution cut-off (Fig. 3.2.32. A). 
All values are within the permitted range. The Ramachandran plot was calculated by Phenix 
and used to analyze the geometry of the model (Fig. 3.2.32. B). 96 % of the residues are 




Table 3.2.9.: Data collection and refinement statistics of AgAtg16 (40-124). Statistics for the 
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Figure 3.2.32.: Refinement statistic plots for AgAtg16 (40-124). A: Polyglon plot. Structure 
statistics (black numbers) are compared to PDB entries with similar resolution (red numbers). B: 
Ramachandran plot of all non Pro/Gly residues. Plots were made by Phenix refine. 
 
3.2.6.8. Structure analysis for AgAtg16 
X-Ray structure of AgAtg16(40-124) reveals that AgAtg16 is a parallel oriented, left-handed 
coiled coil dimer. The asymmetric unit contains four AgAtg16 molecules A, B, C and D that 




Figure 3.2.33.: Four AgAtg16 molecules in the asymmetric unit. Two AgAtg16 molecules form a 
dimer respectively. Cartoon representation. Chains are colored as A dark green, B light green, C 
orange, D light orange. 
 
Packing of the crystal is not very loose and does not explain the low diffraction limit (Fig. 
3.2.34.). The two dimers do not overlap perfectly with a RMSD of 1.536 Å for the Cα atoms. 
Dimer AB comprises residues 43-108 that form nine heptad repeats and has a length of about 
100 Å. The N-terminus of dimer CD is disordered, therefore dimer CD compromises residues 
52 to 108 with a length of about 85 Å and eight heptad repeats. The coiled coil radius of 5.18, 
calculated with TWISTER [130], is similar to coiled coil radius of 4.85 that was measured for 






Figure 3.2.34.: Crystal packing of the AgAtg16 crystal. Four molecules forming two AgAtg16 
dimers in the asymmetric unit are shown in color. Crystallographic symmetry-related molecules are 
shown in grey. 
Calculating the electrostatic potential shows mainly positive charged amino acids at the dimer 
interface and negatively charged amino acids on the AgAtg16 dimer surface (Fig. 3.2.35.). 
For AgAtg16 ccd the coiled coil heptad repeat pattern “abcdefg” is mainly engaged of polar 
residues at position a and hydrophobic residues at position d (Fig. 3.2.36.).  
 
Figure 3.2.35.: Electrostatic potential surface for AgAtg16 dimer AB. Electrostatic potential were 




Figure 3.2.36.: Helical wheel projection of the residues in the AgAtg16 dimer AB. Black: 
hydrophobic residues, Yellow: polar residues, Red: acidic residues, Blue: basic residues. Dashed lines 





3.3. Characterization of the SCOC-FEZ1 complex 
Because SCOC-FEZ1 complex plays a role in the regulation of autophagy the goal of our 
laboratory was to characterize and determine the structure of the SCOC-FEZ1 complex. The 
coiled coil domain of SCOC (78-159) was already solved and published by Dr. Caroline 
Behrens from our laboratory [11]. FEZ1 is a mainly natively unfolded protein and therefore a 
difficult target for crystallography. Furthermore, recombinant expressed full length FEZ1 was 
not soluble under native conditions. Studies from Dr. Caroline Behrens on the SCOC-FEZ1 
complex showed that SCOC dimerization and SCOC residue R117 is vital for complex 
formation. She found that FEZ1 residues M227 to L290 provide the minimal coiled coil 
domain to form a complex with SCOC (78-159) [12]. 
3.3.1. Expression and purification of SCOC-FEZ1 complexes 
Strep tagged SCOC ccd and His tagged FEZ1 ccd were coexpressed. The purification 
protocol of Dr. C. Behrens used a StrepTrap column and then size exclusion chromatography. 
The size exclusion chromatogram shows that there is SCOC that did not form a complex in 
the purified protein solution (Fig. 3.3.1 A, C). Since crystallization attempts resulted in SCOC 
crystals only, the purification of the complex was optimized. An additional Ni-Sepharose 
purification step before the StrepTrap column was introduced. With two steps of affinity 
chromatography interaction partners that did not form a complex are removed. Size exclusion 
chromatography showed only one peak and both proteins were evenly distributed on a 




Figure 3.3.1.: Purification of SCOC (78-159) FEZ1 (227-290) complexes. Elution profiles of SCOC 
(78-159) FEZ1 (227-290) size exclusion chromatography. A: Size exclusion chromatography by 
Superdex 200 10/300 GL after step StrepTrap affinity chromatography. B: Size exclusion 
chromatography by HiLoad 16/60 Superdex 75 prep grade after Ni-Sepharose purification followed by 
StrepTrap affinity chromatography. C: Schägger gel analysis of selected fractions from A. D: 
Schägger gel analysis of selected fractions from B. M: Marker. Numbers correspond to elution 
fractions. 
The minimal complex was not very stable and in crystallization trials only SCOC crystallized 
(see 3.3.3.1). Since SCOC has a mainly negative surface charge and the coiled coil domain of 
FEZ1 has a number of negative charged residues, a longer FEZ1 (225-295) construct was 
chosen for SCOC (78-159) complex formation. The FEZ1 (225-295) construct contains seven 
more mainly positively charged residues. In contrast to FEZ1 (227-290) with a net charge of  
-5, FEZ1 (225-295) has a net charge of -1/0. Indeed, the complex of SOC (78-159)-FEZ1 
(225-295) was much more stable and therefore used for all further experiments. The 
optimized purification was up scaled and done at 4 °C to avoid protein degradation (Fig. 




Figure 3.3.2.: Optimized purification of the SCOC (78-159)-FEZ1 (225-295) complex. A: 
Schägger gel analysis of Ni-Sepharose purification. B: Schägger gel analysis of selected fractions from 
StrepTrap chromatography. C: Schägger gel analysis of selected fractions from size exclusion 
chromatogram by HiLoad 16/60 Superdex 75 prep grade. D: Elution profile from StrepTrap 
chromatography. E: Elution profile from size exclusion chromatography. M: Marker, P: Pellet, S: 
Supernatant, ft: flow through, W1-4: Wash fractions, E1-4: Elution fractions, Start: Material loaded on 
column. Numbers correspond to elution fraction. 
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Since coiled coil proteins are difficult targets for molecular replacement and only the SCOC 
structure is known, structure determination was attempted by SAD phasing using 
selenomethionine labeled protein. FEZ1 contains only two methionines at the C- and N-
terminus that might be flexible due to their location, which would give only a weak or no 
anomalous signal. To achieve a stronger anomalous signal two mutants were created with an 
additional methionine site, FEZ1 (225-295) L251M and L273M. FEZ1 mutants were 
coexpressed with SCOC (78-159) L105M that was used for solving the SCOC ccd structure 
by SAD phasing. Selenomethionine labeled protein complexes were purified in the same 
manner as native protein but included 2 mM β-Mercaptoethanol in all buffers.  
 
3.3.2. Biochemical characterization of the SCOC (78-159)-FEZ1 (225-295) complex 
3.3.2.1. Analysis of secondary structure and stability of the SCOC-FEZ1 complex by CD 
spectroscopy 
The SCOC-FEZ1 complex was analyzed by CD spectroscopy. The CD spectrum was 
measured from 180 to 260 nm at 20 °C. The CD spectrum shows a maximum at 195 nm and 
two minima around 208 and 222 nm (Fig. 3.3.3. A), giving a typical curve for α-helical 
secondary structure as expected for coiled coil domain proteins. This confirms folding of the 
protein complex. A melting curve was recorded at 222 nm from 20 to 90 °C, the complex is 
stable with a melting temperature of 48 °C (Fig. 3.3.3. B). 
 
Figure 3.3.3.: CD spectroscopy of the SCOC(78-159)-FEZ1 (225-295) complex. 10 µM SCOC (78-
159) FEZ1 (225-295) was dialyzed overnight in 20 mM HEPES pH 7.5 and 200 mM NaF. A: CD 
Spectrum of SCOC (78-159) FEZ1 (225-295) from 180 to 260 nm. B: Melting curve for SCOC (78-
159) FEZ1 (225-295) measured at 222 nm from 20 to 90 °C.  
 
126 
3.3.2.2. Stoichiometric analysis of the SCOC(78-159)-FEZ1 (225-295) complex by SEC-
MALLS 
The composition of the SCOC (78-159) FEZ1 (225-295) complex was investigated by SEC-
MALLS measurements. After separation by size on a Superdex 10/300 GL samples were 
loaded into a MALLS detector (Fig. 3.3.4.). MALLS gives the molecular weight of a protein 
independent of its shape and can therefore be used for the determination of molecular weights 
of non-globular proteins. The calculated molecular mass of Strep-SCOC (78-159) is 11.004 
kDa. SEC-MALLS measurements by C. Behrens gave 26.3±0.3 kDa, which correlates to a 
dimer [12]. The calculated molecular mass of His-FEZ1 (225-295) is 10.256 kDa. SEC-
MALLS measurements of the Strep-SCOC (78-159)-His-FEZ1 (225-295) complex give a 
molecular mass of 43.9±0.2 kDa, which is consistent with a stoichiometry of 1:1 assuming 
that both proteins are dimers (Table 3.3.1.). 
 
 
Figure 3.3.4.: SEC-MALLS of SCOC(78-159)-FEZ1(225-295) complex. Left chromatogram: Peaks 
correspond to size exclusion chromatography elution volume (x-axis). Horizontal lines indicate 
differential refractive index (y-axis). Measured value was only considered for the main peak (green 
line). Right chromatogram: Size exclusion chromatography using a Superdex 200 10/300 GL column 






Table 3.3.1.:  SEC-MALLS measurements of SCOC(78-159)-FEZ1(225-295) complex. Listed are 
the average molar mass measured by SEC-MALLS and the theoretical mass calculated from the 
protein sequence including Tags. The average molar weight of SCOC (78-159) was measured by Dr. 
C. Behrens [12]. 
Protein SCOC(78-159) FEZ1(225-295) SCOC(78-159) 
-FEZ1 (225-295) 
complex 
Average molar weight 
(g/mol) 
2.63x104 (±0.3 %) 
(Dr. C. Behrens) 
- 4.439x104 (±0.010 %) 
Theoretical molar 







3.3.3. Crystallization of the SCOC-FEZ1 complex 
3.3.3.1. SCOC(78-159)-FEZ1(227-290) crystallization 
Purified SCOC(78-159)-FEZ1(227-290) was used for crystallization with commercial 
crystallization screens in 96-well plates. Crystals in different shapes were obtained in different 
conditions in MIDAS and ProComplex screens (Fig. 3.3.5.). Crystals were soaked in 
cryoprotectant and flash cooled in liquid nitrogen. Crystals were measured at beamline 
X10SA at the Swiss Light Source (SLS) and diffracted up to 3.3 Å. Indexing gave the same 
space group and cell dimension as SCOC crystals and structure determination using molecular 




Figure 3.3.5.: Initial crystals from SCOC(78-159)-FEZ1(227-290) crystallization. Letters A-D 
correspond to the crystallization conditions stated in table 3.3.2. 
 
Table 3.3.2.: Initial crystallization conditions for SCOC(78-159)-FEZ1(227-290) crystallization 
from 96-well plate screening 
Crystals Buffer composition 
A 10 % (v/v) Polypropylene glycol P 400 
B 0.1 M Tris pH 8, 0.2 M sodium sulfate decahydrate, 20 % (w/v) Sokalan® HP56 
C 0.2 M potassium citrate tribasic monohydrate, 15 % (v/v) Sokalan® CP42 
D 0.1 M Tris pH 8.5, 25 % (v/v) Sokalan® CP5 
 
3.3.3.2. SCOC(78-159)-FEZ1(225-295) crystallization 
After optimization of the purification protocol the SCOC(78-159)-FEZ1(225-295) complex 
was used for crystallization. Using the more stable complex new crystal forms were obtained 
in commercial crystallization screens. 96-well plates with 200 nl sitting drops at 20 °C gave 
several crystallization hits (Fig. 3.3.6.). Only crystals from PEG 20000 (Fig. 3.3.6. D) and 
isopropanol conditions (Fig. 3.3.6. B) could be reproduced on 24 well plates and were a target 




Figure 3.3.6.: Initial crystals from SCOC(78-159)-FEZ1(225-295) crystallization. Letters A-D 
correspond to the crystallization conditions stated in table 3.3.3. 
 
Table 3.3.3.: Initial crystallization conditions for SCOC(78-159)-FEZ1(225-295) crystallization 
from 96-well plate screening 
Crystals Buffer composition 
A 0.1 M Tris pH 8, 0.15 M sodium chloride, 8 % (w/v) PEG 6000 
B 0.1 M Tris pH 8, 0.1 M sodium chloride, 8 % (w/v) PEG 20000 
C 0.1 M Tris pH 7.5, 0.2 M lithium sulfate monohydrate, 5 % (w/v) PEG 4000 
D 20 % (v/v) 2-Propanol, 0.1 M tri-sodium citrate dihydrate pH 5.6,  
20 % (w/v) PEG 4000 
 
In order to get data for SAD phasing methionine mutants of SCOC- FEZ1 complex were used 
for crystallization trials as well. Purified selenomethionine labelled proteins were used in the 
same crystallization conditions as native complex. SCOC (78-159) L105M - FEZ1 (225-295) 
L273M complex crystallized in the same conditions as the native complex. The FEZ1 (225-
295) L251M mutant did not crystallize. 
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3.3.3.3. Optimization of SCOC(78-159)-FEZ1(225-295) crystals in PEG 20000 conditions 
Crystals obtained from commercial ProComplex screen condition 65 (0.1 M Tris pH 8, 0.1 M 
Sodium chloride, 8 % (w/v) PEG 20000) had a nice shape and promising size. Initial crystals 
diffracted up to 4.5 Å. To further optimize these crystals different methods were applied as 
summarized in table 3.3.4.. 
Table 3.3.4.: Optimization approaches for SCOC(78-159)-FEZ1(225-295) crystallization  
Optimization method Influence on morphology Influence on diffraction 
Grid screen Larger and more defined crystals Enhanced diffraction from initial 
4.5 Å to 3.4 Å 
Streak seeding Faster crystallization No further influence on 
diffraction 
Ratio of protein to 
precipitant 
Larger and more defined crystals No further influence on 
diffraction 
Additive Screen Overnucleation Not tested 
In-situ proteolysis Different shape Less diffraction 
Cryoprotectant screen  
Molecular Dimensions 
CryoProtX™  
Less ice on crystals No influence on diffraction 
Tag removal by Thrombin 
cleavage 
Crystals very similar to native 
crystals 
Loss of diffraction 
Manual Dehydration Crystals break or turn yellow   Loss of diffraction 
Oil to control vapor 
diffusion rate 
No difference  No influence on diffraction 
Drop size 
Ratio of protein to 
precipitant 
Crystals grew smaller or same size  No influence on diffraction 
Crystallization at 4 °C Crystal did not grow until plate was 
moved to 20 °C 
No influence on diffraction 
  
Grid screen 
First commercial screen conditions were reproduced using solutions prepared with ultrapure 
chemicals. The condition was optimized with grid screens on a 24-well plate using hanging 
drops. Drop size was up scaled from 200 nl to 2 µl. For grid screening the pH and precipitant 
concentration of the crystallization solution was varied along row and column. Crystals in 24-
well hanging drop plates appeared after 5-7 days and grew for 5 days to a larger size than in 
96-well sitting drop plates. Protein concentrations from 5 to 15 mg/ml were tested and biggest 




Figure 3.3.7.: Elongated hexagonal SCOC(78-159)-FEZ1(225-295) crystals from grid screen 
optimization. 24-well Linbro plate. Drop size 2 µl. Letters A-B correspond to the crystallization 
conditions stated in table 3.3.5. 
Table 3.3.5.: Crystallization conditions for SCOC(78-159)-FEZ1 (225-295) crystals from grid 
screen optimization 
Condition Buffer composition 
A 0.1 M Tris pH 7.5, 0.1 M sodium chloride, 10 % (w/v) PEG 20000 




While refining crystallization conditions in 24-well plates, streak seeding using small crushed 
crystal that provide nucleation sites were tested. Using streak seeding crystals grew faster and 
less multiple crystals were observed. 
Ratio of protein to precipitant 
Different ratios of protein to precipitant were tested to further improve crystal growth. Best 
results were observed for crystals grown in 2 µl protein of 15 mg/ml with  




Figure 3.3.8.: Elongated hexagonal SCOC(78-159)-FEZ1(225-295) crystals from drop size 
optimization. Optimized crystals after Grid Screen refinement using streak seeding and a drop size of 
2 µl protein 15 mg/ml and 1 µl precipitant solution. 24-well Linbro plate. Letters A-D correspond to 
the crystallization conditions stated in table 3.3.6. 
Table 3.3.6.: Crystallization conditions for SCOC(78-159)-FEZ1(225-295) crystals from drop 
size optimization 
Condition Buffer composition 
A 0.1 M Tris pH 8, 0.1 M sodium chloride, 6 % (w/v) PEG 20000 
B 0.1 M Tris pH 8, 0.1 M sodium chloride, 8 % (w/v) PEG 20000 
C/D 0.1 M Tris pH 7.5, 0.1 M sodium chloride, 8 % (w/v) PEG 20000 
 
Additive Screen 
The Hampton Additive Screen was used to find additives that could optimize crystallization. 
Therefore, two drops composed of 1.5 µl 15 or 10 mg/ml protein complex and 1.5 µl 
crystallization solution (0.1 M Tris pH 7.5, 0.1 M Sodium chloride, 10 % (w/v) PEG 20000) 
was pipetted on a 24-well Linbro plate. 0.3 µl of each additive was added respectively. 
Additives that further optimized crystallization were not found. Instead a shower of very 
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small crystals was observed in many conditions (Fig. 3.3.9. A) or crystals did not grow as 
large as without additives (Fig. 3.3.9. B). 
 
 
Figure 3.3.9.: SCOC(78-159)-FEZ1(225-295) crystals from additive screen. Precipitant contained 
0.1 M Tris pH 7.5, 0.1 M Sodium chloride, 10 % (w/v) PEG 20000 A: Additive 0.1 M Copper(II) 
chloride dihydrate resulted in a crystal shower. B: Crystal grew only to very small size with additive 
0.1 M Zinc chloride. 
 
Manual Dehydration 
One reason for poor diffraction of crystals is loose packing of protein molecules in the crystal 
lattice. Dehydration can reduce the solvent content in the crystal, lead to tighter packing and 
thereby improve the diffraction limit. Dehydration was approached by the step-wise addition 
of increasing PEG 400 concentrations (5 – 25 %) or of 4 M Trimethylamine oxide (TMAO) 
as described in [52]. Crystals were transferred from 24-well Linbro plates into fresh drops of 
mother liquor and increasing dehydration conditions. Crystals were equilibrated at each step 
for ~5 minutes. Most crystals cracked, vanished or turned yellow during this treatment. 
Crystals that remained intact after step-wise dehydration were cryoprotected and flash-cooled 
in liquid nitrogen. Another approach was to transfer coverslips with crystals into a new 24-
well plate with crystallization conditions of increasing PEG or conditions as described in [52]. 
Crystals were equilibrated over the fresh mother liquor for 12 hours. Crystals appeared yellow 
and jelly-like after this dehydration approach (Fig. 3.3.10.). Crystals were cryoprotected and 





Figure 3.3.10.: SCOC(78-159)-FEZ1(225-295) crystals after manual dehydration. Crystals turned 
yellow after manual dehydration. Crystals grew in 0.1 M Tris pH 8, 0.1 M Sodium chloride, 8 % (w/v) 
PEG 20000. A: Step-wise transfer to 4 M TMAO or B: 20 % PEG 400 additional to the mother liquor. 
 
In situ proteolysis crystallization of SCOC(78-159)-FEZ1(225-295)  
Flexible regions of a protein can hamper crystallization and limited proteolysis can be used to 
crop flexible elements and thus enhance crystallization. Because in situ proteolysis was used 
to solve the structure of the SCOC ccd, limited proteolysis was also used for the SCOC(78-
159)-FEZ1(225-295) to identify stable fragments. The complex was digested with twelve 
different proteases from the Proti-Ace Kit 1&2 (Hampton Research) at 37 °C. The complex 
was incubated for 60 min at 37 °C without addition of protease as a control. Samples were 
taken at different time points of protease incubation. Analysis by Schägger gels showed that 
most proteases digested the complex resulting in bands with lower molecular weight (Fig. 
3.3.11. A). PE, α-C, TR and SU were used in higher concentrations to further investigate their 






Figure 3.3.11.: Limited proteolysis of SCOC(78-159)-FEZ1(225-295) complex. A: 10 mg/ml 
SCOC (78-159)-FEZ1 (225-295) complex was incubated without (-) or with 1:1000 protease for 5, 10, 
15 minutes at 37 °C. Protease assay was repeated with B: 1:500 and C: 1:200 proteases. P-K: 
Proteinase-K, CL: Clostripain, PE: Pepsin, TH: Thermolysin, BR: Bromelain, A-E: Actinase E, α-C: 
α-Chymotrypsin, TR: Trypsin, EL: Elastase, PA: Papain, SU: Substilisin, EG-C: Endoproteinase Glu-
C. M: Marker. 
 
The most promising proteases P-K, TH, A-E, α-C, TR, SU and EG-C were used for in situ 
crystallization in PEG 20.000 conditions, as a control H2O was added instead of protease. 
Crystals grew after treatment with TH, P-K and α-C (Fig. 3.3.12.). Crystals from in situ 
crystallization with TH resulted in somewhat different shaped crystals. Crystals were soaked 
in cryoprotectant and flash cooled in liquid nitrogen. Crystals were measured at beamline 





Figure 3.3.12.: In situ crystallization of SCOC(78-159)-FEZ1(225-295). Crystals grew in 0.1 M 
NaCl, 0.1 M Tris pH 8, 10 % PEG 20 000. Drops: 2 µl protein 15 mg/ml + 1 µl ML + 0.3 µl protease 
1 µg/µl or H2O. A: H2O B: TH, C: P-K D: α-C. 
Automated Dehydration 
Because unit cell dimensions of SCOC(78-159)-FEZ1(225-295) crystals from PEG 20.000 
crystals indicated a high solvent content another dehydration approach was tested. Using a 
humidity control device the dehydration of crystals can be controlled [16]. Because this 
device can be attached to a synchrotron beamline effects on diffraction can be directly 
observed during the dehydration. For automated dehydration the HC1c crystal humidifier at 
beamline BL14.3 (BESSY, Helmholtz Zentrum Berlin) was used with technical support of Dr. 
Manfred S. Weiss. The HC1c is equipped with an open air stream at room temperature with 
adjustable relative humidity (RH) of 45- 99.7 %. Prior to the experiment the equilibrium 
relative humidity (RH) was calculated to be 99.8 % for crystals grown in 0.1 M NaCl, 0.1 M 




Crystals were mounted on mesh loops at the beamline. Excess liquid was removed using filter 
paper. Crystals were then mounted at room temperature and a first test shot was taken at the 
starting point (Fig. 3.3.13. A). The relative humidity was then stepwise reduced. When the 
relative humidity was reduced to 97.5 % the diffraction was slightly enhanced (Fig. 3.3.13. 
B). At 95 % RH diffraction started to decrease but could be rescued by increasing the RH to 
97.5 % again. At 95 % RH crystals almost completely lost diffraction. The optimal RH for 
SCOC(78-159)-FEZ1(225-295) crystals was 97.5 %. Crystals were dehydrated to 97.5 % RH 
and flash cooled in liquid N2 without addition of a cryoprotectant. Frozen crystals were taken 
to beamline X10SA at the SLS to measure a full data set. Without cryoprotectant crystals 
were covered in ice and did not diffract.  
 
Figure 3.3.13.: Diffraction pattern of SCOC(78-159)-FEZ1(225-295) crystals at beamline BL14.3 
(BESSY, Helmholtz Zentrum Berlin). Diffraction was measured at A: 99.8 % relative humidity (RH) 
and B: 97.5 % RH. 
3.3.3.4. X-ray data collection and analysis of SCOC(78-159)-FEZ1(225-295) crystals 
from PEG 20.000 conditions 
SCOC(78-159)-FEZ1(225-295) crystals were soaked in crystallization solution supplemented 
with cryoprotectant before flash cooling in liquid nitrogen. Data from native or 
selenomethionine labeled crystals were collected at 100 K at beamline X10SA (Swiss Light 
Source, Paul Scherrer Institute, Villigen, Switzerland). A fluorescence spectrum was recorded 
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tor selenomethionine labeled crystals to define the selenium absorption spectrum (Fig. 
3.3.14.). The wavelength was tuned to the selenium peak prior to data collection. 
 
Figure 3.3.14.: Fluorescence spectrum of selenomethionine labeled SCOC(78-159)-FEZ1(225-
295) PEG 20 000 crystals. Crystals grew in PEG 20 000 conditions. Spectrum measured at beamline 
X10SA (Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland). Counts in the region of 
interest (ROI) are recorded as a function of energy (in eV). Blue curve: Counts (ROI), red curve: fitted 
f´, green curve: fitted: f´´. 
Complete datasets with 360 degrees total oscillation were collected at the Se peak wavelength 
or at 1 Å. The hexagonal SCOC(78-159)-FEZ1(225-295) crystals from PEG 20.000 
conditions revealed a hexagonal diffraction pattern with a maximum diffraction of 3.4 Å (Fig. 
3.3.15.).  
 
Figure 3.3.15.: SCOC(78-159)-FEZ1(225-295) crystals grown in PEG 20 000 conditions at 
beamline X10SA (Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland). A: Crystal 
mounted at the beamline. The yellow square indicates the X-ray beam and its size with 10 x 50 µm. B: 
Diffraction pattern observed from the same crystal.  
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Data were processed with input values specific for the PILATUS 6M detector using the XDS 
software package. Consistent with the hexagonal shape of the crystals and diffraction pattern 
the crystals are hexagonal primitive. The enantiomorphic space groups P6122 or P6522 were 
indexed with unit cell dimensions of a = b = ~104 Å, c = ~ 148 Å, α = β = 90°, γ = 120°. The 
hexagonal space group was confirmed by the absences of reflections along the screw axis 
(0,0,6n).  
Structure determination was attempted using the SAD phasing programs hkl2map and Phenix 
AutoSol. The structure of the SCOC(78-159)-FEZ1(225-295) complex could not be 
determined using crystals from PEG 20.000 conditions because the anomalous signal derived 
from SAD datasets was too weak. Another approach using the structure of a SCOC dimer 
(PDB code 4BWD) as a model for molecular replacement failed as well. 
 
3.3.3.5. Optimization of SCOC(78-159)-FEZ1(225-295) crystals in isopropanol 
conditions 
Crystals obtained from commercial Protein Complex screen condition number 31 had a sharp 
triangular shape but were little (Fig. 3.3.6. D). Because crystals from PEG 20000 conditions 
could not be further improved these were the only crystals found in different conditions, an 
optimization approach was started for the isopropanol condition. Initial crystallization 
condition 20 % (v/v) 2-Propanol, 0.1 M Tri-Sodium Citrate Dihydrate pH 5.6, 20 % (w/v) 
PEG 4000 was reproduced with self-made crystallization solutions in 24-well hanging drop 
Linbro plates. Crystals started growing after 24 hours in conditions at various pH and 
isopropanol concentrations. Initial crystals from 24-well plates had an irregular shape and a 
very smeary diffraction pattern was observed at the synchrotron (Fig. 3.3.16. A-C).  
Optimization included a 96-well Hampton Additive Screen that identified glycerol as a 
successful additive. The initial conditions were optimized to a final condition containing 20 % 
(v/v) 2-Propanol, 0.1 M Tri-Sodium Citrate Dihydrate pH 4.6, 5 % (w/v) PEG 4000, 10 % 
(w/v) glycerol. Optimized crystals had sharp edges and a well-defined triangular shape (Fig. 
3.3.26. D, E). Crystals were cryoprotected in reservoir solution supplied with additional 15 % 
glycerol and flash cooled in liquid nitrogen. Crystals diffracted to a resolution of 2.3 Å with 




To analyze the content of the crystals, whether they contained both SCOC and FEZ1 they 
were fished from the crystallization drops, washed in mother liquor and solubilized in gel 
filtration buffer before Schägger gel electrophoresis. Comparison with the purified complex 
revealed that both proteins crystallized in isopropanol conditions (Fig 3.3.27.). 
 
Figure 3.3.16.: SCOC(78-159)-FEZ1(225-295) crystals grown in isopropanol  conditions at 
beamline X10SA (Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland). A: Initial 
crystals grown in 24-well Linbro plates, B: Initial crystal mounted at the beamline, C: Diffraction 
pattern observed from the same crystal (B). D: Optimized crystals grown in 24-well Linbro plates, E: 
Optimized crystal mounted at the beamline, F: Diffraction pattern observed from the same crystal (E). 





Figure 3.3.17.: Schägger gel electrophoresis of Ni-Sepharose purified SCOC(78-124)-FEZ1(225-
295) complex and isopropanol crystals. M: Marker. First three line shows the elution fractions of 
SCOC(78-124)-FEZ1(225-295) from Ni-Sepharose purification. Sixth line show washed and 
solubilized SCOC(78-124)-FEZ1(225-295) isopropanol crystals. 
3.3.3.6. X-ray data collection and analysis of SCOC(78-159)-FEZ1(225-295) crystals 
from isopropanol conditions 
Data sets from native or selenomethionine labeled crystals were collected at 100 K at 
beamline X10SA (Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland). For 
selenomethionine labeled crystals a fluorescence spectrum was recorded to measure the 
selenium absorption spectrum (Fig. 3.3.18.). The wavelength was tuned to the selenium peak 
prior to data collection. Calculations by XDS revealed a strong anomalous signal for 
selenomethionine labeled crystals. Datasets were collected with a 0.1° oscillation for 360 ° at 




Figure 3.3.18.: Fluorescence spectrum of selenomethionine labeled SCOC(78-159)-FEZ1(225-
295) isopropanol crystals. Crystals grown in isopropanol conditions. Spectrum measured at beamline 
X10SA (Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland). Counts in the region of 
interest (ROI) are recorded as a function of energy (in eV). Blue curve: Counts (ROI), red curve: fitted 
f´, green curve: fitted: f´´. 
 
Data were processed with input values specific for the PILATUS 6M detector using the XDS 
software package. An unambiguous space group could not be determined (Table 3.3.7.).  
Table 3.3.7.: Determination of lattice character and bravais lattice from XDS IDXREF for 




Phenix Xtriage analysis revealed that SCOC(78-159)-FEZ1(225-295) crystals from 
isopropanol conditions are twinned (Fig. 3.3.19. and 3.3.20.). Two pseudo-merohedral twin 
operators were found. Precise determination of the space group and cell dimensions failed as 




Figure 3.3.19.: Britton analyses from Phenix Xtriage for SCOC-FEZ1 isopropanol crystals 
 




3.3.4. Cross-linking of the SCOC-FEZ1 complex and analysis by mass spectrometry 
In order to gain more insight in the SCOC-FEZ1 complex architecture, chemical cross-linking 
of the complex and analysis by mass spectrometry were conducted. Therefore the SCOC(78-
159)-FEZ1(225-295) complex was cross-linked with the amine-reactive 
bis(sulfosuccinimidyl) suberate (BS3) cross-linker at different concentrations. The amount of 
cross-links was analyzed by native gel electrophoresis (Fig. 3.3.21.). Without cross-linker 
only the two bands for SCOC and FEZ1 below 15 kDa were observed. In contrast after 
addition of BS3 more bands with a higher molecular weight appeared. The number of these 
bands enriched with increasing cross-linker concentration. Two bands, marked with black 
arrows (Fig. 3.3.21.) were sent for mass spectrometry analysis. This work was conducted in 
collaboration with Dr. Momchil Ninov (Department of Neurobiology) and Dr. Chung-Tien 
Lee (Bioanalytical Mass Spectrometry). 
 
Figure 3.3.21.: Cross-linking of the SCOC(78-159)-FEZ1(225-295) complex. Native gel 
electrophoresis of the SCOC-FEZ1 complex (5 mg/ml), cross-linked with 0, 0.25, 0.5, 1, 2 and 4 mM 
BS3. Arrows mark bands that were analyzed by mass spectrometry. Left arrow flags band1, right 
arrow band2. M: Marker. 
 
Bands were cut from the gel, digested with trypsin and sent to LC-MS/MS analysis. Each 
sample was analyzed in two technical replicates. Raw data were searched against a FASTA 
database containing the full length sequences of human SCOC and FEZ1 using the target-
decoy strategy of pLink. Results are shown with the count of spectrum and the maximum 
score for each cross-link (Table 3.3.8.). Inter- and intramolecular cross-links were visualized 
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with xiNET [26] (Fig. 3.3.22.). To exclude false positive cross-links the threshold for the 




Figure 3.3.22.: Visualization of the mass spectrometry analysis of the cross-linking of the 
SCOC(78-159)-FEZ1(225-295) complex. A: shows analysis of band1, B: shows analysis of band2 
from (Fig 3.3.21.) Samples were run in two technical replicates. Threshold was set to 5.1. Turquoise 
lines inter cross-links between SCOC and FEZ1. Purple lines inter- or intra molecular cross-links, Red 








Table 3.3.8.: Data of the mass spectrometry analysis of the SCOC(78-159)-FEZ1(225-295) 
complex cross-linking. Samples were run in two technical replicates. Threshold was set to 5.1.  
    Band1 Band2 













127 10 16.74 4 12.84 
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The cross-linked lysine residues were mapped onto the SCOC structure (PDB code: 4BWD) 
and Cα-Cα distances were measured using PyMol. To evaluate the intramolecular cross-links 
found for FEZ1 a coiled coil model was prepared using CCBuilder V1.0 [145] for either a 
parallel or antiparallel coiled coil dimer formed of residues 225-295. Intramolecular cross-
links of SCOC are in good agreement with the known structure of the parallel coiled coil 
SCOC dimer (Fig. 3.3.20.). This suggests that BS3 cross-links one chain of the dimer to the 
other subunit. Due to the fact that all lysine residues are in close proximity to each other, only 
short range cross-links in allowed distance were found. The most prominent cross-link of 




Figure 3.3.23.: Intra molecular cross-links of SCOC. Cartoon representation of SCOC in red (PDB 
code 4BWD). Lysines are presented as sticks in yellow. Cα-Cα distances (Å) between intra molecular 
cross-links are shown as dashed lines.  
 
Intramolecular cross-links for FEZ1 were mapped onto models of either a parallel or 
antiparallel coiled coil dimer. Intramolecular cross-link distances still lay in a possible range 
for the parallel coiled coil model (Fig. 3.3.21.). In the antiparallel coiled coil model, cross-link 
distances are too long and exceeded the distance restrains of the cross-linker (Fig. 3.3.22.). 
Especially the cross-link between K264 and K289 has a very long distance of ~50 Å, when 
mapped between the two chains. However, a short intramolecular cross link on the same chain 
is possible as well. The cross-link between K282 and K289 is also either short (10 Å) when 
mapped on the same chain or very long (77 Å) between the two chains (Fig. 3.3.22.) taking 
into account the cross-linker arm length. Considering an anti-parallel coiled coil a cross-link 
between K264 and K264 on the other chain is expected but was not found. Intramolecular 






Figure 3.3.24.: Intra molecular cross-links of parallel FEZ1 model. Cartoon representation of 
parallel FEZ1 coiled coil dimer model (made with CCBuilder) in green. Lysines are presented as 
sticks in magenta. Cα-Cα distances (Å) between intra molecular cross-links are shown as dashed lines.  
 
Figure 3.3.25.: Intra molecular cross-links of antiparallel FEZ1 model. Cartoon representation of 
antiparallel FEZ1 coiled coil dimer model (made with CCBuilder) in turquoise. Lysines are presented 




The maximum of score for intra molecular cross-links is similar for both SCOC and FEZ1, 
the maximum score of inter molecular cross-links between SCOC and FEZ1 is higher. 
Assuming a stable complex formation where lysine residues come in a distance favorable for 
cross-linking. To analyze the possible architecture of the SCOC-FEZ1 complex two models 
were visualized assuming that FEZ1 forms a parallel dimer (Fig. 3.3.23.). One model 
represents antiparallel binding of the two parallel coiled coil dimers (Fig. 3.3.23. A), whereas 
the other shows parallel binding of the two dimers (Fig. 3.3.23. B). Cα-Cα distances of inter 
molecular cross-links were mapped but not measured.  
Cross-links between FEZ1 residues K280, K282 and K289 and SCOC residues K122, K127 
and K129 are close and in a possible range for both models. In contrast, in the antiparallel 
model inter molecular cross-links with highest scores between SCOC residue K155 to FEZ1 
K282 and K289 and between FEZ1 K264 and SCOC K122 and K127 lay in a long distance 
and intersect with each other (Fig. 3.3.23. A). Cross-links between SCOC K155 and FEZ1 
K264 are more likely to be expected for an antiparallel complex model. The same cross-links 
are seen in a more likely distance for the parallel model (Fig. 3.3.23. B). Therefore, I propose 




Figure 3.3.26.: Inter molecular cross-links of SCOC and a parallel coiled coil FEZ1 model. 
Cartoon representation of SCOC in red (PDB code: 4BWD) and parallel coiled coil FEZ1 dimer 
model (made with CCBuilder) in green. A: Antiparallel binding model. B: Parallel binding model. 
Lysines are presented as sticks in yellow for SCOC and magenta for FEZ1. Cα-Cα distances (Å) 






4.1. Two Rab33B molecules form a complex with the diverging C-termini of an Atg16L1 
dimer 
During autophagy a double layered isolation membrane forms de novo that expands and 
encloses its cargo. The membrane supply of the growing isolation membrane involves various 
sources at different stages and is still under discussion [74]. In 2008 Itoh et al. first described 
the direct interaction between a small Rab GTPase and an Atg protein [54]. They 
demonstrated complex formation of Rab33B with the coiled coil domain of Atg16L1 in a 
GTP-dependent manner. In more detail Rab33B forms a complex with the 
Atg12~Atg5/Atg16L1 complex via direct interaction with the Atg16L1 coiled coil domain. It 
was proposed that Rab33B-Atg16L1 interaction may facilitate the recruitment of vesicles 
originating from the Golgi to the growing isolation membrane [54].  
Insights into the molecular details of Rab33-Atg16L1 interaction were still lacking, which 
would help to understand the function of this complex. In this study I present the X-ray crystal 
structure of the mRab33B(30-202)Q92L-mAtg16L1(153-210) complex at 3.47 Å resolution. 
It reveals that two Rab33B molecules form a complex with the diverging C-terminus of an 
Atg16L1 dimer respectively. A 1:1 stoichiometry of the complex was proposed before by Dr. 
Amanda Schalk in our laboratory and was verified by the structure. The Rab33B binding site 
for Atg16L1 is typical for binding of effector proteins and explains the GTP dependency of 
the interaction. 
Protein cross-linking experiments done in solution support the architecture of the Rab33B-
Atg16L1 complex found in the crystal structure. Lysines that are in proximity in the crystal 
structure were cross-linked with high scores. Several lysines that formed inter-molecular 
cross-links lay in a distance of 40 Å between Cα atoms. These values are in the range of 
values observed in other structures [87]. Cross-linking was done in solution where lysine side 
chains are often flexible and proteins are dynamic and cross-linking can lock proteins in a 
closer position than they normally adopt. 
In this study I found that the minimal Rab33B binding site of Atg16L1 comprises residues 
163-210. Previous studies in our group showed that a truncation to residue 204 of the 
Atg16L1 coiled coil domain disrupted complex formation, while constructs extending to 210 
still formed a complex with Rab33B. The crystal structure revealed that Rab33B-Atg16L1 
interaction takes place at the very C-terminal end of the Atg16L1 coiled coil domain within 
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residues 191 to 208. This confirms the proposal that the Atg16L1 site of homo-
oligomerization (80-200) and Rab33B binding site (141-265) are spatially separated [54]. 
Interestingly, the N-terminal part is also important for complex formation because a deletion 
of residues 163-172 disrupted complex formation even when the construct extended to residue 
210. I observed that the mRab33B(30-202)Q92L-mAtg16L1(153-210) complex was much 
more stable than the complex with the minimal binding site mRab33B(30-202)Q92L-
mAtg16L1(163-210), which dissociated during purification.  
Bachelor student Johannes Groffmann analyzed the Rab33B-Atg16 interactions with Ni-
Sepharose pulldown experiments under my supervision. Co-expressed mRab33B(30-
202)Q92L-Atg16L1 samples were purified with Ni-Sepharose beads. Eluted samples were 
then analyzed with Schägger gels and western blots and showed complex formation for 
mRab33B(30-202)Q92L with mAtg16L1 (125-234), (153-210) and (163-210). No complex 
formation was observed for mRab33B(30-202)Q92L with mAtg16L1 (172-210) and (153-
200) (Fig. 4.1.).   
 
Figure 4.1.: Ni-Sepharose pull down of His-Rab33B(30-202)Q92L co-expressed with different 
Atg16L1 constructs. Experiment was done by bachelor student Johannes Groffmann. 
The crystal structure shows that the N-terminal part of Atg16L1 mediates dimerization of the 
complex and a truncation at the N-terminal domain beyond residue 153 might destabilize the 
coiled coil formation. In contrast, at the C-terminus of the Atg16L1 coiled coil domain helices 
diverge from residue 189 onwards, which is the site (191-208) of complex formation with 
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Rab33B. Studies on human Atg16L1 that shares 94 % identity with murine Atg16L1 
confirmed a stable coiled coil domain for residues 126-207 [107].  
No structure is known for the mammalian Atg16 coiled coil alone, so we do not know 
whether complex formation with Rab33B affects the conformation of the Atg16L1 coiled coil 
C-termini. However, divergence of the helices at the C-terminal end of the coiled coil domain 
is favored by the mainly charged residues at the a/d heptad position in this region (E201, 
R204 and E208). Coiled coil domains are stabilized by hydrophobic core packing with the 
typical repeating pattern “hxxhcxc”. Polar residues at heptad position a or d have a 
destabilizing effect on the coiled coil packing [50]. Until now this feature of the Atg16L1 
dimer was not described before.  
The physiological role of the diverging C-termini remains unassigned. All mammalian 
homologs of Atg16L1 share a WD40 repeat domain at the C-terminus, other than yeast 
Atg16. The WD40 repeat domain is predicted to fold as a seven bladed β-propeller most 
probably providing a platform for protein complex assembly as reported for other WD40 
repeat proteins [126]. Until now the function of the Atg16L1 WD40 repeat is unknown. The 
diverging C-termini may affect the orientation of the two WD40 repeats and thus may also 
control potential interactions with either membranes or other not yet identified interaction 
partners. The WD40 domain could help to localize Atg16L1 to membranes but Atg16L1 
alone is not able to associate with membranes, expecting the requirement of other proteins 
[90]. To validate this hypothesis further investigations are required, like identification of 
mammalian autophagy specific proteins as interaction partners for the Atg16L1 WD repeat. 
Atg16L1 binds to switch I and II of Rab33B. These regions are important for nucleotide 
binding and their conformations depend on whether GTP or GDP is bound, supporting the 
finding that complex formation is GTP-dependent [54]. I further investigated nucleotide 
dependent Rab33B binding of Atg16L1 in vitro and in vivo. The dominant negative mutant 
Rab33B(30-202)T47N that binds GDP did not bind Atg16L1(153-210) in in vitro pull down 
assays. Moreover, also in vivo co-immunoprecipitation experiments showed that Atg16L1 
bound Rab33B T47N in significant lower amounts compared to GTP-bound Rab33B Q92L. 
Interestingly wild type Rab33B bound Atg16L1 in same amounts as Rab33B Q92L both in 
vitro and in vivo indicating that Rab33B WT is mainly present in the GTP bound state. 
Since the structure was determined at low resolution (3.47 Å) mutagenesis studies were done 
to verify the Rab33B-Atg16L1 interactions observed in the crystal structure. The following 
single site point mutants were prepared: F70A, F70E and W87A for Rab33B Q92L and 
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K198A, A202W, N206K for Atg16L1. The in vitro pulldown assays showed that all point 
mutations abolished complex formation thus verifying the Rab33B-Atg16L1 crystal structure.  
When these mutations were introduced in the full-length proteins and co-overexpressed in 
HEK cells, for Rab33B Q92L mutants F70A and W87A and Atg16L1 K198A, A202W and 
N206K complex formation was nearly entirely abolished. For Rab33B Q92L/F70E a 
significantly reduced binding to Atg16L1 was observed. While the results of the in vitro and 
in vivo experiments are overall in good agreement, the small differences might be due to 
additional interaction partners being present in cells and variations in protein and salt 
concentrations. The conserved residues Rab33B F70 and W87, which I showed to be essential 
for complex formation with Atg16L1, are also important for complex formation of Rab9A 
with its effector RUTBC2 [148] and Rab5 mutants F57A and W74A disrupted complex 
formation with Rabaptin5 [151].  
Fluorescence microscopy of cells co-overexpressing Rab33B and Atg16L1 were done to 
study the localization of the proteins and the complex. In cells overexpressing Atg16L1 and 
either Rab33B Q92L or wild-type Rab33B both proteins co-localized in punctate structures in 
the cytoplasm. Co-expression of GTP-bound Rab33B Q92L with Atg16L1 leads to enlarged 
punctate structures. In contrast, these punctate structures were dramatically decreased for the 
Rab33B T47N mutant and the single-site Rab33B Q92L and Atg16L1 mutants, which also 
abolished complex formation in vitro. Furthermore the Rab33B T47N mutant localized 
mostly to the perinuclear area, while Rab33B and Atg16L1 are evenly distributed in the 
cytosol upon inhibition of complex formation. The results of co-localization studies are in 
agreement with in vitro and in vivo co-immunoprecipitations.  
Atg16L1 positive punctate structures were shown to co-localize with the pre-autophagosomal 
marker protein LC3 [111]. Rab33B may be essential for Atg16L1 recruitment to the pre-
autophagosomal membrane. Since co-localization was studied under nutrient-rich conditions 
further experiments under starvation conditions and staining with LC3 or a Golgi specific 
marker need to be done to proof the identity of the punctuate structures. Furthermore GTP-
bound Rab33B Q92L increased LC3-II levels in co-immunoprecipitation experiments and the 
lipidation assay and enlarged punctuate structures were observed for cells overexpressing 
Atg16L1 with Rab33B Q92L. Results propose an effect of Rab33B Q92L on basal autophagy in 
nutrient rich conditions independent of complex formation with Atg16L1. Increased LC3-II 
levels regardless of nutrient conditions were observed before by Itoh et al. when Rab33B 
Q92L was overexpressed [54]. Rab33B may promote LC3 lipidation to recruit the 
Atg5~Atg12/Atg16 complex at specific sites amongst others. To further understand the role of 
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Rab33B on LC3 lipidation experiments will be repeated with cells transfected with either 
Rab33B or Atg16L1 mutants alone. 
To fully understand the physiological role of the Rab33B-Atg16L1 complex the role of 
regulatory factors of Rab33B like GAPs and GEFs needs to be considered. The Rab-GAP 
OATL1 was identified to inactivate Rab33B [55]. OATL1 is localized to autophagosomal 
membranes by direct interactions with LC3, GABARAP and GATE16. Overexpression of 
OATL1 delays autophagosome maturation and fusion with the lysosome. Furthermore 
Rab33B and its regulator OATL1 are involved in the delivery of nano particles to autophagy-
related membranes [104]. Overexpression of Rab33B increases LC3-II levels [55]. Similar to 
overexpression of OATL1 increased LC3-II levels slow down autophagosome maturation and 
fusion with the lysosome [54]. Taken together, OATL1 could hypothetically regulate 
Atg12~Atg5/Atg16L1 recruitment to the pre-autophagosomal membrane by inactivating 
Rab33B when enough LC3 is lipidated and thereby favor maturation of the autophagosome.  
For some mammalian Rab GTPases involved in autophagy orthologues have been found in 
yeast but no Rab33 counterpart was detected in the S. cerevisiae genome [150]. However, 
mammalian WIPI2B directly interacts with Atg16L1 [28]. WIPI2B is an orthologue of the 
yeast core autophagy protein Atg18 [108]. Very similar to yeast Atg21, it binds to PI(3)P at 
the phagophore, scaffolds the Atg5~Atg12/Atg16L1 complex and brings LC3 close to the 
membrane promoting LC3 lipidation. Atg21-Atg16 and WIPI2B-Atg16L1 binding sites are 
not conserved. The WIPI2B binding site of Atg16L1 includes residues 207 to 230 and is 
located at the extended C-terminus that is not conserved in yeast. The WIPI2B binding site of 
Atg16L1 is very close to but not identical with the Rab33B binding site (191-208). 
Preliminary co-immunoprecipitation experiments revealed that WIPI2 co-precipitates with 
Atg16L1 as well, as shown with a WIPI2 specific antibody (Fig. 4.2.) but findings must be 
verified. Still, results suspect that Rab33B and WIPI2B can simultaneously bind to Atg16. 
The Atg12-Atg5/Atg16L1 complex is localized at the mammalian isolation membrane and 
mediates LC3 lipidation. Atg16L1 may additionally recruit vesicles originating from the 
Golgi by simultaneously interacting with Rab33B and thus bringing these vesicles in close 





Figure 4.2.: GFP co-immunoprecipitation of Atg16L1-EmGFP and V5-Rab33B variants. 
Overexpression was done in HEK cells. Western blots were probed with either anti-GFP, anti-V5 
antibodies or antibody specific for WIPI2B. 
 
Rab33B is not the only factor that affects Atg16L1. Autophagy is a precisely orchestrated 
process that involves multiple localization factors. Recent studies propose a direct link 





4.2. The Atg16 dimer forms the center of the Atg21-Atg16 complex 
The Atg12~Atg5/Atg16 complex is part of the core autophagy machinery. The complex acts 
as an E3-like ligase for Atg8 lipidation. Atg21 functions in selective subtypes of autophagy 
and was recently discovered to recruit both the Atg12~Atg5/Atg16 complex and Atg8 via 
PI(3)P binding to the phagophore. In this way Atg12~Atg5/Atg16 and Atg3 are able to 
lipidate Atg8. Structural characterization of the Atg21-Atg16 complex gives more insights 
into the coordination of Atg8 lipidation. 
In this study the minimal binding site of AgAtg16 for Atg21 interaction was identified and 
compromises residues 70 to 124. The structure of the AgAtg16 coiled coil domain alone was 
determined at 3.4 Å resolution and revealed a left-handed parallel homodimeric coiled coil 
similar to the previously reported ScAtg16 coiled coil domain. The AgAtg16 coiled coil 
dimer is mainly negatively charged at the surface and hydrophobic at the dimer interface. 
SEC-MALLS measurements of the KlAtg21-AgAtg16(70-124) complex gave a molar weight 
of 67 kDa. The measured value for the AgAtg16 dimer is 15.4 kDa and for KlAtg21 43.1 
kDa. This suggests that one Atg21 molecule binds one Atg16 dimer. However, this does not 
fit to the observations from the crystal structure where two KlAtg21 molecules and one Atg16 
dimer form a complex. High protein concentration during crystallization probably favored 
formation of the 2:2 complex. It is very likely that the complex of two Atg21 molecules and 
one Atg16 dimer also forms in vivo because of the high local concentration of the membrane 
bound PROPPIN. 
In this study, the structure of the KlAtg21-AgAtg16 complex was determined at 4.0 Å 
resolution and the Atg16 binding site of Atg21 was identified. KlAtg21 forms a seven bladed 
β-propeller like KlHsv2, KmHsv2 and PaAtg18. The structure was determined by molecular 
replacement using the structures of PaAtg18 and KmHsv2 as a search model. KlAtg21-
AgAtg16 crystallized upon in situ proteolysis with clostripain that most probably digested all 
flexible loops, therefore flexible loops of the search model were truncated as well. At this low 
resolution most side chains cannot be built and because no SeMet crystals were obtained no 
sequence assignment could be done. Still the complex structure was determined with great 
confidence because both search models gave solutions where the propellers adopted the same 
orientation.  
Furthermore, the known PROPPIN structures are highly conserved, only the C-terminal β-
strand seven differs. In blades one to three and five to six even the connecting loops are 
conserved. Especially, the phosphoinositide binding sites with the FRRG motif are conserved. 
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PaAtg18 was used as a model for KlAtg21 because of the stronger conservation and its better 
molecular replacement values. Two KlAtg21 molecules bound to the C-terminus of an 
AgAtg16 coiled coil dimer. The AgAtg16 binding site is located between KlAtg21 blade two 
and three, similar to Atg2 binding to Atg18 loops 2AB and 2BC [143]. Binding of Atg8 to 
Atg21 was reported opposite of the Atg16 binding site [58].  
Several molecular replacement calculations were done to place the Atg16 structure using the 
dimer structures of ScAtg16 (PDB code 3A7O or 3A7P) and AgAtg16 with or without side 
chains as search models. Due to the low resolution only a few side chains of the Atg16 dimer 
are visible and the sequence cannot be built in with confidence for this reason. Therefore, the 
vertical localization of the coiled coil dimer is unknown. Coiled coil proteins are built of a 
repeating heptad pattern and it is possible that the coiled coil is shifted seven positions amino 
acid up or down. The majority of calculations placed the Atg16 dimer in a way that residues 
ScAtg16 ~90 to 108 or corresponding residues AgAtg16 ~67 to 85 are in close contact to 
Atg21. The final model was built of two KlAtg21 molecules based on the structure of 
PaAtg18 with one AgAtg16 dimer based on the truncated structure of AgAtg16 placed in the 
most frequently observed orientation. In this model a close contact for KlAtg21 R103 and 
AgAtg16 D78 was observed. Structural characterization of the ScAtg16 coiled coil domain 
revealed the significance of residues E102 and D101 which corresponds to AgAtg16 D78. 
Mutations of these residues to alanines affected autophagy and the Cvt pathway [37]. Another 
recent study showed that these residues directly interact with Atg21 [58]. I introduced charge 
reversing mutations KlAtg21 R103E and AgAtg16 (70-124) D78R to test complex formation 
by analytic gel filtration in vitro. Complex formation was disrupted for KlAtg21 WT with 
AgAtg16 (70-124) D78R and KlAtg21 R103E with AgAtg16 WT. But complex formation 
was not restored for Atg16 (70-124) D78R with KlAtg21 R103E in vitro. The interruption of 
complex formation for both point mutations with the corresponding wild type partner supports 
the importance of residues KlAtg21 R103 and AgAtg16 D78 for complex formation. 
The overall structure of the KlAtg21-AgAtg16 complex shows that the bottoms of the two 
Atg21 propellers are facing to one side of the Atg16 dimer respectively in a reversed V shape. 
In contrast, the Atg21-Atg8 interaction site is on the top site of the propeller [58]. The FRRG 
motif with the two PIP binding sites is located opposite to the Atg16 binding site at blade five 
of the β-propeller. For both KlHsv2 and AgAtg18 a perpendicular or slightly tilted orientation 
toward the membrane was proposed [19, 69]. 
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Taking these findings together membrane binding of the Atg21-Atg16 complex suggests a U-
shaped membrane around the complex. This finding is in contrast to in vivo observations that 
Atg12~Atg5/Atg16 is restricted to the outer side of the phagophore that is bent the other way 
round [63, 93, 133]. On the other hand Atg21 binds to PI(3)P that is evenly distributed at the 
inner and outer side of the membrane [100]. The two ubiquitin-like systems are tightly 
coupled. To favor Atg8 lipidation at the early stage of phagophore elongation Atg21 possibly 
localizes the Atg12~Atg5/Atg16 complex to the inner side of the cup-shaped growing 
isolation membrane. The Atg21-Atg16 complex is most probably formed before binding to 
the membrane as observed for the Atg18-Atg2 complex [101]. Furthermore, Atg16 homo-
dimerization is independent of Atg5 and Atg12 [91]. This would suggest a mechanism where 
at the first step homo-oligomerized Atg21-Atg16 complex binds to the membrane and recruits 
the Atg5~Atg12 conjugate. Atg21 binds Atg8 and thereby brings it close to the membrane, 
where it is positioned for lipidation. Atg8-Atg21 binding is independent on the 
Atg5~Atg12/Atg16 complex but stabilized by Atg16 [58]. Both Atg8 and Atg5~Atg12/Atg16 
are recruited to the membrane last [133]. Atg21 and the Atg12~Atg5/Atg16 probably bind to 
both sides of the phagophore. The distribution of the Atg21-Atg16 complex at 
autophagosomal membranes need to be further investigated for example by more precise 
microscopy techniques. 
Of notice this study gives structural evidence to the model proposed earlier by Michael 
Thumm and Roswitha Krick (Fig. 4.3.) [72], where Atg21 binds via PI(3)P to the phagophore 
and recruits the Atg12~Atg5/Atg16 complex and Atg8 to the membrane in a distinct position. 
In this way Atg12~Atg5/Atg16 and Atg3 are localized to the lipidation site of Atg8 and act as 
an E3-like enzyme. Different to the model proposed Atg21 binds to negative curved 





Figure 4.3.: Hypothetical model of the assembly of the autophagy ubiquitin-like conjugation 
system at the membrane. A: Model by superimposition of the PROPPIN-AgAtg16 model and 






4.3. Insights into SCOC-FEZ1 complex formation 
The human SCOC-FEZ1 complex plays a role in neuronal transport processes and is involved 
in the induction and regulation of autophagy [86]. SCOC-FEZ1 complex formation is 
conserved. Mutation or deletion of the SCOC and FEZ1 orthologues in C. elegans led to a 
phenotype with defects in axonal outgrowth and presynaptic organization [132]. Complex 
formation is mediated through the highly conserved coiled coil domains of both proteins. The 
minimal complex SCOC(78-159)-FEZ1(227-290) was determined before [11]. 
In this study, I showed that the positively charged amino acids at the C-terminal part of the 
FEZ1 coiled coil domain stabilized complex formation with SCOC. An optimized purification 
protocol for the complex was developed that removes SCOC and FEZ1 that did not interact. 
CD measurements showed that the SCOC(78-159)-FEZ(225-295) complex adopts an overall 
α-helical secondary structure as expected for coiled coil proteins that is stable with a melting 
temperature of 48 °C. The molecular weight of the complex (44 kDa) was determined with 
SEC-MALLS measurements, which corresponds to a complex composed of one SCOC and 
one FEZ1 dimer. This result confirms the findings of McKnight et al. [86] who reported a 2:2 
stoichiometric complex of about 300 kDa complex for full length FEZ1-GFP in complex with 
full length FLAG-SCOC and the observation that SCOC dimerization is crucial for complex 
formation with FEZ1 [11].  
My aim was to solve the structure of the SCOC-FEZ1 complex and while this was not 
achieved I still gained important new insights into the complex architecture. Although native 
and selenomethionine labeled crystals were obtained, which diffracted up to 2.2 Å resolution 
all attempts to solve the structure from these crystals were not successful due to a twinning 
problem. However, cross-linking of the complex and analysis by mass spectroscopy gave new 
insights into SCOC-FEZ1 complex formation. Results strongly suggest that the FEZ1 dimer 
has a parallel orientation and that it interacts with the parallel coiled coil SCOC in a parallel 
orientation. In this model the C-terminal part of the FEZ1 coiled coil domain (264-293) 
interacts with the C-terminus of SCOC (122-155). To prove this model mutagenesis studies 
could be done but that was not possible here due to time limitations. 
The importance of the SCOC C-terminus for complex formation could be studied by binding 
experiments with a C-terminal truncated SCOC construct. Although an interaction of SCOC 
with the FEZ1 homolog FEZ2 was found in a yeast-two-hybrid screen [3], no direct SCOC-
FEZ2 complex formation has been demonstrated so far. FEZ1 and FEZ2 share a conserved 
coiled coil domain but only little is known about FEZ2 until now [3]. Autophagy is also 
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regulated by the interaction of the SCOC-FEZ1 complex with ULK1 and UVRAG, 
components of the Beclin-1 complex [86]. Further investigations on the trimeric SCOC-
FEZ1-UVRAG complex and interaction on SCOC-FEZ1 with ULK1 would help to 
understand how autophagy initiation is regulated. SCOC and FEZ1 also interact with a 
diverse range of proteins. Almost all FEZ1 interaction partners share a coiled coil domain as 
common binding motif [6]. Structural characterization of the FEZ1 coiled coil domain alone 
or in complex with another interaction partner would be of great interest because it might help 
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